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Norsk sammendrag 
Translasjonsforskning i fedme: Dyremodeller for fedmekirurgi og underliggende mekanismer 
Antallet mennesker med fedme øker raskt og fører til en global fedmeepidemi. Det eneste 
alternativet som gir langvarig terapeutisk effekt per dags dato er fedmekirurgi og bruken av slike 
operasjoner er derfor omfattende. Tatt i betraktning det store antallet pasienter med fedme, 
risikoen for kirurgiske komplikasjoner og høye kirurgiske kostnader, så er behovet for utvikling 
av nye, mer skånsomme behandlinger påtrengende. Hovedmålet med denne doktorgraden var 
derfor å øke kunnskapen om de fysiologiske mekanismene bak fedmekirurgi for å utvikle nye, 
mindre invasive behandlingsalternativer for fedme, ved bruk av dyremodeller. 
I denne doktorgraden fant vi at vagusnerve stimulering/blokkering (VNSB) reduserte 
kroppsvekten med 10% i normalvektige rotter og at dette var assosiert med redusert matinntak, 
økt uttrykk av anoreksigene nevropeptider i hjernestammen og hippocampus, samt økt uttrykk av 
oreksigene nevropeptider i hypothalamus. Injeksjon av Botox i magesekken reduserte 
kroppsvekten med 20-30% i normalvektige rotter, overvektige rotter og overvektige rotter som 
hadde fått sleeve gastrektomi. Vekttapet var assosiert med redusert matinntak, økt energiforbruk 
og økt uttrykk av oreksigene nevropeptider i hypothalamus. Muskarinisk acetylkolin M3 reseptor 
knockout mus hadde redusert kroppsvekt, økt energiforbruk og økt uttrykk av oreksigene 
nevropeptider i hypothalamus, men uendret totalt matinntak. Ileal interposisjon og sleeve 
gastrektomi økte uttrykket av glukagon-lignende peptid-1 (GLP-1) i henholdsvis ileum og 
bukspyttkjertel i normalvektige rotter. Gastrisk bypass økte energiforbruket og reduserte 
kroppsvekten med 15%, mens duodenal omkobling reduserte matinntaket, endret spisemønsteret, 
økte energiforbruket, ga malabsorpsjon og førte til et vekttap på 54% i normalvektige rotter. 
Hjerne-mage aksen spiller en viktig rolle i regulering av kroppsvekt, noe som gjør den til 
et ideelt mål i fedmebehandling. Resultatene fra denne doktorgraden viser at blokkering av den 
gastriske vagusnerven, ved VNSB eller Botox-injeksjon, kan brukes som minimal invasiv 
fedmebehandling. I tillegg kan antagonister mot M3 reseptor ha potensiale som behandling av 
fedme. Kombinasjonen av ileal interposisjon og sleeve gastrektomi er gunstig for å maksimere 
sekresjon av GLP-1 og har potensiale som metabolsk kirurgi. Resultatene fra denne doktorgraden 
viser i tillegg at duodenal omkobling gir et større vekttap enn gastrisk bypass gjennom ulike 
mekanismer. Ved bruk av translasjonsforskning har denne doktorgraden økt kunnskapen om 
fysiologiske mekanismer bak fedmekirurgi og funnet mindre invasive behandlingsalternativer for 
fedme. 
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Støttet av European Union Seventh Framework Programme (FP7/2007-13, nº266408) 
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Abstract 
 
Background/Aims: The number of obese individuals is increasing rapidly, leading to a global 
obesity epidemic. Only bariatric surgery has demonstrated long-term therapeutic effects, and the 
use of these procedures is extensive. Considering the large number of obese patients, the risk of 
surgical complications and high surgery-related cost, development of new, minimally invasive 
procedures to treat obesity is urgently needed. The principal objective of this thesis was to better 
understand the physiological mechanisms of bariatric surgery in order to develop minimally or 
non-invasive obesity treatments using experimental animal models. To this end, specific 
objectives were i) to evaluate the vagus nerve and the muscarinic acetylcholine M3 receptor as 
possible therapeutic targets, ii) to investigate the potential of ileal interposition alone and 
combined with sleeve gastrectomy as bariatric and metabolic surgery, and iii) to investigate the 
underlying mechanisms of gastric bypass and duodenal switch. 
 
Materials and Methods: A total of 229 animals (rats and mice) were used. Seven different 
surgical procedures or genetic manipulation have been tested, i.e., vagus nerve 
stimulation/blocking (VNSB), gastric botulinum toxin type A (Botox) injection, gene knockout of 
the muscarinic acetylcholine M3 receptor (M3KO), ileal interposition, ileal interposition with 
sleeve gastrectomy, gastric bypass, and duodenal switch. Physiological variables measured 
included body weight development, body composition, food intake, eating behavior, metabolic 
parameters, gastric acid secretion, energy-balance regulating genes in the brain, gut hormones, 
gastric emptying, fecal energy content, pancreatic and ileal glucagon-like peptide-1 (GLP-1), 
pancreatic insulin, and cytokines. Dual energy X-ray absorptiometry, open circuit indirect 
calorimeter, gastric fistula model, taqman array, in situ hybridization, RNA sequencing, 
radioimmunoassay, acetaminophen absorption assay, adiabatic bomb calorimeter, western blot, 
immunohistochemistry, and multiplex cytokine assay were used. 
 
Results: VNSB reduced body weight by 10% in normal chow-fed rats, which was associated 
with reduced food intake, increased expression of anorexigenic neuropeptides in brainstem and 
hippocampus, and increased expression of hypothalamic orexigenic neuropeptides. Botox 
injection reduced body weight by 20-30% in normal chow-fed rats, diet induced obese (DIO) rats 
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and DIO rats that had underwent sleeve gastrectomy. The body weight loss was associated with 
reduced food intake, increased energy expenditure, and increased expression of hypothalamic 
orexigenic neuropeptides. M3KO mice had a lean phenotype and displayed increased energy 
expenditure, increased expression of hypothalamic orexigenic neuropeptides but unchanged total 
food intake. Ileal interposition and sleeve gastrectomy did not reduce body weight, but increased 
GLP-1 expression in the ileum and pancreatic islets, respectively. Gastric bypass increased 
energy expenditure and reduced body weight by 15%, while duodenal switch reduced food 
intake, altered eating behavior, increased energy expenditure, and caused malabsorption, leading 
to a 54% body weight loss.  
 
Conclusions: The brain-gut axis plays an important role in the regulation of body weight, which 
makes it an ideal target for obesity treatments. Blocking the gastric vagus nerve, by VNSB or 
Botox injection, can be used as non- or minimally invasive obesity treatment, and muscarinic 
acetylcholine M3 receptor antagonists might have potential as obesity treatment. Combining ileal 
interposition and sleeve gastrectomy would be beneficial to maximize GLP-1 secretion, and holds 
potential as a metabolic surgery. Duodenal switch induces greater body weight loss than gastric 
bypass through different mechanisms. 
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1. Background 
 
1.1 Translational Research 
 Translational research can be defined as the process of applying insights, ideas, and 
discoveries generated through basic research for treatment or prevention of human disease. 
However, it also involves taking insights, ideas, and discoveries from the clinic back to the basic 
experimental settings to identify underlying mechanisms. This can shortly be described as “from-
bench-to-bedside-and-back” (Fig. 1) [1]. Translational research can be studies discovering new 
therapeutic strategies, studies defining the effects of therapeutics in humans, studies providing 
basis for improving therapeutics, studies identifying clinically relevant biomarkers, and studies 
developing new drugs and procedures [2].  
 
Figure 1 | Model illustrating translational research from-bench-to-bedside-and-back, modified from [1]. 
  
In this thesis, the research questions and hypotheses have been generated from clinical 
practice and research (Table 1).  
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Table 1 | Hypotheses of translational research investigated in each paper in this thesis. 
Clinical practice Research Hypothesis Paper 
No significant weight loss in 
patients after vagotomy or 
vagal blocking for obesity 
control (VBLOC)  
Role of the vagus nerve in 
regulation of food intake and 
energy expenditure  
Targeting gastric vagus 
nerve for new methods 
in obesity treatment 
I – II 
Ileal interposition as 
metabolic surgery? 
Ileum as main source of GLP-1 
in the circulation 
Combination of ileal 
interposition and sleeve 
gastrectomy as metabolic 
and bariatric surgery 
III 
Greater weight loss after 
duodenal switch than gastric 
bypass in morbidly obese  
Different postsurgical 
anatomies 
Different physiological 
mechanisms 
IV 
 
 This thesis was designed to identify the underlying mechanisms in the right experimental 
models, i.e. rat models of bariatric surgeries (Papers I, III, and IV) and to identify the right target 
and test the right treatments (Papers I-IV). The thesis focuses on obesity, therefore biological 
variables including eating behavior, metabolic parameters, hormones, and neuropeptides in the 
gut-brain axis have been studied, and the main endpoint has been the body weight loss (Papers I-
IV). 
The ultimate goal in clinical medicine is to improve patient outcome by maximizing 
medical efficacy and minimizing adverse effects. To achieve this, evidence-based medicine 
should be performed wherever it applies. Evidence-based medicine is the integration of clinical 
expertise, patients’ values and research evidence (Fig. 2A). Research evidence includes animal 
research and preclinical trials, expert opinion, case series/reports, case-controlled studies, cohort 
studies, and randomized controlled trials (RCTs) (Fig. 2B) [3]. 
 
Figure 2 | Illustrations of the components of A) evidence-based medicine and B) research evidence. 
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 However, it is difficult to perform RCTs in the surgical practice where double blinding 
and placebo controls are both practically challenging and unethical. Therefore, RCTs should not 
be considered the de facto and sole source of high-level evidence in surgery [4]. There are a 
number of challenges in evaluating surgical innovation due to the complexity of a surgical 
intervention, which includes modifications of surgical techniques and procedures, surgical skills, 
collaborations with medical, nursing, and anaesthesia teams, pre- and post-operative care, and 
quality of the surgical theatre [5]. Thus, the evidence obtained by animal research and preclinical 
trials, which have been conducted in this thesis, should be considered a high-level evidence in 
surgery. Usually, translation of new knowledge into the surgical practice is slow and incomplete, 
which is frequently due to the animal studies not being timely executed [6]. In this thesis, the 
animal studies and trials (Papers I, III, and IV) have been conducted either prior or immediately 
post pilot clinical trials [7-11]. In fact, a clinical phase II trial of gastric antral Botox injection for 
obesity treatment (REK ref no. 2013/1597, EudraCT no. 2012-004381-18) has been initiated 
based on and due to the results generated in this thesis (Paper I).   
 
1.2 Obesity  
Obesity is a condition where accumulation of excess adipose tissue causes adverse effects 
on health. In humans, overweight and obesity are assessed by body mass index (BMI), defined as 
an individual’s body mass in kilograms divided by the height in meters squared (kg/m2). A BMI 
above 25 kg/m2 is defined as overweight, while a BMI of more than 30 kg/m2 is defined as obese. 
The number of obese individuals is increasing rapidly, leading to a global obesity epidemic 
[12,13]. Obesity is a major contributor in the development of type 2 diabetes, cardiovascular 
diseases, certain forms of cancer, overall reduced quality of life, and premature mortality [14,15]. 
In addition, obesity affects fertility, sexual function, and psychosocial factors such as 
dissatisfaction with body image and depression [16-19]. Of special concern is the increasing 
prevalence of obesity in children [20]. Not only is obesity a great health burden, it is also an 
economic burden to the society as the medical costs for an obese individual is 40% higher than 
for a normal weight individual [21].  
All living organisms, including humans, obey the first law of thermodynamics, stating 
that the change in internal energy of a closed system is equal to the amount of heat added to the 
system, minus the amount of work done by the system. This means that imbalance between 
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energy intake and energy expenditure will result in a change in the body’s amount of energy 
stores (mainly white adipose tissue). It is generally believed that increased consumption of more 
energy-rich food with high levels of carbohydrate and saturated fats, combined with reduced 
physical activity, has led to the obesity epidemic [22]. Looking at this from an evolutionary 
perspective one can explain why this life style is so detrimental. In the ancient hunter-gatherer 
society food was dependent on physical activity. At this time food supply was never consistent, 
causing cycles of feast and famine, and of physical activity and rest. To ensure survival during 
famine, certain genes, the so-called “thrifty genes”, evolved to regulate highly efficient intake 
and utilization of food. For example genes promoting efficient adipose tissue accumulation were 
beneficial for survival in times of famine. These genes are still a part of our genome, but 
combining them with today’s continuous food supply and physical inactivity can cause metabolic 
dysfunctions such as obesity [23]. However, in addition to the generally higher energy intake 
than energy expenditure in today’s society, genetics, diseases, psychiatric disorders, medications, 
environmental factors, and eating disorders are also factors that can cause or contribute to obesity 
development [16,24-28].    
 
1.3 Obesity Treatment and Bariatric Surgery  
Theoretically, treatment of obesity can be achieved by decreasing energy intake and/or 
increasing energy expenditure. Today, weight loss treatments include diet control, physical 
exercise, medications, and bariatric surgery [29]. Exercise and diet often fail to induce a long-
term body weight reduction [30]. This is because many factors (including the thrifty genes) have 
evolved to oppose life-threatening weight loss, for example during famine, and will work to 
attenuate the body weight loss. As energy deficit can threaten survival, pathways increasing food 
intake and reducing energy expenditure are more powerful than pathways reducing food intake 
and increasing energy expenditure [31]. In addition, long-term life style changes in diet and 
physical activity can be difficult to maintain [30]. Pharmacotherapy also have yet limited efficacy 
[32]. Up to date, only bariatric surgery has been demonstrated to exhibit long-term therapeutic 
effect [33,34].  
The first bariatric surgery, i.e., jejunoileostomy, was performed by Dr. Richard Varco in 
1953 and the first gastric bypass was performed by Dr. Edward Mason in 1966. Since then 
bariatric procedures have gone through many modifications to create the procedures seen in the 
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clinics today and have been designed to induce restriction and/or malabsorption in the 
gastrointestinal tract [35]. Restriction is obtained by reducing the gastric volume in order to 
induce early satiety, reduce food intake, and body weight. Malabsorption is obtained by 
bypassing the small intestine in order to reduce nutrient absorption and thereby reducing body 
weight. 
Bariatric surgeries are frequently performed worldwide in order to induce weight loss in 
obese patients (Fig. 3). 
 
Figure 3 | Number of bariatric surgeries performed worldwide, modified from [36]. RYGB: Roux-en-Y 
gastric bypass, AGB: adjustable gastric banding, SG: sleeve gastrectomy, BPD/DS: bilio-pancreatic 
diversion/duodenal switch. 
 
Today, the most frequently performed bariatric surgeries include Roux-en-Y gastric 
bypass (RYGB), sleeve gastrectomy (SG), and adjustable gastric banding (AGB). In 2011, 
RYGB, SG, AGB, and duodenal switch (DS) were performed in 47%, 28%, 18%, and 2% of 
patients, respectively [36]. The RYGB is both a restrictive and malabsorptive procedure where a 
small gastric pouch is created and a portion of the small intestine is bypassed. SG is a restrictive 
procedure where 75% of the stomach is removed and AGB is also a restrictive procedure 
performed by placing an adjustable band around the upper part of the stomach making a small 
gastric pouch [33]. DS is both restrictive and malabsorptive and consists of a sleeve gastrectomy, 
an alimentary limb 50% of the total small intestine length, a common channel of 100 cm and a 
cholecystectomy. While RYGB is most popular, DS seems to have higher efficacy regarding 
weight loss and improvement of comorbidities, especially in super-obese individuals (BMI  45) 
[37,38]. 
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Weight loss is often expressed as percent excess weight loss (%EWL), where excess 
refers to the weight that exceeds “ideal” weight adjusted for height. RYGB, AGB, and DS has 
been found to induce 62%, 48%, and 70% EWL, respectively [39], while SG has been found to 
induce 52% EWL one year after surgery [40]. A prospective controlled study showed that 
bariatric surgery in general induced 23% and 16% weight loss 2 and 10 years after surgery, 
respectively. After surgery, the patients also recovered from type 2 diabetes, 
hypertriglyceridemia, low levels of high-density lipoprotein (HDL) cholesterol, and hypertension 
[41]. Bariatric surgery has also been found to improve mortality [42]. 
 
1.4 Need for Minimally Invasive Procedures 
There is always a risk of surgical complications, both in general and in particular in 
bariatric surgery. Even though obesity is in itself a risk factor when surgery is performed 
perioperative mortality in bariatric surgery is generally seldom and lies around 1% [41,43]. 
However, a study reported a complication rate up to 40% after bariatric surgery [44]. Such 
complications can be leaks, infections, small bowel obstruction, anastomotic stenosis, bleeding, 
pulmonary embolism, vomiting, diarrhea, and respiratory failure [43-45]. Another problem after 
the malabsorptive procedures is nutritional deficiencies such as calcium, folate, vitamin-B12, 
vitamin D, and iron-deficiency [46,47]. In addition, many obese patients have diseases that are 
contraindications for bariatric surgery, and cannot go through today's standard bariatric surgeries. 
In fact, only 1-2% of the obese people worldwide that are suitable for bariatric surgery undergo 
these procedures, due to lack of surgical professionals and resources [36,48]. 
In consideration of the large number of obese patients, the risk of surgical complications, 
high surgery-related cost, higher demand than capacity for bariatric surgery, and the number of 
obese patients not qualified for conventional bariatric surgery, development of new, minimally 
invasive procedures and pharmacological interventions to treat obesity is urgently needed [44].  
 
1.5 The Gut-Brain Axis 
The gut-brain axis (communication between the gastrointestinal tract and the central 
nervous system) plays an important role in the pathogenesis of obesity [49]. Peptide hormones 
released from the gastrointestinal tract and adipose tissue convey information about the body’s 
energy balance to the brain. This occurs via the vagus nerve or by the hormones acting on brain 
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regions implicated in energy homeostasis, such as the hypothalamus and brainstem, regulating 
food intake and energy expenditure. Ingested food interacts with the gut and stimulates or inhibits 
the release of these peptide hormones [50].  
Upon ingestion of food, there is an increase of several anorexigenic peptides in the 
gastrointestinal tract, such as peptide YY (PYY), cholecystokinin (CCK), glucagon-like peptide-1 
(GLP-1), amylin, and insulin. Ghrelin is the only known orexigenic peripheral peptide in the 
gastrointestinal tract, which decrease in concentration when food is ingested and increase in 
concentration when energy stores are low. The role of ghrelin in regulation of food intake and 
other physiological functions has been intensively studied since 1999 [50-52]. However, ghrelin 
knockout mice do not display any phenotype [53]. Secretion of the hormones leptin and insulin is 
regulated by adiposity, where high levels of adiposity increase the secretion of leptin and insulin, 
acting on the central nervous system (CNS), reducing appetite. While insulin is secreted by 
pancreatic ȕ-cells, leptin is secreted by the adipose tissue itself (Fig. 4) [50,51,54]. 
The vagus nerve is the main neuronal substrate in the gut-brain axis (Fig. 4). In addition 
to peptide hormones, the vagus nerve responds to mechanical distention of the lumen or gut 
contraction and to the chemical properties of ingested food, and transmits information about 
ingestion, absorption, and metabolism of energy to sites in the CNS that regulate ingestive 
behavior (including the hypothalamus and brainstem) [51,55].  
In the brain, the hypothalamus is regarded as a key regulatory component in regulation of 
food intake and energy expenditure. The arcuate nucleus (ARC) in the hypothalamus acts as a 
feeding control center, where orexigenic neuropeptide Y (NPY) and agouti-related peptide 
(AgRP) neurons and anorexigenic pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART) neurons are thought to play a central role in regulation 
of food intake and energy expenditure [51]. This nucleus has a modified blood-brain barrier 
allowing entry of peripheral peptides and proteins. There are extensive reciprocal connections 
between the hypothalamus and the brainstem, particularly via the nucleus of the solitary tract 
(NTS) (Fig. 4). The NTS is where the afferent (from periphery to the CNS) vagus nerve signals 
enter the CNS. Even though the hypothalamus often is regarded as the central feeding organ, the 
brainstem may have an equally important role in food intake and body weight regulation [56].  
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Figure 4 | Illustration of the gut-brain axis, modified from [57,58]. 
 
Given that obesity is a long-term disturbance of energy balance, and the central role of the 
vagus nerve in regulation of food intake and energy expenditure, this nerve could be an ideal 
target for new, minimally invasive obesity treatments.  
 
1.6 The Vagus Nerve 
The latin word vagus means “wandering” and accurately describes the distribution of this 
nerve, which innervates multiple organs in the neck, thorax, and abdomen [59]. In addition to the 
regulation of food intake, the vagus nerve is also involved in regulation of cardiac rate, breathing, 
blood pressure, swallowing, gastric acid, and pancreatic secretions [60-63]. It is the tenth and 
longest cranial nerve, consisting of 80% afferent and 20% efferent (from CNS to the periphery) 
nerve fibers [59,64].  
Neurons in the vagus nerve has a resting membrane potential of -65 mV, i.e. the voltage 
inside the cell is 65 mV more negative than outside the cell. Following stimulus from dendrites, 
sodium ion (Na+) channels open, causing depolarization and action potentials that propagate 
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down the length of the neuron unidirectionally. When the action potential reaches the presynaptic 
nerve terminals it opens voltage gated calcium (Ca2+) channels, causing synaptic vesicles to fuse 
with the presynaptic membrane and release neurotransmitters into the synaptic cleft through 
exocytosis. In the synaptic cleft the neurotransmitters diffuse and bind to receptors on the 
postsynaptic neuron, causing ion channels to open or close, leading to a synaptic potential (Fig. 
5). The synaptic potential may further either stimulate or inhibit development of an action 
potential in the postsynaptic neuron. After generation of an action potiential, Na+ channels close 
and potassium ion (K+) channels open, causing the membrane to repolarize towards its resting 
potential. However, this repolarization typically overshoots the resting potential to -90 mV and 
causes a hyperpolarization, which raises the threshold for new stimulus. After hyperpolarization, 
the Na+/K+ pump eventually brings the membrane back to its resting state of -65 mV [65]. 
 
 
Figure 5 | Illustration of a typical neuron and synapse [66]. 
 
The vagus nerve is divided into A, B and C fibers, with the A fibers being the fastest, 
biggest and most easily activated, followed by B fibers being slower, smaller and somewhat 
harder to activate, and the C fibers that are slow, small and hard to activate [59,67]. While the A 
and C fibers contain both afferents and efferents, the B fibers consist only of efferents (Table 2) 
[68]. 
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Table 2 | Overview of the characteristics of A, B, and C fibers in the vagus nerve [59,67,68]. 
  A B C 
Diameter (mm) 5-20 <3 0.40-2 
Myelinated Yes Also unmyelinated Mostly unmyelinated 
Conductance velocity (ms) 30-90 10-20 0.30-6 
Threshold (mA) 0.02-0.20 0.04-0.06 2+ 
Afferents/efferents Both Efferents Both 
 
 The vagus nerve originates from four nuclei in the medulla oblongata; dorsal motor 
nucleus of the vagus nerve (DMN), nucleus ambiguous (NA), NTS, and spinal nucleus of 
trigeminal nerve. It exits the cranium through the jugular foramen [69] and as the vagus nerve 
goes from the medulla to the periphery it divides into different branches along the way, 
innervating different organs. Two gastric branches innervate the stomach and a portion of the 
proximal duodenum; the celiac branches innervate the gastrointestinal tract from the duodenum 
to the transverse colon and the pancreas, while the hepatic branch innervates the distal stomach, 
liver and proximal duodenum (Fig. 6) [70,71].  
The vagus nerve carries afferent signals to the nodose ganglion that relay information to 
the NTS in the brainstem. Through the NTS, afferent vagal signals reach several parts of the 
brain including the reticular formation in the medulla, locus coeruleus, parabrachial nucleus, 
hippocampus, thalamus, dorsal motor nucleus of the vagus, nucleus ambiguous, amygdala, and 
the hypothalamus (arcuate, paraventricular, and dorsomedial nucleus of hypothalamus) [72-74]. 
The incoming sensory information is relayed to these regions through autonomic feedback loop, 
direct projections to the reticular formation, amygdala, and hypothalamus, and ascending 
projections to the forebrain through the parabrachial nucleus and locus coeruleus [73,75-77]. The 
dorsal motor nucleus of the vagus nerve is the primary location of gut vagal efferent motor 
neurons and is found just ventral to the NTS [78].  
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Figure 6 | Distribution of the vagus nerve in the neck, thorax, and abdomen [79]. 
 
With so many destinations in both the peripheral and central nervous system the vagus 
nerve affects a broad range of basic functions, and can be a good target in treatment of different 
disorders. 
 
1.7 Vagus Nerve Stimulation  
 Manipulation of the vagus nerve in disease treatment is not a new idea. Vagotomy has 
been used to treat peptic ulcers with a great success and it was also used for treatment of obesity 
without success [80-83]. Therefore, it has been replaced by bariatric surgery. 
Vagus nerve stimulation (VNS) is a procedure where electrodes are implanted around the 
vagus nerve, attached to an implanted power source and used to electrically stimulate the nerve. 
The electrodes used in this thesis are bipolar, i.e. each pole is either a cathode or an anode. As 
described, the charge in nerve cells is carried by ions, however, the charge in electrical currents is 
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carried by electrons. The electrical current provided by the electrodes in VNS does not affect the 
neuronal ion concentrations directly. The anode and cathode generate a negative and positive 
field respectively and ions with opposite charge are then attracted. At the cathode positive ions 
are attracted, leaving the outside of the nerve negative. This alters the voltage across the 
membrane and depolarizes the membrane. When the membrane is sufficiently depolarized this 
triggers an action potential. The opposite happens at the anode, where the membrane gets 
hyperpolarized. This hyperpolarization creates an anodic block and the action potential generated 
by the cathode may be blocked in this direction, resulting in the cathodic pulse only traveling in 
full extent in one direction (Fig. 7) [84]. Since the cathode is placed proximal and the anode is 
placed distal in this thesis, the cathodic pulse travels toward the brain (personal communication 
with Cyberonics, Inc.).  
 
Figure 7 | The mechanism of vagus nerve stimulation. 
 
The first reported use of VNS was in 1883 and in 1938 it was found that VNS induced 
synchronized activity in the orbital cortex in cats [85,86]. Further animal experiments led to the 
first human use of VNS for epilepsy treatment in 1988 [87,88]. Several studies have found VNS 
to be an efficient treatment of epilepsy, reducing seizure frequency by 50% after more than one 
year of therapy in 50% of patients [87,89,90]. Studies of VNS for epilepsy have indicated 
improved mood, anxiety, cognitive function, and altered pain threshold and food cravings in 
patients [91-95], which has led to clinical trials of VNS for depression, anxiety, Alzheimer’s 
disease, and obesity [7,96-98].   
Today VNS is an FDA approved treatment of epilepsy and treatment-resistant depression 
(approved in 1997 and 2005, respectively). During VNS, the electrodes are implanted around the 
left cervical vagus nerve in order to avoid cardiac complications and to get maximal effect in the 
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brain, where the effect is thought to occur. To avoid side-effects (hoarseness, coughing, throat 
pain, paraesthesias, and headache) the stimulation current is generally increased steadily [89,99]. 
Studies suggest that epilepsy improvement increase steadily over time and that stimulation recruit 
A and B fibers, while C-fiber activation is not required for epilepsy treatment, since destruction 
of C fibers does not attenuate anti-seizure response to VNS and electrophysiological studies 
indicate that typical VNS parameters do not activate C-fibers [59,100,101]. 
Although the use of VNS is increasing, the precise mechanism is still unknown. Animal 
models suggest that the anti-seizure effect of VNS may be related to locus coeruleus activation 
[102,103]. Locus coeruleus is the major site for norepinephrine-producing cells in the brain and 
has axons extending to the brainstem, thalamus, hippocampus, amygdala, and neocortex. In fact, 
it has been found that VNS increase norepinephrine concentration in the prefrontal cortex in rats 
[104]. Effects of VNS has also been found on other neurotransmitters such as serotonin, GABA, 
and glutamate [72,103,105]. VNS in rats has been found to increase c-fos labeling in amygdala, 
cingulate, locus coeruleus, hypothalamus, and the brainstem [106], while human studies have 
found increased cerebral blood flow in bilateral thalamus, hypothalamus, inferior cerebellar 
hemispheres, and right postcentral gyrus after acute and chronic VNS [107]. In addition, fMRI 
studies have found VNS to cause changes in hypothalamus, left amygdala, and orbito-frontal, 
parieto-occipital and left temporal cortex, along with an overall increase in brain activity [108].  
Several human studies of VNS for depression have found that VNS reduced body weight 
and altered appetite, and a study in epileptic patients found that VNS increased energy 
expenditure [94,109-111]. Some animal studies have also found VNS to induce weight loss 
[112,113], while others found no effect on body weight [114,115]. These results have inspired 
more studies of VNS as a possible obesity treatment. For this purpose, VNS has been performed 
at the subdiaphragmatic level with electrodes attached to vagal branches in proximity to the 
gastro-esophageal junction [7]. By this method, vagal signals from the periphery can be modified 
and both branches can be targeted without any detrimental effects on cardiac function. 
Subdiaphragmatic vagus nerve stimulation is minimally invasive and more studies are needed in 
order to determine whether this procedure can be a new, minimally invasive obesity treatment. 
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1.8 Botulinum Toxin Type A Injection 
Botulinum neurotoxin is a neurotoxin produced by the gram-positive bacteria Clostridium 
botulinum and can cause the neuroparalytic disease botulism [116]. This neurotoxin can be 
categorized into seven different serotypes (A-G) with different toxicities, where botulinum 
neurotoxin type A gives the longest lasting paralysis [116-118]. Botulinum neurotoxin type A is 
sold under different brand names, such as Botox, Dysport, and Xeomin [119], where Botox is the 
term and product used in this thesis. 
Botox consists of a heavy (HC) and light (LC) chain of 100 kDa and 50 kDa, respectively 
[116]. The heavy chain of the toxin binds irreversibly and selectively to high affinity receptors at 
presynaptic neurons. These receptors have been identified as gangliosides, synaptic vesicle 
glycoprotein 2 (SV2), and possibly fibroblast growth factor receptor 3 (FGFR3) [120,121]. This 
binding causes the receptor-toxin complex to be taken up by receptor-mediated endocytosis 
[122,123] and subsequently the disulphide bond that connects the heavy and light chain is 
cleaved by proteases [116,124]. The light chain is a zinc endopeptidase, and causes cleavage of 
synaptosomal associated protein 25 (SNAP-25), a SNARE (Soluble NSF attachment protein 
receptor) protein essential for exocytosis of synaptic vesicles containing neurotransmitters, such 
as acetylcholine [125,126]. This inhibits the release of acetylcholine from presynaptic terminals, 
causing a paralysis of the adjacent muscle cells at the neuromuscular junction (Fig. 8) [122]. By 
this mechanism, Botox leads to paralysis. 
 
Figure 8 | The mechanism of action of botulinum neurotoxin [127]. 
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Today, Botox is used to treat many conditions and there are few reports of adverse effects 
[128,129]. Among the conditions treated with Botox are strabismus, headache, hypersalivation, 
spastic movement disorders, hyperhidrosis, achalasia, anal fissure, spasticity, pain, arthritis, and 
hemifacial spasm [130-140]. It is also extensively used in the cosmetic and beauty industry [119]. 
The paralysis caused by Botox can vary in duration, but is estimated to be 3-4 months in patients 
[141]. 
The stomach wall is composed of mucosa, submucosa, smooth muscle, and serosa. All 
these layers are innervated by the gastric vagus nerve [142]. Botox injections here would block 
the release of neurotransmitters (e.g. acetylcholine), and are thought to paralyze the smooth 
muscles, thereby inhibiting the gastric propulsive activity and subsequently delaying gastric 
emptying. This gastroparesis might prolong satiety, reduce food intake, and subsequently induce 
weight loss. Consequently, injection of Botox into the gastric antral wall has been proposed as a 
new, minimally invasive treatment of obesity [143]. However, currently there is inconsistency in 
the literature and unclear results regarding body weight and gastric emptying after Botox 
injection. More research is needed in order to determine the efficacy and underlying mechanism 
of this as a minimally invasive obesity treatment. 
 
1.9 Muscarinic Acetylcholine M3 Receptor 
After acetylcholine is released into the synaptic cleft it will bind to either nicotinic 
acetylcholine receptors (nAChR) or muscarinic acetylcholine receptors (mAChR), where nAChR 
are ligand-gated ion channels and mAChR are G protein-coupled receptors (GPCRs) (Fig. 9). 
Muscarinic acetylcholine receptors (M1-M5) are expressed throughout the body and have roles in 
regulation of many physiological functions such as motor control, memory, temperature 
regulation, glandular secretion, cardiac rate, cardiovascular regulation, and smooth muscle 
contraction [144]. 
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Figure 9 | Illustration of neuronal production and exocytosis of acetylcholine into the synaptic 
cleft, which subsequently binds to either muscarinic or nicotinic acetylcholine receptors [145]. 
 
The muscarinic acetylcholine M3 receptor is distributed in the brain, glands, and smooth 
muscle [144]. Interestingly, the M3 receptor has been shown to be important in food intake and 
body weight regulation, as mice deficient of this receptor display a lean phenotype with reduced 
food intake, total body fat, and serum levels of leptin, insulin, and triglyceride [146,147]. Based 
on this, a M3 receptor-dependent cholinergic pathway regulating appetite has been suggested 
[146]. Interestingly, these mice have also been found to be protected against diet induced obesity, 
obesity-associated glucose intolerance, insulin resistance, hyperinsulinemia, and hyperglycemia. 
This study also reported increased energy expenditure in these mice and hypothesized that this 
was caused by enhanced central sympathetic outflow and rate of fatty-acid oxidation [147]. This 
phenotype has not been observed in mice lacking M1, M2, M4, or M5 receptors [148-151]. 
Given the role of the M3 receptor in regulation of energy homeostasis, pharmacological 
targeting of this receptor could have potential for obesity treatment. It has been suggested that 
antagonists targeting the M3 receptor in the CNS would be preferable since peripheral M3 
antagonists could induce significant side effects [152]. However, more research is needed to 
determine whether the M3 receptor is a potential pharmacological target in obesity treatment.   
 
1.10 Metabolic Surgery 
In 2008, 347 million people suffered from diabetes worldwide, 90% of these from type 2 
diabetes and the numbers are increasing. Type 2 diabetes is a serious disease developing parallel 
to the obesity epidemic, as many people suffering from obesity develop type 2 diabetes. In this 
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disease the body is unable to effectively utilize insulin produced by pancreatic ȕ-cells and since 
insulin regulates blood glucose levels this leads to hyperglycemia [153,154]. 
Obesity and type 2 diabetes are closely tied together. In obese individuals, adipose tissue 
increase lipolysis and secretion of non-esterified fatty acids (NEFAs), which can lead to insulin 
resistance and reduced ȕ-cell function. Impaired insulin secretion from pancreatic ȕ-cells 
decrease insulin levels and thereby increase food intake, leading to obesity, which again could 
give insulin resistance. Decreased insulin secretion also increases glucose production in the liver 
and reduces the efficacy of glucose uptake in muscle (Fig. 10) [155]. Obesity is associated with a 
low-grade inflammation, where adipocyte hypertrophy, hypoxia, and endoplasmic reticulum 
stress may increase the levels of pro-inflammatory cytokines and chemokines.  These cytokines, 
together with NEFAs, can hamper insulin signaling through activation of intracellular 
serine/threonine kinases [156]. 
 
Figure 10 | Model illustrating the link between obesity and type 2 diabetes, modified from [155]. 
  
 There is an increasing line of evidence of bariatric surgeries having therapeutic effect not 
only on obesity, but also on type 2 diabetes. Roux-en-Y gastric bypass (RYGB), adjustable 
gastric banding (AGB), and bilio-pancreatic diversion/duodenal switch (BPD/DS) have given 
respectively 84%, 48%, and 98% mean ratios of type 2 diabetes remission [39,157]. Multiple 
studies have shown these metabolic effects to be weight-independent and to be a result of 
endocrine changes from the surgical alterations of the gastrointestinal tract, as the improved 
glucose tolerance has been observed before and even without substantial weight loss and in 
nonobese individuals. The term “metabolic surgery” refers to surgery attempting to achieve 
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improved glucose homeostasis in both obese and nonobese patients [157]. However, little is 
known about the exact mechanisms behind these metabolic changes and much investigation is 
ongoing to identify the source of this diabetes remission. There are several hypothesis regarding 
these mechanisms, such as the foregut, hindgut, and metabolic reprogramming hypotheses 
[158,159]. In this thesis the hindgut hypothesis was investigated. 
GLP-1 is secreted by the endocrine L-cells located in the distal ileum in response to 
ingested nutrients [160]. This hormone has several activities, including delaying gastric emptying 
and reducing food intake [161,162]. In the pancreas GLP-1 works as an incretin, increasing 
secretion and production of insulin, ȕ-cell proliferation, and neogenesis [163]. It also acts upon 
the Į- and į-cells in the pancreas, decreasing secretion of glucagon [164,165]. By this mechanism 
GLP-1 lowers blood glucose levels. GLP-1 has been suggested to be involved in the pathogenesis 
of type 2 diabetes. This is supported by findings of type 2 diabetes patients having reduced GLP-
1 secretion in both basal and postprandial conditions [166-168]. However, GLP-1 administration 
to diabetic patients is not feasible as the half-life of the native molecule is 60-90 seconds [169]. 
Several bariatric procedures that improve type 2 diabetes lead to higher ileum stimulation by 
nutrients, suggesting that the mechanism by which these procedures lead to type 2 diabetes 
remission may be through an increased secretion of GLP-1 in ileum (the hindgut hypothesis). 
Interestingly, GLP-1 receptors are distributed on vagal afferents in the gastrointestinal tract, 
pancreatic ȕ-cells, and on neurons in the CNS. Due to its short half-life, it is likely that the 
incretin action of GLP-1 is through activation of GLP-1 receptors on vagal afferents in the 
gastrointestinal tract, leading to vagal efferent signals to pancreatic ȕ-cells, increasing insulin 
secretion [170].  
According to the hindgut hypothesis, ileal interposition (II) has been proposed as a 
metabolic surgery where a small segment of ileum is surgically interposed to the proximal small 
intestine. This procedure increases the stimulation of ileum by ingested nutrients and has been 
found to increase secretion of GLP-1 from L-cells in ileum [171-177]. This may be the 
mechanism by which ileal interposition has been shown to improve type 2 diabetes in animal 
studies [173-175,177-180]. 
Sleeve gastrectomy (SG) was developed as a first step bariatric surgery for high-risk 
patients intended for a second procedure, however, due to good clinical outcomes the procedure 
is now performed as an independent bariatric surgery [181]. The procedure has been shown to 
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reduce body weight and give remission of type 2 diabetes in both animal and human studies 
[40,182-189]. Some suggest that this is due to reduced ghrelin levels [182-189], while others 
suggest it to be caused by increased gastric emptying and GLP-1 secretion [190-192]. 
Interestingly, an animal study showed the effect to be independent of ghrelin [193]. Combining 
ileal interposition with sleeve gastrectomy was initially proposed to combine increased GLP-1 
and reduced ghrelin levels [194]. All clinical studies of ileal interposition involves this 
combination (II-SG), and the procedure has been found to reduce body weight, resolve type 2 
diabetes, increase GLP-1, PYY, and insulin and to decrease glucagon, ghrelin, and leptin levels 
[195-198]. 
Although promising, the exact mechanism behind the remission of type 2 diabetes after 
ileal interposition alone or combined with sleeve gastrectomy is still unknown and more research 
is needed to determine the potential and mechanisms of these procedures as metabolic and/or 
bariatric surgeries. 
 
1.11 Mechanisms of Bariatric Surgery: State-of-the-Art 
As mentioned, today´s bariatric surgeries efficiently induce weight loss and improve 
comorbidities, such as type 2 diabetes. However, the underlying physiological mechanisms are 
unclear, although the procedures are frequently performed worldwide [33,36]. While animal 
behavior is mostly driven by instincts, human behavior is much more complicated. Especially 
after bariatric surgery food intake can be strongly affected by postoperative instructions that are 
designed to induce weight loss and minimize side effects. This does not occur in animal studies 
and makes it easier to detect physiological effects and underlying mechanisms of surgical 
procedures in these models, which also provide more opportunity for control and manipulation 
[199]. Animal studies are also an excellent way of developing bariatric surgical techniques which 
can be adopted back into the clinics. Most importantly, discovering the underlying mechanisms 
of bariatric surgery can lead to development of new, minimally invasive procedures and/or 
pharmacological intervention through the same mechanisms, ultimately increasing quality of 
patient care [200]. Also, by identifying the different underlying mechanisms of the different 
procedures, it can be possible to identify personalized treatment.  
The classical proposed mechanisms of bariatric surgery are restriction and malabsorption. 
However, sleeve gastrectomy (SG), which does not give malabsorption, has similar effects as 
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Roux-en-Y gastric bypass (RYGB) [201], and research indicate that reduction in food intake, 
rather than malabsorption, is the main reason for weight loss. It has been suggested that this is 
caused by restriction of the gastric volume, however, the stomach volume after SG is much 
greater than after adjustable gastric banding (AGB), but SG induces greater weight loss than 
AGB [202,203]. Also, several studies show that the size of the gastric pouch in RYGB does not 
correlate with amount of weight loss [204-206]. Thus, it is most likely that the mechanisms of 
bariatric surgery deal with physiological, rather than mechanical alterations (Fig. 11).  
Bariatric surgery leads to altered gut hormone secretion, such as increased levels of GLP-
1 and PYY and reduced levels of ghrelin [207-209]. However, GLP-1 receptor and ghrelin 
knockout mice have shown no change in the effects of bariatric surgeries, indicating that these 
factors may not be essential [193,210]. Interestingly, weight loss after gastrointestinal bypass was 
impaired in PYY knockout mice [211]. CCK has also been suggested to have importance, but 
studies show that RYGB is effective also in CCK-1 deficient rats [212]. Leptin has been 
suggested to be important after bariatric surgery, as leptin levels are reduced weight-
independently [207,213]. However, SG is effective also in rodents that lack the leptin receptor, 
indicating that the effects of bariatric surgeries do not rely on leptin sensitivity [214].  
Several studies have shown that bariatric surgeries increase plasma levels of bile acids 
[215]. Bile acids are central in lipid absorption, activating the farsenoid-X receptor (FXR), and 
modulating hepatic lipid metabolism. They have also been found to increase energy expenditure 
and prevent obesity in mice [216]. In FXR knockout mice SG had no effect, indicating that this 
could be an important pathway. In addition, SG did not alter gut microbiota in the knockout mice, 
in contrast to wild-type mice [217]. Several studies have found altered gut microbiota after 
bariatric surgery [218]. This study indicates a link between bile acids, the FXR, and gut 
microbiota that could play an important role after bariatric surgery.  
Several studies have found RYGB to induce weight loss by increasing energy expenditure 
[219-221] and therefore, energy expenditure could also be an important mechanism behind 
bariatric surgeries. 
Altered gastric emptying has been proposed to have importance for increased satiety after 
bariatric surgeries, which might be caused by alterations of the gastrointestinal tract or by 
response to endocrine and/or neuronal mechanisms. The vagus nerve is also affected by bariatric 
surgeries as they cause disruption and/or altered pattern of the nerve. Therefore, neuronal changes 
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affecting gastrointestinal signals to the brain has been proposed as a mechanism of bariatric 
surgery [222]. It is likely that bariatric surgeries give alterations in the CNS and some studies 
indicate that after bariatric surgery the homeostatic set-point in hypothalamus is altered, making 
the body defend a lower body weight [223].  
Other mechanisms suggested include altered food preferences, reduced hunger, and 
reduced food reward [224-228]. In fact, animal models of RYGB and SG select less fat, increase 
liking of diets of lower calorie density, and reduce liking of sweet food [224,228]. Studies of food 
reward indicate that intrinsic food reward is not reduced, but that more rapidly achieved satiation 
reduces motivation after initiation of a meal [224,228].  
Several of the mechanisms mentioned above have been suggested to be the underlying 
mechanisms of RYGB, SG, and duodenal switch (DS). We have previously reported that DS in 
rats reduce food intake, alter eating behavior, and cause malabsorption [82]. However, other 
animal studies of this procedure are lacking. SG induces body weight loss in most clinical and 
animal studies, often comparable to RYGB [189,190,229-231]. However, there are also animal 
studies finding no significant weight loss [82,187,232,233].  
Although much research in this field is ongoing, the underlying mechanisms of bariatric 
procedures, such as Roux-en-Y gastric bypass, sleeve gastrectomy, and duodenal switch, are still 
unknown, and more research on these procedures in the right experimental setting is needed.  
 
Figure 11 | Illustration of the different proposed underlying mechanisms of bariatric surgeries. 
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2. Aims of Thesis 
 
2.1 Principal Objective 
 
This thesis aimed to better understand the physiological mechanisms of bariatric surgery in order 
to develop minimally or non-invasive obesity treatments using experimental animal models.  
 
2.2 Specific Objectives 
 
I. To evaluate the vagus nerve as a possible target in development of new, minimally 
invasive obesity treatments (Paper I) 
 
II. To evaluate the muscarinic acetylcholine M3 receptor as a possible pharmacological 
target in obesity treatment (Paper II) 
 
III. To investigate the potential of ileal interposition alone and combined with sleeve 
gastrectomy as bariatric and metabolic surgery (Paper III) 
 
IV. To investigate the underlying mechanisms of gastric bypass and duodenal switch (Paper 
IV) 
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3. Materials and Methods 
 
3.1 Ethics 
 The use of animals in scientific experiments raises ethical issues, especially when the 
experiments are likely to cause harm, pain, and/or distress. Therefore, animals should only be 
used in experiments if the objectives of the study can contribute to animal or human welfare, if 
the study is likely to meet these objectives, if there are no other alternatives, and if the harm to 
the animals is not excessive. It is general consensus that the use of animal models is only 
ethically acceptable when the studies are well designed, efficiently executed, correctly analyzed, 
clearly presented, and correctly interpreted [234]. In 1959 Russel and Burch defined the 3Rs 
(replace, refine and reduce) as guidelines for humane use of animals, stating that animals should 
be replaced by other alternatives whenever possible, experiment protocols should be refined to 
minimize adverse effects, and the number of animals should be reduced to a minimum in order to 
obtain the objectives of the study, without using too few as to miss biologically significant effects 
[235].  
In this thesis the animal experiments could not have been replaced by any in vitro 
experiment as the systemic effects of surgical procedures or knockout of receptors cannot be 
studied by models such as cell cultures or computers. The protocols have been refined, including 
gas anesthesia, local as well as systemic analgesia, and surgical improvements. Throughout the 
studies the general condition and behavior of the animals have been closely observed and if there 
were any abnormalities the veterinarian at the animal facility was contacted. Scoring schemes 
were used to evaluate whether a humane endpoint was reached. The number of animals in each 
group was determined based on previous studies and statistical estimation. All studies in this 
thesis were approved by the Norwegian National Animal Research Authority 
(Forsøksdyrutvalget).  
 
3.2 Experimental Design and Statistics 
The experimental designs in this thesis were made based on the objectives of the 
individual studies (Papers I-IV).  In this thesis confirmatory research (data is collected in order to 
answer a question) was performed. The “experimental units” were the individual animals, which 
were assigned to treatment groups randomly with an equal probability (using a random number 
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table) and the groups were treated equally throughout the experiments. Completely randomized 
designs like this are widely used due to its simplicity and tolerance for unequal numbers in each 
group. In this thesis, untreated animals, animals treated with vehicle, animals implanted with 
sham devices, or sham-operated animals were used as negative controls. To avoid bias, 
experiments were performed “blindly” with regards to treatments whenever possible. 
Quantitative data was analyzed, which is preferable as it normally requires a smaller sample size 
than qualitative data. To avoid random variables, such as circadian rhythms and different people 
performing experiments, affecting the data, body weight was measured at the same time of day 
and a limited number of people handled the animals [234]. 
The results of an experiment should be analyzed using appropriate statistics, reflecting the 
purpose of the study. In this thesis, all individual studies were performed to test a null hypothesis, 
H0, stating that the treatment (either surgery in Papers I, III, and IV or gene knockout in Paper II) 
had no effect. The results are expressed as means ± SEM. Statistical comparisons were performed 
using independent t-test or Mann Whitney U test between the experimental groups. When 
suitable, ANOVA with Tukey’s or Bonferroni post hoc test was performed. Analysis of 
covariance (ANCOVA) with Sidak test was performed for energy expenditure analysis using fat-
free mass or body weight as covariate. A p-value of <0.05 (two-tailed) was considered 
statistically significant. The data analysis was performed in SPSS version 15.0 and 20.0. It is 
important to note that results can be significantly different using statistics but to be of little or no 
biological significance [234].  
Laboratory animals were used as models for humans in this thesis. Accordingly, the 
differences between humans and the animal models were taken into consideration in the 
experimental designs and data analysis in this thesis. It should be noticed that even though a 
response is found in animals, its true relevance to humans is still unknown [234]. However, if a 
treatment shows an effect in animals it is more likely to give an effect in humans, than if it does 
not induce an effect. 
 
3.3 Animals 
A total of 229 animals were used in this thesis, including 37 rats in vagus nerve 
stimulation/blocking (VNSB) studies, 88 rats in Botox studies, 46 mice in muscarinic 
acetylcholine M3 receptor knockout (M3KO) studies, 24 rats in ileal interposition and sleeve 
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gastrectomy (II and SG) studies, and 34 rats in gastric bypass (GB) and duodenal switch (DS) 
studies (Paper I: 125 rats, Paper II: 46 mice, Paper III: 24 rats, and Paper IV: 34 rats).  
Rats (Sprague-Dawley, male, adults) were purchased from Taconic, Denmark, Janvier 
Labs, France, and Harlan™, The Netherlands. Males were mainly used because female rats have 
food intake coinciding with ovarian hormones and males grow faster than females, making it 
easier to detect changes in body weight. Long Evans rats (adult, female) were obtained at 
Norwegian University of Science and Technology, Trondheim, Norway. Muscarinic 
acetylcholine M3 receptor knockout (M3KO) mice were generated by Prof. Koji Takeuchi’s 
group at Kyoto Pharmaceutical University, Kyoto, Japan, and imported to Norway by Professor 
Chen. These mice were further bred through sibling matings for two generations. Age-matched 
control mice, C57BL/6, were purchased from Taconic, Denmark. All animals had free access to 
tap water and standard rat pellet food (RM1 811004, Scanbur BK AS, Sweden), high-fat-diet in 
pellets (D12492, Research Diets, Inc., NJ, USA), or standard mice pellet food (RM1 801002, 
Scanbur BK AS, Sweden). They were housed three-four together in individually ventilated cages 
on wood chip bedding with a 12-h light/dark cycle, room temperature of 22ºC, and 40-60% 
relative humidity. The standard housing conditions were specific pathogen free and in agreement 
with FELASA (Federation of European Laboratory Animal Science Association) 
recommendations.  
 
3.4 Surgical Models 
All surgeries were performed under general anesthesia with isofluran (4% for induction, 
2% for maintenance) (Baxter Medical AB, Kista, Sweden). When beneficial the animals were 
fasted overnight before surgery. Atropin (0.04 mg/kg) (Nycomed Pharma AS, Asker, Norway) 
was given subcutaneously 20 min before surgeries with duration of more than 45 min. Marcain (1 
mg/kg) (Astrazeneca, London, UK) was injected subcutaneously locally at the incision place. 
Buprenorphine (Schering-Plough Europe, Brussels, Belgium) was injected subcutaneously (0.05 
mg/kg) immediately after surgery in all animals, and one day postoperatively when needed.  
Physiological saline (0.9% NaCl) was given subcutaneously at 10-15 mL after surgeries to keep 
the animals hydrated.  
 
 
36 
 
3.4.1 VNSB and -VNSB 
The vagus nerve stimulation/blocking (VNSB) implantation was performed through a 
midline abdominal incision. The subdiaphragmatic truncal vagus nerve was dissected from the 
esophagus and two electrodes (Lead Model 302, Cyberonics, Houston, TX, USA) were wrapped 
around the anterior and posterior vagus nerve of the gastric branch together with extra tissue from 
esophagus (Fig. 12). The wire from the electrodes was attached to fat tissue around the stomach 
(the greater omentum) and to the muscular layer using 6-0 and 4-0 absorbable sutures (Vicryl, 
Ethicon Inc., Sommerville, NJ, USA), respectively. On the back of the rat a subcutaneous pocket 
for the stimulator (Model 102 Pulse Generator, Cyberonics, Houston, TX, USA) was made and 
here it was connected to the wire. The abdomen was closed in two layers using 4-0 absorbable 
sutures and the back was closed using the same sutures (Ethicon). The control and VNSB rats 
received the same procedure. Implantation of the -VNSB device followed the same procedure, 
except that the control animals were implanted with stimulators without electrodes. 
 
Figure 12 | VNSB model. A) Illustration of the electrode implantation and B) photograph of  VNSB 
electrodes attached to the vagal nerves at the gastro-esophageal junction. 
 
The current of vagus nerve stimulation/blocking can be monophasic or biphasic. In this 
thesis the current was biphasic, meaning it was first induced in one direction and then in the 
opposite direction. Stimulation frequency is the number of times a stimulus pulse is applied in a 
period of time and pulse width is the duration of the stimulus pulse, i.e. the time that the current 
is applied to the electrode. The duty cycle is defined as the percentage of time during which 
stimulation occur [236]. In this thesis VNSB was at a current ranging from 0.5 mA to 3.5 mA, a 
frequency of 30 Hz, a pulse width of 500 ђs, and a duty cycle of 30 s ON and 5 min OFF. These 
settings are regarded as standard, safe, and effective [90,237].  
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3.4.2 Botulinum Toxin Type A Injection 
Botulinum toxin type A 100 U (Botox® Allergan Cooperation, Irvine, CA, USA) was 
diluted in 0.9% cold saline and 1% methylene blue (Sigma-Aldrich, St. Louis, MO, USA) (for 
visualization of the injection) achieving a concentration of 40 U Botox/mL. Total volume 
injected into pyloric antrum of each rat was 0.5 mL (20U/rat). The control rats were injected with 
0.5 mL 0.9% saline and 1% methylene blue. Following a short median laparotomy, the stomach 
was exposed and antrum isolated. Botox was injected to both anterior and posterior side of the 
antrum with a 30 G needle according to earlier reports [143,238]. In contrast to previous studies 
the injection was made through one injection on each side and allowed for the fluid to spread 
over the whole subserosal area of the pyloric antrum (Fig. 13). Abdomen was closed in two 
layers using 4-0 absorbable sutures (Ethicon).  
 
Figure 13 | Botox model. A) Illustration and B) photograph of gastric subserosal Botox injection 
in the whole area of the pyloric antrum through one injection. 
 
3.4.3 Ileal Interposition 
Ileal interposition (II) was performed through a midline abdominal incision. The ligament 
of Treitz was located and the insertion location for the transposed ileum segment, approximately 
3 cm distal to the ligament, was marked with saline-soaked gauze. Cecum was located and a 2-3 
cm segment of ileum located 0.5 - 1 cm proximal to the ileocecal valve was isolated and 
transected. An anastomosis was made with the two open ends of cecum and jejunum. The marked 
position distal to the ligament of Treitz was found and the isolated ileal segment with intact 
vascular and nervous supplies was inserted here in the original peristaltic direction by making 
two end-to-end anastomoses (Fig. 14). All anastomoses were performed with 6-0 absorbable 
sutures (Ethicon). The abdomen was closed in two layers using 4-0 absorbable sutures (Ethicon). 
38 
 
 
Figure 14 | Ileal interposition model. A) Rat gastrointestinal anatomy, B) ileal interposition, and C) ileal 
interposition with sleeve gastrectomy. 
 
3.4.4 Sleeve Gastrectomy 
Sleeve gastrectomy (SG) was performed through a midline abdominal incision. The 
stomach was located, blood supply to the spleen and greater omentum was shut down, and the 
stomach was clamped along the greater curvature from the antrum to the fundus across the 
forestomach and glandular stomach. A scissor was used along the clamp to excise the greater 
curvature of the stomach, removing approximately 70% of the stomach. Subsequently, the 
stomach was closed with 6-0 absorbable sutures (Ethicon). Hemostasis and suture-line integrity 
were checked, and additional stitches were applied when necessary. The abdominal wall was 
closed in two layers using 4-0 absorbable sutures (Ethicon). In diet induced obese (DIO) rats the 
procedure was performed in a similar manner. However, the stomach was clamped using staples 
(Fig. 15) (Endo GIA, Articulating Reload with Tri-Staple™ Technology, 45 mm, EGIA45AVM, 
Covidien™, Dublin, Ireland).  
 
Figure 15 | Sleeve gastrectomy model. A) Rat gastrointestinal anatomy, B) the suture/staple line across the 
greater curvature of the stomach, and C) sleeve gastrectomy. 
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3.4.5 Gastric Bypass and Duodenal Switch 
Micro-gastric bypass (GB) was performed through a midline abdominal incision by 
anastomosing the distal esophagus to the proximal jejunum about 2-3 cm distal to the Treitz 
ligament in an end-to-side manner (Fig. 16B) [221,239]. Duodenal switch (DS) was achieved in 
two stages. The two-stage procedure has been recommended in patients since the single-stage 
procedure increases the risk of postoperative complications and staged duodenal switch may 
avoid biliopancreatic diversion in some patients [240]. Sleeve gastrectomy was performed by 
resecting approximately 70% of the stomach along the greater curvature using sutures, as 
described above.  Three months later, duodenal switch was achieved by creating a biliopancreatic 
limb, an alimentary limb (approximately 95% of total small bowel length), and common channel 
length of 5 cm (Fig. 16C) [82].  
 
Figure 16 | Gastric bypass and duodenal switch models. A) Rat gastrointestinal anatomy, B) 
gastric bypass, and C) duodenal switch. 
 
3.4.6 Sham Surgeries 
Sham surgery, or laparotomy, was generally performed through a midline abdominal 
incision, and viscera was gently manipulated. However, in the VNSB studies control animals 
received the same implantation as experiment animals, in the -VNSB study control animals 
received the stimulator without electrodes, and in the Botox studies control animals received 
vehicle injection. 
   
3.5 Methods to Study Effects and Mechanisms  
3.5.1 Body Weight and Body Composition 
Body weight was determined using a standardized balance throughout the studies (one-
three times per week). Body composition was determined by dual energy X-ray absorptiometry 
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(DXA) (Hologic QDR 4500A, Hologic Inc., Bedford, MA, USA). Total fat mass, total fat-free 
mass, total bone mineral content, and total bone area were measured. From this data bone mineral 
density and total body mass were calculated.  
 
3.5.2 Food Intake, Eating Behavior, and Metabolic Parameters 
Food intake, eating behavior, and metabolic parameters were accurately determined by 
the Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments 
International, Columbus, OH, USA). This system is composed of a four-chamber open circuit 
indirect calorimeter designed for continuous monitoring of individual rats or mice in each 
chamber (Fig. 17 and 18). Parameters that were obtained during daytime (7 am – 7 pm) and 
nighttime (7 pm – 7 am) for each individual animal were number of meals, meal size (g/meal, 
kcal/meal), meal duration (min, min/meal), accumulated food and calorie intake (g, g/100g body 
weight, kcal, kcal/100g body weight), intermeal interval (min), eating rate (g/min), satiety ratio 
(min/g), drinking activity (mL, mL/100g body weight, mL/time), energy expenditure (kcal/h, 
kcal/h/100g body weight, kcal/h/cm2 body surface), and activity. The high-resolution feeding 
data was generated by monitoring feeding balances every 0.5 sec and air samples were drawn 
from the cages every 5 min for determination of metabolic parameters.  
 
Figure 17 | Photographs of CLAMS. A) The whole CLAMS system, B) a single chamber with 
feeder, feeder balance, re-circulating tube and the lid with activity sensors and tubes for airflow 
regulation, and C) urine beakers underneath the chambers and their balances. 
41 
 
 
Figure 18 | Illustration of the open circuit indirect calorimeter, CLAMS, and how it monitors O2 
consumption and CO2 production in laboratory animals for determination of metabolic parameters. 
 
3.5.3 Gastric Acid Secretion 
For determination of gastric acid secretion, a gastric fistula was implanted into the 
stomach and acid was measured at several time points with and without subcutaneous 
pentagastrin injections (5 M/kg) (Sigma-Aldrich, St. Louis, MO, USA). Pentagastrin is a 
peptide that stimulates secretion of gastric acid [241]. The gastric acid was investigated for pH, 
H+-secretion, and amount (mL). 
 
3.5.4 Gene Expression in the Brain  
Taqman array was performed to analyze expression of specific genes in the brainstem 
(medulla and pons) and hypothalamus. In this method RNA was extracted using RNeasy Lipid 
Tissue Mini Kit (Qiagen, Hilden, Germany) and reversely transcribed for cDNA synthesis using 
random hexamers (Applied Biosystems, Sundbyberg, Sweden) and Superscript III reverse 
transcriptase (Invitrogen Life Technologies, Paisley, UK). This was followed by real-time reverse 
transcription polymerase chain reaction (RT PCR) using TaqMan®Low Density Array (LDA) 
custom-made platforms with TaqMan probe and primer sets for target genes chosen from an 
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online catalogue (Applied Biosystems). Gene expression values were calculated based on the Ct 
method [242]. 
In situ hybridization was used to analyze gene expression in ARC, dorsomedial 
hypothalamic nucleus, and NTS. In this procedure brain samples were snap-frozen and cut in 
slices that were mounted onto poly-L-lysine-coated slides and fixed. Anti-sense radioactive 
riboprobes for target mRNA were generated by PCR and applied to the slides. Slides were then 
dried and exposed to Kodak Biomax MR film, and autoradiographic films were scanned at 600 
dpi and analyzed using Image Pro Plus v.7.0 (Media Cybernetics UK, Marlow, Bucks, UK) 
analysis software (Media Cybernetics UK, Wokingham, UK). Integrated optical density was 
obtained by reference to the 14C microscale.  
RNA sequencing was performed to analyze gene expression in hippocampus. Total RNA 
was isolated from hippocampus and high-throughput cDNA sequencing (RNA-seq) was 
performed at Norwegian Sequencing Centre, Dept. of Medical Genetics, Oslo University 
Hospital, Oslo, Norway, using HiSeq2000 (Illumina, Inc., San Diego, CA, USA). Differential 
expression analysis on the data was performed, where reads for all samples were aligned to the 
rat genome using Bowtie2 (http://bowtie-bio.sourceforge.net/index.shtml) and Tophat2 
(http://tophat.cbcb.umd.edu) and differential expression was calculated using cuffcompare in the 
Cufflinks2 (http://cufflinks.cbcb.umd.edu) package. 
 
3.5.5 In Vivo Electrophysiology 
For determination of electrical and neuronal signals during VNSB in vivo 
electrophysiology was performed. Following placement of the VNSB the animals were mounted 
in a stereotaxic frame and the cranium was exposed. A hole was drilled over the hippocampal 
area (coordinates AP -3.2, ML 2.2) [243], the dura was removed, and a bundle of 4 tetrodes 
(0.005”, Pt/Ir, Fine Wire, California, USA) were lowered into the brain until stable neuronal 
activity was measured. The drill hole was subsequently filled with mineral oil and a surgical 
screw was placed into the scull to serve as ground. During VNSB, data was recorded at 40Khz 
using a Multineuron Acquisition Processor (MAP) recording system (Plexon, Dallas, TX, USA). 
Signals were passed through a unity-gain amplifier (20×), amplified, and filtered with a Plexon 
16-channel preamplifier (PBX3 /16sp-r-G50, 50x amplification, 150-8000 Hz filtered). 
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3.5.6 Plasma Concentrations of Hormones 
 For determination of plasma hormone concentrations in-house radioimmunoassays using 
specific antibodies were performed, except for PYY where a commercial kit was used 
(Rat/mouse PYY RIA kit, Cat. no. RMPYY-68HK, EMD Millipore Corporation, St. Charles, 
MO, USA).  
 
3.5.7 Fasting Blood Glucose  
Blood glucose levels were measured after 12 h fasting by taking a drop of blood from the 
tail vein and analyzing with a glucose meter and test strips (FreeStyle Freedom Lite, Abbot 
Diabetes Care, CA, USA). 
 
3.5.8 Gastric Emptying 
For determination of gastric emptying an acetaminophen absorption assay was performed. 
An oral gavage of 100 mg/kg acetaminophen (Sigma-Aldrich, St. Louis, MO, USA) in 1.5% 
methyl cellulose (Sigma-Aldrich) was administrated before tail vein blood samples (100 l) were 
collected at 15, 30, 45, 60, 90, 120, and 180 min after the oral gavage. Subsequently, plasma 
concentrations of acetaminophen were measured using an acetaminophen kit (Acetaminophen-sl 
assay, ref. 505-30, Sekisui Diagnostics, PE Canada) and spectrophotometer (UV-1800, UV-
Spectrophotometer, Shimadzu, USA). 
 
3.5.9 Fecal Energy Content 
For fecal energy measurement, feces were dried at 60°C for 72 h and subsequently the 
energy density was measured using an adiabatic bomb calorimeter (IKA-Calorimeter C 5000, 
IKA-Werke GmbH & Co. KG, Staufen, Germany).  
 
3.5.10 Western Blot Analysis and Immunohistochemistry 
 Western blot analysis was applied to test GLP-1 antibody specificity. Ileum and 
pancreatic tissues were homogenized in RIPA Buffer and protein concentrations were determined 
by BioRad assay and absorbance measurement at 595 nm. 100 g ileum and pancreatic tissue 
extracts, 1 g GLP-1 peptide (code: 028-11, Phoenix Pharmaceuticals, Inc., CA, USA) and M.M 
(4.0 L Seeblue + 0.5 L Magic Marker, Invitrogen, Carlsbad, CA, USA) were subjected to 1DE 
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separation in 4-12% Novex Bis-Tris gels using MES running buffer (Invitrogen) at 200 V. The 
tissue extracts, the GLP-1 peptide, and M.M were transferred to a Nitrocellulose membrane 
(UltraCruz, SantaCruz Biotechnology, Inc., Dallas, TX, USA) (Blot 30 V, 30 min, 220 mA, room 
temperature). The membrane was dried and blocked in 5% fat-free dry milk in PBS-T and 
incubated overnight in rabbit monoclonal GLP-1 primary antibody (code: 2914-1, Epitomics, 
Inc., CA, USA). After washing in PBS-T, membranes were incubated with secondary antibody 
swine anti-rabbit (1:5000). After washes in PBS-T blots were developed using SuperSignal West 
Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Inc., DE, USA) and scanned in 
a Kodak IS4000R imager (Thermo Fisher Scientific). 
For determination of expression of GLP-1 and insulin in ileum and pancreas, quantitative 
immunohistochemistry was performed. The tissues were fixed in formaldehyde, dehydrated and 
embedded in paraffin. The tissue sections were cut, thawed on superfrost glass slides, 
deparaffinized and then rehydrated. For immunostaining, the tissue sections were blocked with 
normal goat serum and incubated with primary antibodies (GLP-1; dilution: 1:3000, code: H-028-
13, Phoenix Pharmaceuticals, Inc., CA, USA, insulin; dilution: 1:300, code: A0564, 
DakoCytomation, Denmark) and subsequently incubated with secondary antibody. Following this 
the tissue was examined under a microscope (Olympus BX50) with epiflourescence illumination.  
 
3.5.11 Plasma Concentrations of Cytokines 
To determine cytokine concentrations in plasma a multiplex cytokine assay was used (Cat 
no:171-K1002M, Bio-plex Pro Rat Cytokine Th1/Th2 12-plex Panel; Bio-Rad Laboratories, 
Hercules, CA, USA).  
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4. Results   
 
4.1 Body Weight Loss  
Vagus nerve stimulation/blocking (VNSB) for 48 h or at low current (0.5-1 mA) did not 
affect the body weight, but when the current was increased to 2 mA a body weight reduction of 
10% compared to control was reached (p>0.05) (Fig. 19A). However, when VNSB was started at 
2 mA a 10% body weight reduction compared to controls was reached instantly (p<0.05) (Fig. 
19B) (Paper I).  
Subserosal gastric injection of Botox into the whole pyloric antrum in normal chow-fed 
rats induced a body weight reduction of 17% after the 1st injection and a 24% reduction after 2nd 
injection compared to vehicle-treated animals (p<0.05) (Fig. 19C). In diet induced obese (DIO) 
rats, Botox injection induced a 24% and 33% body weight reduction after 1st and 2nd injection, 
respectively, compared to vehicle-treated animals (p<0.05) (Fig. 19D). Sleeve gastrectomy (SG) 
in DIO rats induced a 10% weight loss compared to sham-operated animals (p>0.05), while a 
subsequent Botox injection gave a 25% weight loss compared to vehicle-treated sham-operated 
animals (p<0.05) (Fig. 19E) (Paper I).  
Muscarinic acetylcholine M3 receptor knockout (M3KO) mice weighed 20-30% less than 
their age-matched wild-type (WT) mice throughout the lifespan. At 6, 11, and 15 months of age 
the M3KO mice weighed significantly less than WT (p<0.01), but not at 2 months of age 
(p>0.05) (Fig. 19F) (Paper II).  
Ileal interposition (II) reduced the body weight by 10% 1 week after surgery compared to 
sham-operated animals (p<0.05) (Fig. 19G). Although the body weight remained lower than the 
control group throughout the study, this was not significant. Combining ileal interposition with 
sleeve gastrectomy (II-SG) induced a body weight reduction of about 10% compared to sleeve 
gastrectomy alone (p>0.05) (Fig. 19H). Sleeve gastrectomy alone reduced body weight only 
transiently at 1 week postoperatively by about 10% compared to before surgery (p<0.05) (Fig. 
19I) (Paper III). 
 Gastric bypass (GB) induced a weight loss of about 15% (p<0.05), while duodenal switch 
(DS) caused a weight loss reaching 54% (p<0.05), compared to sham-operated animals (Fig. 19J) 
(Paper IV).  
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Figure 19 | Body weight loss 
in animal models established 
in this thesis. A) VNSB in 
normal chow-fed rats where 
current was gradually 
increased, B) VNSB in 
normal chow-fed rats when 
current was started at 2 mA, 
C) Botox injection in normal 
chow-fed rats, D) Botox 
injection in DIO rats, E) 
Sleeve gastrectomy (SG) in 
DIO rats and Botox injection 
6 weeks later, F) M3KO mice 
at 2, 6, 11, and 15 months of 
age, G) Ileal interposition (II)  
in normal chow-fed rats, H) 
Sleeve gastrectomy added to 
ileal interposition (II-SG) in 
normal chow-fed rats, I) SG 
in normal chow-fed rats, J) 
Gastric bypass (GB) (black) 
and duodenal switch (DS) 
(grey) in normal chow-fed 
rats. 
 
 
 
 
 
 
 
 
 
47 
 
4.2 Key Results Regarding Mechanisms  
4.2.1 Paper I  
VNSB altered hypothalamic gene expression after 48 h and in vivo electrophysiology 
confirmed the parameters used, showing that the stimulation/blocking signals could reach the 
brain. Basal and pentagastrin-stimulated gastric acid secretions were not affected by VNSB.  
Long-term VNSB reduced body weight and food intake at high current, while analysis of 
gene expression in the hypothalamus showed changes with a drive for increased food intake and 
reduced energy expenditure (Fig. 20A). Gene expression in brainstem and hippocampus on the 
other hand were indicative of appetite suppression, compatible with the phenotype of these 
animals (Fig. 20B and C). Gut hormones were unchanged after VNSB both in short-term and 
long-term. 
 
Figure 20 | Gene expression in the brain after long-term VNSB (2 mA). Effect of VNSB on mRNA 
expression in A) hypothalamus, B) brainstem, and C) hippocampus. *, **, ***:p<0.05, 0.01, 0.001 
between sham-VNSB and VNSB. Cckbr: CCKB/2 receptor, Foxa2: forkhead box protein A2, Insr: insulin 
receptor, Mc4r: melanocortin 4 receptor, Lepr: leptin receptor, Il1b: interleukin-1ȕ, Tnf: tumor necrosis 
factor, Tgfb1: transforming growth factor ȕ1. 
 
Subserosal Botox injection in the whole area of the pyloric antrum efficiently induced  
weight loss in normal chow-fed, DIO rats, and DIO rats receiving SG (Fig. 19C, D, and E). The 
weight loss was associated with reduced food intake and blood glucose levels and increased 
resting (daytime) and active (nighttime) energy expenditure (Fig. 21A). Interestingly, 
hypothalamic gene expression after injection showed changes with a drive for increased food 
intake and reduced energy expenditure (Fig. 21B).  
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Figure 21 | Effect of Botox injection in normal chow-fed rats on energy expenditure and 
hypothalamic gene expression. Effect of Botox injection on A) 24 h energy expenditure and B) 
hypothalamic mRNA expression at 8 weeks. *, **:p<0.05, 0.01 between vehicle (control) and Botox. 
 
Botox injection reduced plasma levels of CCK, gastrin, and PYY. There were no clinical 
signs of gastroparesis and gastric emptying was not delayed after Botox injection (Fig. 22).  
 
 
Figure 22 | The effect of Botox injection on gastric emptying in DIO rats. Gastric emptying was 
measured before and 1, 3, and 5 weeks after Botox injection. Note: no significant difference. 
 
4.2.2 Paper II 
Muscarinic acetylcholine M3 receptor knockout (M3KO) mice had a lean phenotype, but 
unchanged total (24 h) food intake. Lacking the M3 receptor induced an altered eating behavior, 
with tendency for reduced food intake during daytime and increased food intake during nighttime 
compared to age-matched wild-type (WT). However, cumulative food intake adjusted for body 
weight (g/100g body weight) was significantly higher in M3KO mice than WT at 15 months of 
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age (p<0.01). The M3KO mice had increased resting and active energy expenditure throughout 
the whole lifespan (Fig. 23A). Hypothalamic mRNA expression showed changes with a drive for 
increased food intake and reduced energy expenditure (Fig. 23B). Respiratory exchange ratio 
(RER) was increased until over 1.0 during both daytime and nighttime in M3KO mice. 
 
Figure 23 | Energy expenditure and hypothalamic gene expression in WT and M3KO mice. A) Energy 
expenditure during daytime and nighttime of WT and M3KO mice at 6, 11, and 15 months of age. B) 
Hypothalamic mRNA expression at 15 months of age. **, ***: p<0.01, 0.001 between WT and M3KO. 
MCH: melanin-concentrating hormone. 
 
4.2.3 Paper III 
Ileal interposition (II) reduced body weight and fat compartment transiently, but did not 
reduce food intake. II increased food intake and altered the eating cycle, with fewer, but larger 
(g/meal) and longer lasting meals (min). After II, respiratory exchange ratio (RER) was 
significantly increased until over 1.0, indicating increased use of carbohydrates as predominant 
fuel for cellular respiration. Adding sleeve gastrectomy (SG) induced a marginal weight loss, and 
fat compartment was lower in rats subjected to II–SG than those subjected to SG alone, albeit 
insignificantly. SG alone reduced body weight transiently (p<0.05 at 1 week) and increased food 
intake and reduced rate of eating (g/min) compared to baseline. II-SG increased both food intake 
and meal duration (min), while it reduced rate of eating (g/min), and resting and active energy 
expenditure. The combination of II and SG increased the expression of GLP-1 in the interposed 
ileum and in pancreatic Į-cells, the latter was also found after SG alone (Fig. 24). 
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Figure 24 | Immunofluorescence histomicrographs of GLP-1 (green) and insulin (red) in rat pancreatic 
islets. GLP-1 and insulin in A) non-operated normal rat, B) SG-operated rat nine weeks after SG, and in 
C) II-SG-operated rats nine weeks after SG with II. 
 
4.2.4 Paper IV  
Gastric bypass (GB) reduced body weight, but was not associated with reduced food 
intake, however with increased active energy expenditure 3 weeks after surgery and increased 
resting energy expenditure 14 weeks after surgery (Fig. 25A). Duodenal switch (DS) reduced 
body weight and food intake. After surgery, eating behavior was altered with reduced meal size 
(g/meal) and rate of eating (g/min). In addition, resting energy expenditure was increased shortly 
(2 weeks) after surgery and both resting and active energy expenditure were increased 8 weeks 
after surgery (Fig. 25B). DS also induced diarrhea and malabsorption.  
 
Figure 25 | Energy expenditure after GB and DS and corresponding sham-operated controls (laparotomy, 
LAP). Daytime and nighttime energy expenditure A) 14 weeks after GB and B) 8 weeks after DS. **, 
***:p<0.01, 0.001 between LAPGB vs. GB or LAPDS vs. DS. 
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5. Discussion 
 
5.1 Animal Models of Bariatric Surgery 
In order to achieve the principle objective of the study, it is important to use the right 
animal models in the right experimental settings (Fig. 1). In this field of research, food intake has 
often been quantified by measuring left-over chow in feeders. This is highly inaccurate due to 
spilling and provides no data regarding eating behavior. In this thesis the state-of-the art 
Comprehensive Laboratory Animal Monitoring System (CLAMS) has been used to accurately 
determine food intake, eating behavior, and metabolic parameters in the different animal models. 
Surgical procedures have been performed according to the rat anatomy, where ileal interposition 
was performed by interposing only the ileum (2.5-3.5 cm) and gastric bypass was performed 
without the Roux-en-Y reconstruction as this is not necessary in rats. 
Several animal studies of subdiaphragmatic vagus nerve stimulation for obesity treatment 
have been performed. However, in most of these previous studies, the stimulation was applied 
only to the left vagal nerve with constant voltage stimulation that would ultimately reduce the 
current at the nerve as adhesion and resistance builds up [244-251]. In this thesis we 
stimulated/blocked both vagal branches and used constant current stimulation, ensuring correct 
stimulation of the nerve even as adhesion and resistance were formed around the electrodes. 
Several of the previous studies reported reduced body weight gain and food intake after vagus 
nerve stimulation, but these results were of low quality due to big variations, no presentations of 
standard deviation (SD) or SEM in the presented figures and use of misleading scales [244-251]. 
However, one report showed reduced weight gain in obese minipigs after subdiaphragmatic 
vagus nerve stimulation of both vagal branches using constant current stimulation [252]. To our 
knowledge, our study was the first to show the weight loss after subdiaphragmatic vagus nerve 
stimulation in animals and to describe the effects on expression of energy balance-regulating 
genes in hypothalamus, brainstem, and hippocampus. So far, human studies of vagus nerve 
stimulation for obesity have been inconclusive and they have all been performed by the same 
financial sponsor who produces the stimulators [7,8,253]. Our data suggest that it is beneficial to 
start stimulation at high current, rather than increasing it gradually, in order to achieve the body 
weight loss.  
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Previously, animal studies of Botox reported that gastric antral Botox injections induced 
8-14% weight loss, however the studies were poor due to big variations and no SD or SEM in the 
presented figures [143,238]. Some clinical studies showed weight loss [254-258], while others 
observed no effect on body weight after Botox injection into the gastric wall [9,259-262]. In all 
of these previous studies, Botox injection was performed through point injections in the muscular 
layer of the antrum. However, in our study we repeatedly showed greater body weight loss (about 
20%) with little variations. In our study, subserosal gastric Botox injection into the whole pyloric 
antrum was highly efficient at reducing body weight and food intake in both normal chow-fed 
and DIO rats, even more than sleeve gastrectomy (SG). We also showed that Botox injection had 
higher efficacy than SG at reducing blood glucose levels. Thus, we suggest that Botox injection 
can be performed in patients who regain weight after SG surgery. These results were 
accomplished through subserosal injection of Botox into the whole area of pyloric antrum 
through one injection. As the goal is to induce maximal diffusion of Botox, we added methylene 
blue (1%) to the solution to verify that we successfully injected Botox to the whole area of 
antrum. In addition, we found that Botox injection increased energy expenditure. To our 
knowledge, the effects of Botox injection on energy expenditure and gene expression in 
hypothalamus and brainstem have not been previously reported.  
In several animal and clinical studies of Botox injection for obesity treatment gastric 
emptying has been investigated. Some found delayed emptying [9,238,256-258], while others 
found no effect [259,260,262,263]. However, it should be noticed that in the clinical studies there 
were great differences with regards to selection of patients, doses of Botox, methods of 
administration, and evaluation of gastric emptying. Unexpectedly, we found no effect of Botox 
injection on gastric emptying and no gastroparesis after Botox injection, despite of reducing food 
intake. This suggests that Botox injection-induced weight loss is not due to delayed gastric 
emptying. This is confirmed by clinical observations where reduced body weight have not been 
associated with delayed gastric emptying [9,260,262].   
Our results indicate that in order to improve the clinical trials of Botox injection for 
obesity treatment, injection should be performed in subserosa or submucosa in order to allow for 
maximal diffusion of Botox into the whole area of pyloric antrum. To achieve this, adding 
methylene blue or other colored solutions to the Botox may be beneficial.  
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We found that the lean phenotype of M3KO mice was associated with increased energy 
expenditure, but without effect on total (24 h) food intake. At 2 months of age there was no 
significant difference between M3KO mice and WT with regards to body weight. This, together 
with findings of equal body weights at birth and young age in previous studies, suggest that the 
lean phenotype develops as the mice grow [146,147]. To our knowledge, we were the first to 
report unchanged total food intake, increased cumulative food intake, altered eating pattern and 
increased RER in this mouse model. This was in contrast to previous studies where food intake 
was found to be reduced and RER to be unaltered [146,147]. Taken together, we suggest that the 
M3 receptor can be a good target in obesity treatments, possibly by a CNS antagonist and that 
this may affect energy expenditure rather than food intake.  
In contrast to humans where ileum constitutes about 50% of the small intestine, the ileum 
in rats constitutes only 2% of the small intestine, i.e., 2.5 - 3.5 cm in length [264,265]. In many 
previous studies of ileal interposition (II) using rats, a segment of 8-20 cm in length, dissected 1-
20 cm from the cecum was interposed [171-174,176-179,187,266-280]. This means that in those 
studies, the ileum was in fact not interposed. In this thesis we have used, for the first time, an 
anatomically correct rat model of ileal interposition. The previous studies of “ileal interposition” 
in rats were inconclusive with regards to body weight and food intake, with some reporting 
reduction [176-178,187,267-269,272-275,278] and others reporting no change [172-
174,179,266,270,271,276,277,280-282]. This could be due to the wrong models, big variations in 
surgical procedure (length of “ileal” segment and position), animal strains, inaccurate methods 
for food intake determination, and differences in follow-up time. Surprisingly, we found no effect 
of II on body weight, but increased food intake after the procedure. The combination of II and SG 
(II-SG) did not induce a significant weight loss neither. These results suggest that II is not 
suitable as a bariatric surgery, neither is II-SG. This was in contrast to previous reports of “ileal 
interposition”, where II-SG in animals and humans have reduced body weight 
[10,187,195,197,198,282-285]. For the first time, we reported increased GLP-1 in pancreatic Į-
cells after SG and II-SG. As II-SG increased GLP-1 expression in both the interposed ileum and 
pancreatic islets we propose this to have more clinical relevance than II or SG alone as metabolic 
surgery.  
Sleeve gastrectomy is increasingly performed due to its safety and efficiency. In contrast 
to most animal studies [184-192,224,229,286-288] we found no significant body weight or food 
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intake reduction after SG in neither normal chow-fed or DIO rats, which was in agreement with 
other studies [82,233]. Several studies reported increased GLP-1 secretion after SG and it was 
hypothesized to be caused by increased gastric emptying [185-192,286]. In contrast to our 
findings, a study reported increased GLP-1 in ileum after SG [187]. To our knowledge, we were 
the first to report increased GLP-1 levels in Į-cells in pancreatic islets after SG.  
In this thesis gastric bypass (GB) was performed without the Roux-en-y reconstruction 
according to the rat anatomy [289]. Gastric bypass is believed to restrict food intake and induce 
malabsorption, however, in our study gastric bypass did not reduce food intake or cause 
malabsorption. This was in contrast with some studies [225], but supported by others 
[221,239,290]. We found that gastric bypass reduced body weight due to increased energy 
expenditure, which was in line with some previous animal and human studies [219,221,229,291-
294] but not with others [295,296].   
Similar to gastric bypass, duodenal switch is believed to decrease food intake and induce 
malabsorption, which was confirmed in this thesis. Duodenal switch altered eating behavior by 
reducing meal size (g/meal) and rate of eating (g/min), as previously described [82]. In addition, 
duodenal switch increased resting and active energy expenditure. Consistent with clinical reports, 
we found that duodenal switch induced greater weight reduction than gastric bypass 
[11,297,298].  
From the results of this thesis, the most efficient procedures for weight loss are duodenal 
switch, subserosal gastric Botox injection and knockout of the muscarinic acetylcholine M3 
receptor (Fig. 19C, D, E, F, and J).  
 
5.2 Possible Underlying Mechanisms 
In order to provide strong external evidence for the development of evidence-based 
medicine, animal research on mechanisms and preclinical trials on the efficacy and safety are of 
importance (Fig. 2).  
The results of this thesis suggest that the mechanism behind weight loss and reduced food 
intake after VNSB is stimulation of vagal afferent nerve fibers and at the same time blocking of 
vagal efferent nerve fibers. The effects of VNSB after 48 h were seen only in the brain, 
suggesting that the mechanism is by direct alteration of neuropeptides in the brain and subsequent 
altered body weight and eating behavior. Furthermore, VNSB activates afferent pathways to the 
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brainstem and hippocampus leading to increased expression of anorexigenic neuropeptides, 
further leading to reduced food intake and body weight. The increased expression of orexigenic 
neuropeptides in hypothalamus is likely to be compensatory to the gene expression in the 
brainstem and the weight loss. This implies that the brainstem might be more important in eating 
behavior regulation than hypothalamus after vagal manipulation.  
The results of this thesis suggest that the reduced body weight and food intake after 
gastric antral Botox injection into the whole pyloric antrum is unlikely due to delayed gastric 
emptying rather than local blockade of efferent vagal fibers, as also seen in VNSB. Since the 
effects of Botox on food intake and brain gene expression were not seen shortly after injection, 
the altered expression of neuropeptides in the brain could be secondary to the body weight loss. 
Thus, either VNSB or Botox injection leads to reduced food intake and body weight, causing 
hypothalamic neuropeptides and gut hormones to compensate. 
Lack of the muscarinic acetylcholine M3 receptor impairs the action of acetylcholine in 
the stomach as the M3 receptor is the predominant subreceptor in this location. Detailed 
phenotyping of M3KO mice suggests that the lean phenotype of this animal model is caused by 
increased energy expenditure rather than reduced food intake. In contrast to the phenotype, the 
hypothalamic gene expression of M3KO mice showed a drive for increased food intake and 
reduced energy expenditure. Again, this suggests that the hypothalamic orexigenic neuropeptides 
probably compensated for the lean phenotype. This was supported by the increased cumulative 
food intake. It should be noticed that the compensatory mechanism was without effect on energy 
expenditure. Thus, the net effect of lack of M3 receptor on body weight is a lean phenotype. 
 The results of this thesis indicate that the metabolic beneficial effects after ileal 
interposition is caused by increased levels of GLP-1 in ileum and that sleeve gastrectomy has the 
beneficial effect through increasing GLP-1 in pancreatic Į-cells. The combination of these 
procedures increased GLP-1 at both locations and would therefore be beneficial for glucose 
homeostasis. Due to the short half-life of GLP-1 it is likely that the action of GLP-1 in the ileum 
is through activation of GLP-1 receptors on vagal afferents, leading to vagal efferent signals to 
pancreatic ȕ–cells, increasing insulin secretion [299]. The increased RER after ileal interposition 
could be caused by increased food intake and more carbohydrates available. However it might 
also be linked to the increased GLP-1, causing higher insulin, resulting in an increased cellular 
uptake of glucose and thereby increasing the use of carbohydrates as fuel for cellular respiration. 
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It should be noticed that ileal interposition did not reduce food intake even though GLP-1 
secretion was increased.        
The results of this thesis show that gastric bypass reduced body weight by increasing 
energy expenditure, while duodenal switch induced a greater weight loss by reducing food intake, 
altering eating behavior, increasing energy expenditure, and causing malabsorption. Obesity is 
associated with a state of low-grade, chronic inflammation, however neither gastric bypass or  
duodenal switch altered plasma concentrations of cytokines [300]. 
Interestingly, while the animal models of VNSB, Botox injection, and knockout of 
muscarinic acetylcholine M3 receptor reduced food intake and body weight, the expression of 
energy-balance regulating peptides in the hypothalamus showed a drive for increased food intake. 
This indicates that gene expression in hypothalamus, although regarded as a key regulatory brain 
region in food intake regulation, might not be predictive of the phenotype, but could represent a 
compensatory mechanism. After VNSB, expression of energy-balance regulating peptides in the 
brainstem and hippocampus was compatible with a drive for reduced food intake, consistent with 
the phenotype observed. Based on this, we propose that the brainstem may be more important in 
the regulation of food intake than hypothalamus in the context of the brain-vagus nerve-gut axis.  
Interestingly, the bariatric and metabolic surgeries studied in this thesis also affects the 
vagus nerve by inducing a remodeling of the gastrointestinal tract that alters the pattern and 
activation of this nerve by hormones and nutrients [301]. 
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6. Conclusions 
 
In this thesis, the research hypotheses have been generated from clinical practice and 
research, the underlying mechanisms of bariatric surgery have been studied in animal models, 
and the potential targets for new, minimally invasive obesity treatments have been proposed and 
tested in animal models (Fig. 1).  
Throughout this thesis the brain-vagus nerve-gut axis has been explored as a target for new, 
minimally invasive obesity treatments, including vagus nerve stimulation/blocking (VNSB), 
gastric Botox injections, and muscarinic acetylcholine M3 receptor inhibition. The underlying 
mechanisms behind these new treatments and of currently used bariatric and metabolic surgeries 
such as gastric bypass, duodenal switch, sleeve gastrectomy, and ileal interposition have been 
studied. By this manner, the results from the translational research conducted in this thesis has 
improved our understanding of the physiological mechanisms of bariatric surgery and discovered 
new, minimally invasive obesity treatments.  
In this thesis it was found that blocking the gastric vagus nerve, by VNSB or Botox injection, 
can be used as non- or minimally invasive obesity treatment, and muscarinic acetylcholine M3 
receptor antagonists might have potential as obesity treatment. Also, combining ileal interposition 
and sleeve gastrectomy holds potential as a metabolic surgery and duodenal switch induces 
greater body weight loss than gastric bypass through different mechanisms. Figure 26 illustrates  
the mechanisms and conclusions generated from this thesis.  
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Figure 26 |  Summary of the findings of this thesis. The animal models that have been established in this 
thesis include muscarinic acetylcholine M3 receptor knockout (M3KO) mice, vagus nerve 
stimulation/blocking (VNSB), gastric bypass (GB), sleeve gastrectomy (SG), Botox injection, duodenal 
switch (DS), and ileal interposition (II). The targets of the brain-vagus nerve-gut axis have been studied 
with respect to expression of orexigenic and anorexigenic neuropeptides in hypothalamus, brainstem and 
hippocampus. The possible underlying physiological mechanisms have been suggested: 1) increased 
energy expenditure after the ablation of M3 receptor, 2) reduced food intake, increased anorexigenic 
neuropeptides in brainstem and hippocampus, and increased hypothalamic orexigenic neuropeptides after 
VNSB, 3) increased energy expenditure after GB, 4) increased pancreatic GLP-1 after SG, 5) reduced 
food intake, increased energy expenditure and hypothalamic orexigenic neuropeptides after Botox 
injection, 6) reduced food intake, increased energy expenditure and malabsorption after DS, and 7) 
increased ileal GLP-1 after II. 
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7. Future Perspectives 
 
I. This thesis provides strong basis for designing better clinical trials of VNSB (or so-called 
“VBLOC”) and Botox treatment for obesity. In fact, based on the findings in this thesis 
(Paper I), a clinical phase II trial of gastric antral Botox injection for obesity treatment has 
been initiated (REK ref no. 2013/1597, EudraCT no. 2012-004381-18).  
II. The results of this thesis also suggest that muscarinic acetylcholine M3 receptor 
antagonists could have potential as obesity treatment. It will be of interest to further 
investigate whether peripheral or central specific antagonists has the best effect.  
III. Based on this thesis, the pancreatic GLP-1 could play an important role in diabetes and 
diabetes remission, opening up for more research in this area.  
IV. The findings that the different bariatric surgeries have different mechanisms highlight the 
possibility of personalized obesity treatment in the future.   
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Abstract 
Objective: The vagus nerve has a central role in the regulation of energy intake and 
expenditure, which makes it an ideal target for development of new obesity treatments. The 
aim of the present study was to explore whether blocking of the gastric vagus nerve can be a 
new minimally invasive obesity treatment. Methods: Blocking of the gastric vagus nerve was 
achieved either by an electrical device surgically implanted around gastric vagal trunks (vagus 
nerve stimulation/blocking, VNSB) or by botulinum toxin type A (Botox) injection into the 
gastric wall in the region of antrum in rats. The effect on body weight, food intake, eating 
behavior, metabolic parameters, gut hormone concentrations, gastric acid secretion, and 
expression of candidate energy balance-regulating genes in the hypothalamus and brainstem 
were determined. Results: VNSB reduced body weight and food intake by 10% and 30%, 
respectively. Botox injection reduced body weight and food intake by 17% and 15% in 
normal chow-fed rats and by 24% and 50% in diet induced obese rats, respectively. Both 
procedures affected appetite-regulating neuropeptides mainly in the brainstem. Conclusion: 
Blocking the gastric vagus nerve by VNSB or Botox injection can be new, non-invasive 
obesity treatments.  
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Introduction 
The gut-brain axis plays an important role in the pathogenesis of obesity. Nutritional 
and metabolically relevant information is conveyed to the brain by gut peptide hormones and 
the vagus nerve (1). The vagus nerve responds to peptides and hormones, as well as 
mechanical and chemical stimuli from the gastrointestinal tract and transmits satiety signals to 
sites in the central nervous system that regulate ingestive behavior (2, 3). In addition, the 
vagus nerve regulates gastric acid secretion and pancreatic endocrine function (4, 5). Through 
the nucleus of the solitary tract (NTS) in the brainstem, afferent vagal signals may reach 
several parts of the brain including the parabrachial nucleus, reticular formation, 
hippocampus, amygdala, and hypothalamus (6). The hypothalamus is regarded as a key 
regulatory component of a central network for food intake where orexigenic neuropeptide Y 
(NPY) and agouti-related peptide (AgRP) neurons and anorexigenic pro-opiomelanocortin 
(POMC) and cocaine- and amphetamine-regulated transcript (CART) neurons are thought to 
play a central role (2). Nevertheless, the brainstem is strongly involved in the gut-brain axis, 
particularly via the vagus nerve in regulation of food intake and body weight (7). The central 
role of the vagus in the regulation of food intake and energy expenditure makes it an ideal 
target for the development of new less or non-invasive procedures to treat obesity.  
The aim of this study was to target the gastric vagus nerve in order to create less or 
non-invasive obesity therapies. To this end, we tested whether blocking the vagus nerve by an 
electrical device (vagus nerve stimulation/blocking, VNSB) (Figure 1A) or Botox injection 
(Figure 3A) affected body weight, food intake, eating behavior, metabolic parameters, gut 
hormone concentrations, gastric acid secretion, and the expression profile of candidate energy 
balance-regulating genes in the hypothalamus and brainstem.  
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Materials and Methods 
Animals and experimental designs 
Adult male Sprague-Dawley rats were purchased from Taconic (Ejby, Denmark) and 
Janvier Labs (Le Genest-Saint-Isle, France). They had free access to tap water and standard 
rat pellet food (RM1 811004, Scanbur BK AS, Sweden) or pelleted high fat diet (D12492, 
Research Diets, Inc., NJ, USA). The standard rat diet consisted of 2.57 kcal/g containing 75% 
carbohydrates, 7.5% fat and 17.5% protein, while the high fat diet consisted of 5.24 kcal/g 
containing 20% carbohydrates, 60% fat and 20% protein in terms of kcal. For diet induced 
obesity, rats were fed a mixed normal and high fat diet (50:50) for two weeks, starting when 
they were 5 weeks old. Subsequently, the normal diet was removed and rats continued to feed 
on high fat diet until euthanization. Adult female Long Evan rats were obtained at Norwegian 
University of Science and Technology, Trondheim, Norway. In the present study, all animals 
were housed three to four rats per individually ventilated cage on a wood chip bedding with a 
12-hour light/dark cycle, a room temperature of 22ºC, and 40-60% relative humidity. The 
standard housing conditions were specific pathogen free and in agreement with Federation of 
European Laboratory Animal Science Association recommendations. The study was approved 
by the Norwegian National Animal Research Authority. 
In all studies regarding eating behaviour the animals were acclimatized to the 
Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments 
International, Columbus, OH, USA) for 24h before data collection. At data collection the 
animals were kept in CLAMS for 48h and data from the last 24h were used for analysis. 
Before CLAMS the rats were habituated to their normal food as powder for three days, as the 
food in CLAMS is in powder form. Body weight development was followed three times per 
week throughout the study period. 
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VNSB 
In the short-term VNSB study, the animals had implanted gastric fistula and were 
acclimatized to Bollman cages for 3 hours on three separate occasions before and after VNSB 
and gastric fistula implantation. After gastric acid output measurement the stimulation was 
turned off. Three days after, rats received VNSB (2.0 mA, 30 Hz, 500 s, 30 s ON and 5 min 
OFF) for 48h while eating behavior and metabolic parameters were measured in CLAMS. 
The control group had the same implantations without stimulation. Immediately after 48h of 
VNSB the rats were euthanized and brain samples were collected for in situ hybridization, and 
plasma was collected for radioimmunoassay.  
In the long-term VNSB study, the stimulation was started 4 weeks after VNSB 
implantation and was constantly ON while the current (mA) was gradually increased. Each rat 
was placed in CLAMS at four time points for measurement of eating behavior and metabolic 
parameters; 3 weeks after VNSB implantation (before stimulation, baseline), at 0.5 mA, 1.0 
mA and 2.0 mA stimulation (30 Hz, 500 s, 30 s ON and 5 min OFF). The control group had 
the same implantation without stimulation. The duration of stimulation for each rat was 6-8 
weeks. At euthanization brain samples were taken for Taqman array analysis and RNA 
sequencing, and plasma was collected for radioimmunoassay. 
Smaller VNSB devices, the so-called -VNSB, were developed for use in Long Evan 
rats. The stimulation was continuously on at 2.0 mA, 30 Hz, 500 s, 30 s ON, and 5 min OFF 
for 2 weeks.  
 
In vivo electrophysiology 
In vivo electrophysiology in the hippocampus during VNSB (2.0 mA, 30 Hz, 500 s, 
30 s ON and 5 min OFF) was performed as an acute experiment. 
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Botulinum toxin type A injection 
Normal chow-fed rats received Botox or saline injection on three occasions, and were 
subjected to CLAMS before injection, 2 weeks after 1st injection, and 1 and 2 weeks after 2nd 
injection. A separate set of rats received one Botox/saline injection and were euthanized after 
48h. Brain samples from both long-term (8 weeks) and short-term (48h) Botox treatment were 
collected for in situ hybridization, and plasma collected for radioimmunoassay. 
High fat diet induced obese (DIO) rats received Botox/saline injection on two 
occasions and were subjected to CLAMS before injection, 1 and 3 weeks after 1st injection, 
and 1 week after 2nd injection. Fasting blood glucose was measured 8 weeks after 1st injection. 
DIO rats received sleeve gastrectomy (DIO-SG) or sham surgery. The rats were 
subjected to CLAMS before and 1 week after surgery. Fasting blood glucose levels were 
measured 3 weeks after surgery. Six weeks after SG the rats were treated with Botox/saline 
injection. The rats were then subjected to CLAMS 1 week after injection and fasting blood 
glucose levels were measured 2 weeks after injection. 
  
Gastric emptying in normal chow-fed and DIO rats after botulinum toxin type A 
Both normal chow-fed and DIO rats received Botox/saline injection in antrum. Gastric 
emptying was measured by an acetaminophen absorption assay before injection, 3 days, and 
1, 2, 3, and 5 weeks after injection. 
 
Animal surgery 
All surgeries were performed under general anesthesia with isoflurane. Atropin (0.04 
mg/kg) (Nycomed Pharma AS, Asker, Norway) was given subcutaneously 20 min before 
anesthesia for VNSB and -VNSB implantation. Buprenorphine (0.05 mg/kg) (Schering-
Plough Europe, Brussels, Belgium) was injected subcutaneously immediately after surgery in 
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all animals, and one day postoperatively when needed. Physiological saline (10 mL of 0.9% 
NaCl) was given subcutaneously postoperatively. 
 
VNSB  
VNSB implantation was performed through a midline abdominal incision. The 
subdiaphragmatic truncal vagus nerve was dissected from the esophagus and two electrodes 
(Lead Model 302, Cyberonics, Houston, TX, USA) were wrapped around anterior and 
posterior vagus nerve of the gastric branch. The cathode was placed proximally and the anode 
distally. During stimulation the cathode induced depolarization (stimulation of the afferent 
fibers), while the distal anode hyperpolarized the membrane and imposed an anodic block on 
the efferent fibers (Figure 1B) (8). The wire from the electrodes was attached to fat tissue 
around the stomach and to the muscular layer using 6-0 and 4-0 absorbable sutures (Vicryl, 
Ethicon Inc., Sommerville, NJ, USA), respectively. On the back of the rat a subcutaneous 
pocket for the stimulator (model 102 Pulse Generator, Cyberonics, Houston, TX) was made 
and here it was connected to the wire. The abdomen was closed in two layers using 4-0 
absorbable sutures and the back was closed using the same sutures (Ethicon). The control and 
VNSB rats received the same procedure. Implantation of the -VNSB device followed the 
same procedure. In the gastric acid secretion study a gastric fistula was in addition implanted 
in the stomach. Before this procedure the animals were fasted overnight.  
 
Botulinum toxin type A injection 
Botulinum toxin type A 100 U (Botox Allergan Cooperation, Irvine, CA, USA) was 
diluted in 0.9% cold saline and 1% methylene blue (Sigma-Aldrich, St. Louis, MO, USA) (for 
visualization) achieving a concentration of 40 U Botox/mL. Total volume injected into antrum 
of each rat was 0.5 mL (20U/rat). The control rats were injected with 0.5 mL 0.9% saline and 
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1% methylene blue. Following a short median laparotomy, the stomach was exposed, and 
antrum isolated. Botox was injected subserosally to both anterior and posterior side of the 
antrum with a 30 G needle. In contrast to previous studies, this was performed through one 
injection and allowed for the fluid to spread over the whole area of the pyloric antrum. 
Abdomen was closed in two layers using 4-0 absorbable sutures (Ethicon).  
 
Sleeve gastrectomy 
Animals were fasted overnight before surgery. The surgery was performed through a 
midline abdominal incision. The stomach was clamped along the greater curvature from the 
antrum to the fundus across the forestomach and glandular stomach using staples (Endo GIA, 
Articulating Reload with Tri-Staple™ Technology, 45 mm, EGIA45AVM, Covidien™, 
Dublin, Ireland) and 70% of the stomach was removed. Hemostasis and staple-line integrity 
were checked, and additional stitches were applied when necessary. The abdominal wall was 
closed in two layers with 4-0 absorbable sutures (Ethicon). 
 
Supplementary Information 
Determinations of eating behaviour and metabolic parameters, gastric acid secretion, 
taqman array, in situ hybridization, RNA sequencing, in vivo electrophysiology, 
radioimmunoassay, blood glucose levels and gastric emptying were performed using standard 
procedures described in the Supplementary Information.  
 
Statistical Analysis 
The results are expressed as mean ± SEM. Statistical comparisons were performed 
using independent t-test between the surgical groups. ANCOVA with Sidak test was 
performed for energy expenditure statistics in the VNSB studies. ANOVA with Tukey’s test 
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was performed in the VNSB study and the DIO-SG study to determine eating behavior and 
metabolic parameters. A P-value of <0.05 (two tailed) was considered statistically significant. 
The data analysis was performed in SPSS version 15.0 and 20.0. 
 
Results 
In vivo electrophysiology tetrodes recorded stimulation-induced activity in the brain, 
confirming the stimulation parameters used by VNSB (Figure 1C). In response to short-term 
VNSB (48h at 2.0 mA) gene expression of NPY and AgRP in the arcuate nucleus (ARC) of 
hypothalamus, as well as NPY gene expression in dorsomedial hypothalamic nucleus (DMH) 
were up-regulated. However, there were no changes in body weight, food intake, eating 
behavior, energy expenditure, gene expression in the brainstem, plasma concentrations of gut 
hormones, or gastric acid secretion (Figure S1).  
Next, we performed a long-term VNSB (6-8 weeks) experiment in which the electrical 
stimulation current was gradually increased (0.5 mA - 2.0 mA) over the time period. Initially, 
the body weight was unaffected, but as the current was increased, the body weight and food 
intake (g) were reduced, eventually reaching reductions of 10% (P>0.05) and 30% (P<0.05), 
respectively (Figure 2A, B). Energy expenditure (kcal/h/100g body weight) was reduced 
compared to baseline (Figure S2B). In another study, where the stimulation was started at 2.0 
mA, a 10% body weight reduction was achieved within 1 week (P<0.05) (Figure 2A). In the 
long-term VNSB experiment there was significant increase in hypothalamic gene expression 
of NPY and forkhead box protein a2 (Foxa2), a decrease for CCKb receptor and a tendency 
for decreased expression of the melanocortin 4 receptor (MC4R), and insulin receptor (IR) 
(Figure 2C). Plasma concentrations of cholecystokinin (CCK), gastrin, glucagon, glucagon-
like peptide-1 (GLP-1), and peptide YY (PYY) were unchanged (Figure 2D). Since the 
brainstem is the first target for vagal afferent fibers in the central nervous system, we 
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examined this brain region and found that gene expression of leptin- and CCKb -receptors, 
and interleukin-1ȕ, tumor necrosis factor, and transforming growth factor ȕ1 was increased 
(P<0.05) (Figure 2E), changes compatible with an anorexigenic drive in response to VNSB. 
Given that afferent signals from NTS to hippocampus could be activated by VNSB (9), we 
examined gene expression in the hippocampus and found increased expression of CCK, 
somatostatin, and tyrosine hydroxylase (crucial for production of dopamine) (P<0.05) (Figure 
2F).  
We next examined the effects of blocking the gastric vagus nerve using Botox 
injection into the gastric wall in the region of the antrum. This blocks the release of 
acetylcholine, by cleaving the SNARE protein SNAP-25 (10). At 48h post injection, body 
weight, expression of energy balance-linked genes in hypothalamus and brainstem, and 
concentrations of gut hormones were unchanged (Figure S3). However, in a long-term study 
of Botox, body weight was reduced by 17% at 3 weeks post injection, which was associated 
with reduced food intake, and increased satiety ratio (min/g) (P<0.05). When the rats started 
to regain weight after the 1st Botox injection (as the effectiveness of Botox declined), a second 
injection of Botox was performed 4 weeks after 1st injection. A further body weight loss 
(25%) and reduction in food intake were obtained (P<0.05) (Figure 3B, C). Furthermore, 
energy expenditure was increased (P<0.01) (Figure 3D). Hypothalamic gene expression for 
NPY was increased, POMC was decreased, and AgRP had a tendency to be increased (Figure 
3E), and plasma concentrations of CCK, gastrin, and PYY were reduced (Figure 3F).  
To further validate the efficiency and potential of gastric Botox injection as a non-
invasive therapy for obesity, we treated high fat diet induced obese (DIO) rats with Botox 
injection. At injection DIO rats had a 22% higher body weight than age-matched normal 
chow-fed rats. The Botox treatment, injected 6 weeks apart, successfully led to body weight 
loss, i.e., 24% and 33% reduction after first and second administration, respectively (P<0.05) 
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(Figure 4A). This was associated with decreased food intake (Figure 4B and Figure S4B) and 
increased energy expenditure. Fasting blood glucose levels were reduced 8 weeks after Botox 
injection (P<0.001) (Figure S5A). 
Sleeve gastrectomy (SG) is a commonly used bariatric surgery (11). We treated DIO 
rats with SG and found that the body weight and food intake were reduced by 10% and 20%, 
respectively (P>0.05). Fasting blood glucose levels were not altered (P>0.05) (Figure S5B). 
Subsequently we performed Botox injections in the DIO rats that had SG 6 weeks earlier and 
found that body weight was reduced by 25% and food intake was reduced by 31% (P<0.05) 
(Figure 4C, D). Also fasting blood glucose levels were reduced (P=0.002) (Figure S5C). We 
did not observe any sign of gastroparesis, reflected not only by the general condition of 
animals, but also the shape and size of the solid food-containing stomach. Furthermore, we 
assessed gastric emptying in both normal and DIO rats and found that gastric emptying was 
not delayed by Botox injection, neither in the short-term (3 days) nor long-term (5 weeks) 
post-injection (Figure 5).  
There was no mortality, adverse effects, or pathological changes in rats subjected 
either to VNSB or Botox injection.  
 
Discussion 
By using two different procedures, i.e., VNSB and Botox injection, we have 
demonstrated that targeting the gastric vagus nerve can be a new approach for obesity 
treatment. Furthermore, our results suggest that gastric Botox injection is more efficient than 
sleeve gastrectomy at reducing body weight, food intake, and blood glucose levels, and can be 
performed in case of postsurgical body weight regain, e.g. after sleeve gastrectomy. 
Previously, several animal studies reported reduced body weight gain and food intake 
in response to vagus nerve stimulation which was applied mostly at the left vagal branch. 
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However, the results reported were of low quality due to large variations, and no SD or SEM 
in the figures (12-17). A study using obese minipigs showed that  subdiaphragmatic vagus 
nerve stimulation attenuated weight gain (18). Three clinical trials of vagus nerve stimulation 
for obesity treatment have been performed by the same financial sponsor who produces the 
instrument (19-21). One of the trials was a randomized, prospective, double-blind, multicenter 
trial that showed no significant body weight reduction. The present study shows, for the first 
time, that constant high current stimulation should be applied at the beginning in order to 
achieve body weight loss. 
Botox injection into the gastric antrum has been proposed as an obesity treatment, 
based on the dogma that this will cause gastroparesis and delayed gastric emptying (22). 
Previously, several animal studies reported reduced body weight (by 8-14%) after Botox 
injection which was given by “point injections” into the muscular layers. Again, the results 
were poorly reported; large variations and no SD or SEM in figures (22, 23). Clinical trials of 
Botox injection are controversial; some reporting weight loss (24-27), and others reporting no 
effect (28-31), and some reporting delayed gastric emptying (23, 25, 26, 31, 32), while others 
report no change (28, 30). In the present study, Botox injection was applied to block the vagal 
nerve terminals as did VNSB rather than to delay gastric emptying. Therefore, it was given by 
“area injection” into the subserosal layer of the pyloric antrum without delaying gastric 
emptying, leading to a reduced body weight by 20-25%. We have shown that repeated 
injection of Botox resulted in increased weight loss. The present study shows, for the first 
time, that the area injection of Botox into subserosal layer in the region of pyloric antrum 
should be used in order to achieve body weight loss. Conceivably, it could be injected into 
submucosal layer in patients via gastroscopy.   
Furthermore, the present study shows that gene expression in brainstem and 
hippocampus was altered by VNSB, indicative of appetite suppression. In relation to energy 
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balance, it is noteworthy that the hippocampus has a role in incentive motivation (e.g. for 
food), in processing of hormonal signals (CCK, ghrelin, and, motilin), and that damage to this 
region causes hyperphagia (33-37). The results of the present study suggest that VNSB 
activates afferent pathways to the brainstem and hippocampus leading to reduced food intake. 
On the other hand, both VNSB and Botox injection increased hypothalamic expression of 
orexigenic neuropeptides, probably suggesting compensatory changes. For instance, while 
long-term VNSB reduced body weight and food intake, gene expression in the hypothalamus 
changed with a drive for increased food intake and reduction of energy expenditure (2, 38-
40). Gut hormones are thought to be central in appetite regulation in the gut-brain axis, and 
hormones such as CCK, glucagon, GLP-1, and PYY are known to reduce food intake (1). 
However, these were unaltered after VNSB neither in short-term or long-term. Thus, the 
profile of gene expression in the hypothalamus indicative of appetite stimulation was not 
associated with changes in gut hormones, and was inconsistent with the effects of VNSB to 
reduce food intake and body weight, representing a failed compensatory mechanism to 
counteract the weight loss.  
Clinical trials of VNSB and Botox injection for weight loss have so far been 
inconclusive (19, 20, 31), which is most likely due to improper methods. The present study 
provides evidence that the vagus nerve is a potential target for obesity therapy. VNSB at high 
current has certain potential as a less-invasive therapy for obesity, and gastric Botox area 
injection (via gastroscopy) can be performed as non-invasive therapy for obesity in general, as 
well as in those patients who are not suitable for bariatric surgery, or have failed to respond or 
regained body weight after sleeve gastrectomy. This study could help design better clinical 
trials in the future, particularly in terms of technique and the regime of VNSB and the 
methods of Botox injection.       
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Figure Legends 
Figure 1: Vagus nerve stimulation/blocking (VNSB). (A) Photograph showing the implanted 
VNSB electrodes around the gastric vagus nerve. (B) Illustration of how the cathode induces 
depolarization and stimulation of the afferent fibers, while the anode hyperpolarizes the 
membrane and imposes an anodic block on the efferent fibers. (C) In vivo 
electrophysiological recordings of stimulation-induced activity in the brain. The graph depicts 
the average waveform of measured activity, the insert show the raw data from which the 
average waveform was constructed.  
Figure 2: VNSB reduced body weight and food intake, and altered gene expression in 
hypothalamus, brainstem, and hippocampus. Mean ± SEM (n=4-9). (A) Effect of different 
currents of VNSB on body weight (black column). Note: when current was started at 2.0 mA 
a weight reduction was accomplished instantly (P<0.05) (white column). (B) Effect of VNSB 
on food intake (g/24h). *: P<0.05 between sham-VNSB (white column) and VNSB (black 
column). (C) Effect of VNSB (2.0 mA) on hypothalamic mRNA expression of CCKB/2 
receptor (Cckbr), NPY, Foxa2, insulin receptor (Insr), and melanocortin 4 receptor (Mc4r). 
Note: P=0.067 on Insr and P=0.086 on Mc4r between sham-VNSB (white column) and 
VNSB (black column). (D) Effect of VNSB (2.0 mA) on plasma concentrations of gut 
hormones. Note: no significant difference between sham-VNSB (white column) and VNSB 
(black column). (E) Effect of VNSB (2.0 mA) on mRNA expression of leptin receptor (Lepr), 
Cckbr, interleukin-1ȕ (IL1b), tumor necrosis factor (Tnf), and transforming growth factor ȕ1 
(Tgfb1) in brainstem. *: P<0.05 between sham-VNSB (white column) and VNSB (black 
column). (F) Effect of VNSB (2.0 mA) on mRNA expression of CCK, somatostatin, and 
tyrosine hydroxylase in hippocampus. *, **, ***: P<0.05, 0.01, 0.001 between sham-VNSB 
(white column) and VNSB (black column).  
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Figure 3: Gastric Botox injections reduced body weight and food intake, increased energy 
expenditure and altered gene expression in the hypothalamus and gut hormones in plasma in 
normal chow-fed rats. Mean ± SEM (n=6-12). (A) Photograph showing the site of Botox 
injection. (B) Effect of Botox injection on body weight in normal chow-fed rats. Note: Botox 
was injected at 0 and 4 weeks. (C) Effect of Botox injection on food intake (g/24h) in normal 
chow-fed rats. *,***: P<0.05, 0.001 between vehicle (white column) and Botox (black 
column). (D) Effect of Botox injection on energy expenditure in normal chow-fed rats. **: 
P<0.01 between vehicle (white column) and Botox (black column). (E) Effect of Botox 
injection on hypothalamic mRNA expression of NPY, AgRP, and POMC in chow-fed rats at 
8 weeks. *: P<0.05, or P=0.058 between vehicle (white column) and Botox (black column). 
(F) Effect of Botox injection on plasma concentrations of gastrin, glucagon, GLP-1, PYY, and 
CCK in chow-fed rats at 8 weeks. **, ***: P<0.01, 0.001 between vehicle (white column) and 
Botox (black column) injection.  
Figure 4: Gastric Botox injections reduced body weight and food intake in high-fat diet-
induced obese (DIO) rats and DIO rats with sleeve gastrectomy (DIO-SG). Mean ± SEM 
(n=6-12). (A) Effect of Botox injection on body weight in DIO rats. Note: Botox was injected 
at 0 and 6 weeks. (B) Effect of Botox injection on food intake in DIO rats. *, ***: P<0.05, 
0.001 between vehicle (white column) and Botox (black column). (C) Effect of sleeve 
gastrectomy (SG) and Botox injection in DIO rats (DIO-SG) on body weight. Note: Botox 
was injected 6 weeks post SG. (D) Effect of Botox injection in DIO-SG rats on food intake. 
Note: white column is vehicle and black column is Botox. *: P<0.05 between values before 
and after SG+Botox. 
Figure 5: Gastric Botox injections did not delay gastric emptying or cause gastroparesis in 
normal chow-fed or high fat diet induced obese (DIO) rats. Means ± SEM (n=6-10). (A) 
Gastric emptying 2 weeks after Botox injection in normal chow fed rats. (B) Gastric emptying 
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before and 1, 3 and 5 weeks after Botox injection in DIO rats. Note: no significant difference 
between before and after injection. (C) Gastric emptying in normal chow-fed (ND) and DIO 
rats. Note: no significant difference. In (D) and (E), photographs showing the stomachs after 
vehicle injection (control) and Botox injection in normal chow-fed rats. 
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Supplementary Materials and Methods 
Determination of Eating Behavior and Metabolic Parameters 
Rats were placed in the Comprehensive Laboratory Animal Monitoring System 
(CLAMS; Columbus Instruments International, Columbus, OH, USA) with free access to 
standard rat powder food (RM1 811004, Scanbur BK AS, Sweden) or high fat diet powder 
food (D12492, Research Diets, Inc., NJ, USA) and tap water. Energy expenditure (EE) 
(kcal/h) was calculated according to this equation: (3.815+1.232 RER) × VO2, where RER 
(respiratory exchange ratio) was the volume of CO2 produced per volume of O2 consumed. 
VO2 was the volume of O2 consumed per h per kilogram of mass of the animal. Parameters 
that were obtained during daytime (7 am –7 pm) and nighttime (7 pm –7 am) for each 
individual rat included number of meals, meal size, meal duration, accumulated food intake, 
intermeal interval, rate of eating, satiety ratio, drinking activity, energy expenditure, and 
ambulatory activity. Satiety ratio, an index of the non-eating time produced by each gram of 
food consumed, was calculated by dividing the average intermeal interval by the average meal 
size.  
 
Gastric acid secretion measurement 
The rats were fasted for 24h before measurement. Gastric acid was collected for 30 
min at baseline, 0.5 mA, 1.0 mA, 2.0 mA, 3.5 mA, and at the same settings with pentagastrin 
subcutaneous injection. Between each collection the stimulation was turned off and there was 
a break of 90 min. The rats received 1 mL physiological saline subcutaneously every second 
hour. The gastric acid was expressed as pH and H+ content/30 min. 
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Taqman array 
Brainstem (medulla and pons) and hypothalamus were dissected at euthanization and 
stored in RNAlater (Qiagen, Hilden, Germany) at -80°C. Total RNA was extracted using 
RNeasy Lipid Tissue Mini Kit (Qiagen), and reversed transcribed using random hexamers 
(Applied Biosystems, Sundbyberg, Sweden), and Superscript III reverse transcriptase 
(Invitrogen Life Technologies, Paisley, UK). Real-time RT PCR was performed using 
TaqMan®Low Density Array (LDA) custom-made platforms. Target genes as well as the 
primer sets were Hmbs, Foxa2, Npy, Lepr, Insr, Cckbr, Mc4r, Il1b, Tnf, and Tgfb1 (catalogue 
number Rn00565886_m1,  Rn01415600_m1, Rn01410145_m1, Rn01433205_m1, 
Rn00567070_m1, Rn00565867_m1, Rn01491866_s1, Rn00580432_m1, Rn01525859_g1 and 
Rn00572010_m1, respectively) (Applied Biosystems). 
 
In situ hybridization 
 Brain samples were taken at euthanization and snap-frozen and cut (14 m) in the 
region spanning the hypothalamus between Bregma –0.10 to –2.54 mm and brainstem (NTS). 
Primers for the amplification of AgRP spanned were based on Genbank sequence U89484 to 
amplify the sequence between bases 113-341 (forward primer 5’-
TGTTCCCAGAGTTCCCAGGTC-3’, reverse primer 5’-
GCATTGAAGAAGCGGCAGTAGCAC-3’). Primers for the amplification of POMC were 
based on Genbank sequence J00162 to amplify the sequence between bases 263-665 (forward 
primer 5’-GGGCAAGCGCTCCTACTCCAT-3’, reverse primer 5’-
GCCCTTCTTGTRSRCGTTCTTGA-3’). The DNA sequence for NPY was a full-length 
cloned rat NPY gene sequence. Radioactive 35S antisense probes were made using 150ng 
amplified fragment by T7(AgRP), T3(NPY), or SP6(POMC) RNA polymerase as stated. 
Slides were dried, exposed to Kodak Biomax MR film, and Autoradiographic films were 
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scanned at 600 d.p.i. and analysed using Image Pro Plus v.7.0 (Media Cybernetics UK, 
Marlow, Bucks, UK), analysis software (Media Cybernetics UK, Wokingham, UK). 
Integrated optical density was obtained by reference to the 14C microscale.  
 
RNA sequencing 
Hippocampus was dissected at euthanization and stored in RNAlater (Qiagen) before 
total RNA was isolated. High-throughput cDNA sequencing (RNA-seq) was performed at 
Norwegian Sequencing Centre, Dept. of Medical Genetics Ullevål, Oslo University Hospital, 
using HiSeq2000. Differential expression analysis on the data was performed, where reads for 
all samples were aligned to the rat genome using Bowtie2 (http://bowtie-
bio.sourceforge.net/index.shtml) and Tophat2 (http://tophat.cbcb.umd.edu), and differential 
expression was calculated using cuffcompare in the Cufflinks2 
(http://cufflinks.cbcb.umd.edu) package. 
 
In vivo electrophysiology 
The rats were anaesthetized with 0.1ml/100gr i.m. Hypnorm and 0.05ml/100gr i.p. 
Midazolam. Following placement of VNSB the animals were mounted in a stereotaxic frame 
(Kopf Instruments) and the cranium was exposed. A hole was drilled over the hippocampal 
area (coordinates AP -3.2, ML 22), dura was removed, and a bundle 4 tetrodes (0.005”, Pt/Ir, 
Fine Wire, California) were lowered into the brain (DV -3.2) until stable neuronal activity 
was measured. The drill hole was subsequently filled with mineral oil (Sigma-Aldrich Chemie 
B.V., Zwijndrecht, The Netherlands) and a surgical screw was placed into the scull to serve as 
ground. During VNSB (2.0 mA, 30 Hz, 500 s, 30 s ON and 5 min OFF) data was recorded at 
40Khz using a Multineuron Acquisition Processor (MAP) recording system (Plexon, Dallas, 
USA). Signals were passed through a unity-gain amplifier (20×), amplified and filtered with a 
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Plexon 16-channel preamplifier (PBX3 /16sp-r-G50, 50x amplification, 150-8000 Hz 
filtered). Subsequently, a 1200s digitized data sample was stored by the MAP system 
whenever the signal crossed a preset voltage threshold. The data were subsequently analyzed 
with offline cluster cutting procedures based on the average waveforms across the four leads 
of each tetrode (Offline Sorter x64 V3; Plexon).  
 
Radioimmunoassay 
Plasma samples were collected at euthanization and kept at -80°C. In-house 
radioimmunoassay using specific antibodies was performed to analyze GLP-1, gastrin, CCK, 
and glucagon concentrations, while measurement of PYY concentrations was performed using 
a commercial kit (Rat/mouse PYY RIA kit, Cat. no. RMPYY-68HK, EMD Millipore 
Corporation, St.Charles, MO, USA). Results were reported as pmol/l for GLP-1, gastrin, 
CCK, glucagon and pg/ml for PYY. 
 
Fasting blood glucose  
Blood glucose levels were measured after 12h fasting by taking a drop of blood from 
the tail vein and analyzing with a glucose meter and test strips (FreeStyle Freedom Lite, 
Abbot Diabetes Care, California). 
 
Gastric emptying 
Rats were fasted for 16h before an oral gavage of 100 mg/kg acetaminophen (Sigma-
Aldrich Chemie GmbH, Germany) in 1.5% methyl cellulose (Sigma-Aldrich Chemie GmbH, 
Germany) was administrated. 100 ђl blood samples were collected from the tail at 15, 30, 45, 
60, 90, 120, and 180 min after oral gavage. Plasma levels of acetaminophen were 
subsequently measured using an acetaminophen kit (Acetaminophen-sl assay, ref. 505-30, 
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Sekisui Diagnostics, PE Canada) and spectrophotometer (UV-1800, UV-Spectrophotometer, 
Shimadzu).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Supplementary Figures 
 
 
Figure S1: Effects of short-term VNSB (48h at 2.0 mA) on (A) body weight, (B) food intake, 
(C) gene expression of neuropeptides in hypothalamus and (D) brainstem, (E) plasma 
concentrations of gut hormones, and effects of VNSB on (F) gastric acid secretion. Mean ± 
SEM (n=6-8). Note: no significant difference between sham-VNSB (white column) and 
VNSB (black column), except some hypothalamic genes in (C) (*: P<0.05). In (F), electrical 
currents from 0.5 mA to 3.5 mA; PG: pentagastrin.  
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Figure S2: Effects of long-term VNSB (6-8 weeks) on (A) food intake (g/100g body weight) 
and (B) energy expenditure. Mean ± SEM (n=4-9). In (A), different currents of VNSB. White 
columns: sham-VNSB, black columns: VNSB. *, **:P<0.05, 0.01.  
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Figure S3: Effects of Botox (48h post injection) on (A) body weight, (B) gene expression in 
hypothalamus and (C) brainstem, and (D) plasma concentrations of gut hormones. Mean ± 
SEM (n=5). Note: no significant difference between vehicle (white column) and Botox (black 
column). 
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Figure S4: Effects of Botox injection on food intake (g/100g body weight) in (A) normal 
chow-fed rats, (B) high fat diet induced obese (DIO) rats and (C) DIO rats with sleeve 
gastrectomy (DIO-SG). Mean ± SEM (n=6-12). *, **, ***: P<0.05, 0.01, 0.001. Note: 0 
week: before injection; 1 week: 1 week after the 1st Botox injection (B) or SG (C); 2 weeks: 2 
weeks after the 1st Botox injection (A); 3 weeks: 3 weeks after the 1st Botox injection (B); 5 
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weeks: 1 weeks after the 2nd Botox injection; 6 weeks: 2 weeks after the 2nd Botox injection; 
and 7 weeks: 1 week after the 2nd Botox injection (B) and 1 week after Botox injection (C).  
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Figure S5: Fasting blood glucose levels in DIO rats after (A) Botox, (B) sleeve gastrectomy 
(SG) and (C) the combination (SG+Botox). Mean ± SEM (n=6-14). **, ***: P<0.01, 0.001. 
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Abstract 
Obesity has become a worldwide problem, affecting both rich and poor countries. Up 
to date, bariatric surgery is the only obesity treatment with long-term effect. Due to high 
surgical cost and risk of complications, there is an urgent need for drug discovery against 
obesity. Mice lacking the muscarinic acetylcholine M3 receptor display a lean phenotype. To 
assess this receptor as a potential target for obesity treatment, we performed detailed 
phenotyping of M3 receptor knockout (M3KO) mice with respect to food intake, eating 
behavior, energy expenditure and hypothalamic gene expression by open circuit indirect 
calorimeter and in situ hybridization throughout the lifespan of the mice. In comparison with 
wild-type mice, the M3KO mice had a lean phenotype with increased energy expenditure. 
Surprisingly, these mice had increased cumulative food intake (g/100g body weight) and gene 
expression of orexigenic peptides in the hypothalamus. Thus, we suggest that targeting the 
muscarinic acetylcholine M3 receptor and/or increasing energy expenditure may have great 
potential to streamline the development of anti-obesity drugs.   
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Introduction 
The number of obese individuals is increasing, leading to a global obesity epidemic 
[1,2]. Obesity is a major contributor in the development of type 2 diabetes, cardiovascular 
diseases, certain forms of cancer, overall reduced quality of life and premature mortality [3,4]. 
Not only is obesity a great health burden, it is also an economic burden to society as the 
medical cost for an obese individual is 40% higher than for a normal weight individual [5]. 
Weight loss treatments include diet control, physical training, pharmaceutical drugs, and 
bariatric surgery [6]. To date, only bariatric surgery has demonstrated long-term therapeutic 
effects [7,8]. In consideration of the large number of obese patients, risk of surgical 
complications, high surgery-related cost, and those who are not eligible for conventional 
bariatric surgery, development of new effective pharmacological interventions to treat obesity 
is urgently needed [9].  
Currently, anti-obesity drugs on the market mainly target food intake by acting on 
noradrenergic or serotonergic receptors, or reduce dietary fat absorption (e.g. Orlistat). By 
average, the pharmacological interventions reduce body weight by 4 kg, relative to placebo 
[10]. Although this can be beneficial for health it is not comparable to the effects of bariatric 
surgery [8]. Therefore it is important to explore new targets in drug design for obesity 
treatment. 
The muscarinic acetylcholine M3 receptor is distributed both in the peripheral and 
central nervous system and may play an important role in the regulation of food intake and 
body weight. It has been reported that mice deficient of this receptor (M3KO mice) have 
reduced food intake, body weight, total body fat, and serum leptin, insulin and triglyceride 
levels [11,12]. This phenotype has not been observed in mice lacking M1, M2, M4 or M5 
muscarinic receptors [13-16]. Apparently, the M3 receptor is a new target in treatment of 
obesity. 
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In the report by Yamada and coworkers, M3KO mice had reduced food intake on one 
hand, but increased hypothalamic gene expression of the orexigenic neuropeptide AgRP and 
reduced expression of the anorexigenic neuropeptide POMC on the other hand [11]. 
According to common paradigm, the changes in the hypothalamus indicate a drive for 
increased food intake, which does not coincide with a phenotype of reduced food intake [17]. 
Therefore we performed a detailed phenotyping of the M3KO mice with respect to eating 
behavior, metabolic parameters and hypothalamic gene expression using a more advanced 
method (Comprehensive Laboratory Animal Monitoring System) and in situ hybridization.  
 
Materials and Methods 
Animals and Experimental Design 
M3KO mice were generated [18] and backcrossed 14 generations onto C57BL/6 
background at Prof. Takeuchi’s laboratory, Kyoto Pharmaceutical University and imported to 
Norway by Prof. D. Chen for this study. The M3KO mice were further bred through sibling 
matings for 2 generations. Age-matched wild-type (WT) mice on the same background 
(C57BL/6) were purchased from Taconic (Ejby, Denmark). All the mice including M3KO 
and WT mice were fed in-house together during the study period. The mice had free access to 
tap water and standard pellet food (RM1 801002, Scanbur BK AS, Sweden). All the mice 
were housed three-four together in individually ventilated cages on wood chip bedding with a 
12 h light/dark cycle, room temperature of 22ºC and 40-60% relative humidity. The standard 
housing conditions were specific pathogen free and in agreement with FELASA (Federation 
of European Laboratory Animal Science Association) recommendations. Animal experiments 
were performed according to the guidelines for the design and statistical analysis of 
experiments using laboratory animals after being approved by the Norwegian National 
Animal Research Authority (Forsøksdyrutvalget, FDU, permit number: 4764). 
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The mice were acclimatized to the Comprehensive Laboratory Animal Monitoring 
System (CLAMS; Columbus Instruments International, Columbus, OH USA) for 24 h before 
data collection. At data collection the mice were kept in CLAMS for 48 h and data from the 
last 24 h were used for analysis. Before CLAMS the mice were habituated to their normal 
food as powder for three days, as the food in CLAMS is in powder form.  
M3KO and age-matched WT mice were placed in CLAMS at 6, 11 and 15 months of 
age for determination of food intake, eating behaviour and metabolic parameters. Body 
weight was measured at 2, 6, 11 and 15 months of age. At 2 months of age there were 7 mice 
in each group, 3:4 male:female ratio in M3KO group and 4:3 male:female ratio in WT group. 
At the subsequent time points there were 8 mice in each group, with male:female ratio of 4:4 
ratio in the WT group, and 4:4, 5:3 and 6:2 in the M3KO group at 6, 11 and 15 months, 
respectively. Brain tissue from 15 months old mice were collected for in situ hybridization. 
 
Determination of Eating Behavior and Metabolic Parameters 
Mice were placed in the Comprehensive Laboratory Animal Monitoring System 
(CLAMS; Columbus Instruments International, Columbus, OH, USA) with free access to 
standard mice powder food (RM1 801002, Scanbur BK AS, Sweden) and tap water. This 
system is composed of a four-chamber open circuit indirect calorimeter designed for 
continuous monitoring of individual mice. Eating behavior and metabolic parameters were 
recorded automatically. High-resolution feeding data was generated by monitoring all feeder 
balances every 0.5 seconds. The end of an eating event (meal) was determined when the 
balances were stable for more than 10 seconds and a minimum of 0.05 g of food were eaten. 
An air sample was withdrawn every 5 min. The energy expenditure (EE) (kcal/h) was 
calculated according to this equation: (3.815+1.232 RER) × VO2, where RER (respiratory 
exchange ratio) was the volume of CO2 produced per volume of O2 consumed. VO2 was the 
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volume of O2 consumed per h per kilogram of mass of the animal. Parameters that were 
obtained during daytime (7 am–7 pm) and nighttime (7 pm–7 am) for each individual mouse 
included number of meals, meal size, meal duration, accumulated food intake, intermeal 
interval, rate of eating, satiety ratio, drinking activity, energy expenditure and ambulatory 
activity. The intermeal interval was defined as the interval in minutes between two meals. 
Rate of eating was calculated by dividing the average meal size by the average duration of a 
meal, and satiety ratio, an index of the non-eating time produced by each gram of food 
consumed, was calculated by dividing the average intermeal interval by the average meal size. 
Food intake was higher and satiety ratio lower during nighttime than daytime for all 
animals at every timepoint. 
 
In Situ Hybridization 
Brain samples were taken at euthanization and snap-frozen in isopentane on dry ice 
before stored at -80°C wrapped in aluminum foil. The frozen brains were cut (14 m) in the 
region spanning the hypothalamus between Bregma –0.10 to –2.54 mm according to the 
Mouse Brain Atlas of Franklin & Paxinos 1997 and sections were mounted onto poly-L-
lysine-coated slides.  Briefly, sections were fixed in 4% paraformaldehyde in 0.1 M phosphate 
buffer (PB), washed in 0.1 M PB, acetylated in 0.25% acetic anhydrate in 0.1 M 
triethanolamine, and washed again in PB. Sections were dehydrated using graded ethanol. 
DNA templates for the generation of anti-sense riboprobes for AgRP and POMC were 
generated by PCR. Briefly, primers for the amplification of AgRP spanned were based on 
Genbank sequence U89484 to amplify the sequence between bases 113-341 (forward primer 
5’-TGTTCCCAGAGTTCCCAGGTC-3’, reverse primer 5’-
GCATTGAAGAAGCGGCAGTAGCAC-3’). Primers for the amplification of POMC were 
based on Genbank sequence J00162 to amplify the sequence between bases 263-665 (forward 
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primer 5’-GGGCAAGCGCTCCTACTCCAT-3’, reverse primer 5’-
GCCCTTCTTGTRSRCGTTCTTGA-3’). The DNA sequence for NPY was a full-length 
cloned rat NPY gene sequence. Primers for the amplification of Ob-Rb (leptin receptor)  were 
based on Genbank sequence U49107 to amplify the sequence between bases 5'-
GTGTGAGCATCTCTCCTGGAG-3' (+2829 to +2849) and 5'-
ACCACACCAGACCCTGAAAG-3' (+3362 to +3343). Primers for the amplification of 
MCH were based on Genbank sequence M29712 to amplify the sequence between bases 99-
403 (forward primer bases 99-117 5’-ACGGCATTTTACTTTCGGC-3’; reverse primer bases 
384-403 5’-CTGAACTCCATTCTCAGCTGG- 3’). 35S antisense probes were made using 
150ng amplified fragment by T7(AgRP), T3(NPY), or SP6(POMC, Ob-Rb, and MCH) RNA 
polymerase as stated. The radioactive probes were applied to the slides in 70 l hybridization 
mixture (0.3 M NaCl, 10 mM Tris-HCL (pH 8), 1 mM EDTA, 0.05% transfer RNA, 10 mM 
dithiothreitol, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA and 10% dextran 
sulphate) and hybridized overnight at 58°C. Post-hybridization, slides were rinsed in 4x SSC 
and treated with ribonuclease A (20 g/l) at 37°C before being washed in decreasing 
concentrations of SSC and dehydrated using graded ethanol. Slides were dried and exposed to 
Kodak Biomax MR film for various lengths of time. Autoradiographic films were scanned at 
600 d.p.i. and analysed using Image Pro Plus v.7.0 (Media Cybernetics UK, Marlow, Bucks, 
UK), analysis software (Media Cybernetics UK, Wokingham, UK). Integrated optical density 
was obtained by reference to the 14C microscale. NPY, POMC, AgRP, leptin receptor and 
MCH mRNA expression was measured in three to four sections. Values were averaged for 
each animal.  
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Statistical Analysis 
The results are expressed as means ± SEM. Statistical comparisons were performed 
using independent t-test between the groups. A p-value of <0.05 (two tailed) was considered 
statistically significant. The data analysis was performed in SPSS version 15.0 and 20.0. 
 
Results 
Body Weight 
At 2 months of age the body weight did not differ between M3KO and WT mice when 
comparing all mice (both sexes) (p=0.065) (Fig. 1A). However, the male M3KO mice 
weighed less than male WT mice at this time point (p=0.000) (Fig. 1B). At 6, 11 and 15 
months of age the M3KO mice weighed significantly less than WT mice when comparing all 
mice (both sexes) (p<0.001) (Fig. 1A). When we compared age-matched males, the M3KO 
mice weighed significantly less than WT mice at all time points (p<0.001) (Fig. 1B). The 
same was true for females (p<0.05), except for 2 and 15 months of age when there were few 
female M3KO mice (Fig. 1C). The M3KO mice had a continuous growth throughout the 
lifespan. 
 
Food Intake, Eating Behavior and Metabolic Parameters 
 At 6 months of age the M3KO mice had unaltered total (24 h) food intake, but there 
was a trend of reduced food intake (g) during daytime (p=0.054) (Fig. 2A and 2C). At 11 
months of age the M3KO mice had unaltered total (24 h) food intake, but food intake (g/100g 
body weight) during nighttime was increased (p=0.014) (Fig. 2A and 2B). At 15 months of 
age the M3KO mice had unaltered total (24 h) food intake, but food intake (g) during daytime 
was reduced, while food intake (g/100g body weight) during nighttime was increased 
(p=0.043 and p=0.034, respectively) (Fig. 2A, 2B and 2C). 
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Cumulative food intake, expressed as g per mouse, was unchanged at the three time 
points examined. When adjusted for body weight (g/100g body weight), it was significantly 
higher at 15 months of age in M3KO mice compared to WT mice (p<0.01) (Fig. 3A and 3B). 
At 6 months of age the M3KO mice ate significantly fewer, but bigger meals than WT 
mice (g/meal) (p=0.000 and p=0.005, respectively). The time between each meal was longer 
(min), but the rate of eating (g/min) was faster (p=0.008 and p=0.002, respectively). These 
mice had significantly higher water intake (ml/100g body weight) than WT mice (p=0.050). 
Interestingly, the mice also had significantly higher energy expenditure (kcal/h/100g body 
weight) and respiratory exchange ratio (RER) (VCO2/VO2) (p<0.001) (Fig. 4A and 4B) 
(Table 1).  
  At 11 months of age water intake (ml/100g body weight) was increased, as was 
energy expenditure (kcal/h/100g body weight) and RER in M3KO mice compared to WT 
mice (p=0.001, p=0.003 and p=0.000, respectively) (Fig. 4A and 4B) (Table 2).  
 At 15 months of age water intake (ml/100g body weight) was increased, as was energy 
expenditure (kcal/h/100g body weight) and RER in M3KO mice compared to WT mice 
(p=0.032, p=0.003 and p=0.000, respectively) (Fig. 4A and 4B) (Table 3).  
 Number of meals was reduced at all ages at nighttime in M3KO mice compared WT 
mice (p<0.05) (Tables 1, 2 and 3).  
  
In Situ Hybridization 
 At 15 months of age there were great differences in the phenotype between M3KO and 
WT, therefore brain tissue was collected at this age for analysis. The 15 months old M3KO 
mice had significantly higher mRNA expression of neuropeptide Y (NPY), agouti-related 
peptide (AgRP) and leptin receptor in the arcuate nucleus (ARC) in the hypothalamus 
compared to WT (p=0.001, p=0.000 and p=0.003, respectively). Interestingly, mRNA 
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expression of pro-opiomelanocortin (POMC) in the ARC and melanin-concentrating hormone 
(MCH) in ventromedial hypothalamus was unaltered (p>0.05) (Fig. 4C). 
 
Discussion 
In contrast to previous studies [11,12], we found, for the first time to our best 
knowledge, that M3KO mice do not have significantly reduced 24h food intake by using 
state-of-the art methods for determination of food intake, eating behavior and metabolic 
parameters. Interestingly, we found that M3KO mice had altered eating behavior, with 
tendency for reduced food intake during daytime and increased food intake during nighttime 
compared to WT mice and that cumulative food intake (g/100g body weight) was increased in 
M3KO mice compared to WT mice at 15 months of age. Our results suggest that the lean 
phenotype of M3KO mice is due to increased active (nighttime) and resting (daytime) energy 
expenditure. This was reproducible throughout the whole lifespan of the mice. In contrast to 
the previous studies, where respiratory exchange ratio (RER) was unaltered, we found that 
RER was increased in M3KO mice [11,12]. This implies an increased use of carbohydrates as 
predominant fuel for cellular respiration. Interestingly, this was also found during daytime, 
when the M3KO mice had tendency of reduced food intake compared to WT mice.   
By comparing all the mice (both sexes), the body weight at 2 months of age did not 
differ between M3KO and WT mice. Taking together with the findings of equal body weights 
at birth and at young age in the previous studies [11,12], we suggest that the lean phenotype 
of M3KO mice is not caused by prenatal factors, but develops as the mice grow.  
Hypothalamic mRNA expression in the M3KO mice was indicative of changes with a 
drive for increased food intake and reduced energy expenditure, as reported previously [11]. 
This could represent a compensatory mechanism, which is supported by the increased 
cumulative food intake in these mice at 15 months of age (Fig. 3B). However, the 
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compensatory mechanism was without effect on energy expenditure which was greater than 
the food intake, resulting in a lean phenotype. In the previous studies it was suggested that 
reduced levels of MCH could play an important role in development of the lean phenotype 
[11]. However, we found no significant reduction of MCH expression in the 15-month old 
M3KO mice. To compensate for the low fat compartment and leptin serum levels, as reported 
previously, expression of leptin receptor in hypothalamus was increased [11,12].  
Our results suggest that antagonists of the muscarinic acetylcholine M3 receptor may 
have potential in obesity treatment. However, our pilot study showed that there were severe 
side effects, high mortality and little effect on body weight when peripheral M3 antagonist 
Darifenacin was given continuously for more than two months in mice (Andersen G and Zhao 
C-M, unpublished data). Indeed, it has been suggested that a central nervous system (CNS) 
specific antagonist would be beneficial, due to side effects of peripheral M3 receptor 
antagonists [19].  This is supported by findings of a lean phenotype in brain-specific M3KO 
mice [20]. However, development of CNS specific M3 antagonists is still highly challenging 
[19].   
According to our results, we also suggest that pharmacological interventions aiming to 
increase energy expenditure may have more potential than those aiming to reduce food intake 
in obesity treatment. In fact, there are several possible pharmacological treatments for obesity 
targeting energy expenditure, such as thyroid hormone receptor ȕ agonists (GC-1 and GC-24) 
and NADPH:quinone reductase 1 (NQO1) activators (MB12066) [21,22]. Some of these 
compounds have shown promising results as obesity treatment in animal studies and 
MB12066 has completed Phase I clinical trial [23-25]. 
In conclusion, the results of the present study shows that the lean phenotype of M3KO 
mice is associated with increased energy expenditure rather than reduced food intake. CNS 
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antagonists of the muscarinic acetylcholine M3 receptor may have potential in obesity 
treatment by increasing energy expenditure.  
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Figure Legends 
 
Figure 1: Body weight of M3KO and WT mice at 2, 6, 11 and 15 months of age. (A) Body 
weight of both male and female wild-type (WT) and M3KO mice. (B) Body weight of male 
WT and M3KO mice. (C) Body weight of female WT and M3KO mice. Mean ± SEM (n=7-
8). ***: p<0.001 between WT and KO. 
 
Figure 2: Food intake of M3KO and WT mice at 6, 11 and 15 months of age. (A) Food 
intake 24 h (g/100g body weight) of wild-type (WT) and M3KO mice. (B) Food intake 12 h 
(g/100g body weight) during day and night time of WT and M3KO mice. (C) Food intake 12 
h (g/mouse) during day and night time of WT and M3KO mice. Mean ± SEM (n=8). *: 
p<0.05 between WT and KO. 
 
Figure 3: Cumulative food intake in M3KO and WT mice at 6, 11 and 15 months of age. 
(A) Cumulative food intake (g/mouse) of wild-type (WT) and M3KO mice. (B) Cumulative 
food intake (g/100g body weight) of WT and M3KO mice. Mean ± SEM (n=8). **: p<0.01 
between WT and KO. 
 
Figure 4: Energy expenditure, respiratory exchange ratio and hypothalamic 
neuropeptide expression in M3KO and WT mice. (A) Energy expenditure during day and 
night time of wild-type (WT) and M3KO mice at 6, 11 and 15 months of age. (B) Respiratory 
exchange ratio (RER) (24 h) of WT and M3KO mice at 6, 11 and 15 months of age. (C) 
mRNA expression of AgRP, NPY, POMC and leptin receptor (Lepr) in arcuate nucleus and 
of MCH in ventromedial hypothalamus of WT and M3KO mice at 15 months of age. Mean ± 
SEM (n=8). **, ***: p<0.01, 0.001 between WT and KO.  
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Table 1: Food intake, eating behavior and metabolic parameters in WT and M3KO mice at 6 
months of age.*,**,***:p<0.05, 0.01, 0.001 between WT and M3KO mice. 
    6 months 
Parameters WT (n=8) M3KO (n=8) 
Daytime 
Food Intake (g) 1.55±0.11 0.93±0.27 
Food Intake (g/100g body weight) 4.78±0.37 3.9±1.08 
Number of meals 28.25±4.14 7.25±2.96** 
Meal size (g/meal) 0.06±0.01 0.31±0.1* 
Intermeal interval (min) 27.23±3.64 196.09±51.27* 
Rate of eating (g/min) 0.11±0.03 0.35±0.12 
Water intake (mL) 0.65±0.09 0.62±0.1 
Water intake (ml/100g body weight) 2.01±0.31 2.71±0.43 
Energy expenditure (kcal/h/100g body weight) 1.18±0.04 1.53±0.04*** 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0*** 
RER 0.84±0.01 0.94±0.01*** 
Nighttime 
Food Intake (g) 2.45±0.25 2.56±0.49 
Food Intake (g/100g body weight) 7.55±0.76 10.79±1.78 
Number of meals 52±5.69 16.75±3.44*** 
Meal size (g/meal) 0.05±0.01 0.18±0.03** 
Intermeal interval (min) 13.75±1.54 52.23±9.71** 
Rate of eating (g/min) 0.06±0.01 0.18±0.03** 
Water intake (mL) 1.96±0.17 2.84±0.6 
Water intake (ml/100g body weight) 6.02±0.52 12.23±2.53* 
Energy expenditure (kcal/h/100g body weight) 1.5±0.03 1.88±0.05*** 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0** 
RER 0.93±0.02 1.07±0.02*** 
24 h 
Food Intake (g) 4±0.24 3.49±0.51 
Food Intake (g/100g body weight) 12.33±0.8 14.69±1.79 
Number of meals 80.25±8.76 24±6.17*** 
Meal size (g/meal) 0.05±0.01 0.19±0.04** 
Intermeal interval (min) 18.28±1.92 86.49±18.76** 
Rate of eating (g/min) 0.07±0.01 0.18±0.03** 
Water intake (mL) 2.61±0.2 3.46±0.68 
Water intake (ml/100g body weight) 8.03±0.63 14.94±2.9* 
Energy expenditure (kcal/h/100g body weight) 1.34±0.03 1.71±0.04*** 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.005±0*** 
RER 0.89±0.01 1±0.01*** 
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Table 2: Food intake, eating behavior and metabolic parameters in WT and M3KO mice at 11 
months of age.*,**,***:p<0.05, 0.01, 0.001 between WT and M3KO mice. 
    11 months 
  Parameters WT (n=8) M3KO (n=8) 
Daytime 
Food Intake (g) 1.19±0.31 0.77±0.17 
Food Intake (g/100g body weight) 3.48±1.06 3.02±0.7 
Number of meals 26.5±5.95 22.25±7.98 
Meal size (g/meal) 0.05±0.01 0.18±0.09 
Intermeal interval (min) 39.93±10.26 151.88±61.13 
Rate of eating (g/min) 0.1±0.03 0.34±0.17 
Water intake (mL) 0.76±0.14 0.78±0.2 
Water intake (ml/100g body weight) 2.14±0.42 2.97±0.72 
Energy expenditure (kcal/h/100g body weight) 1.05±0.1 1.43±0.04** 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 
RER 0.83±0.02 0.97±0.03** 
Nighttime 
Food Intake (g) 1.85±0.27 2.33±0.24 
Food Intake (g/100g body weight) 5.3±0.99 9±0.88* 
Number of meals 46.13±5.85 24.13±8.36* 
Meal size (g/meal) 0.05±0.01 0.52±0.36 
Intermeal interval (min) 16.26±1.8 82.67±40.89 
Rate of eating (g/min) 0.07±0.01 0.49±0.29 
Water intake (mL) 1.52±0.17 2.97±0.42** 
Water intake (ml/100g body weight) 4.34±0.67 11.65±1.9** 
Energy expenditure (kcal/h/100g body weight) 1.25±0.12 1.85±0.06*** 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0** 
RER 0.88±0.02 1.11±0.02*** 
24 h 
Food Intake (g) 3.04±0.56 3.1±0.25 
Food Intake (g/100g body weight) 8.78±1.99 12.03±0.73 
Number of meals 72.63±9.47 46.38±16.07 
Meal size (g/meal) 0.04±0.01 0.32±0.18 
Intermeal interval (min) 21.91±3.23 112.61±56.13 
Rate of eating (g/min) 0.08±0.01 0.4±0.22 
Water intake (mL) 2.28±0.27 3.74±0.41** 
Water intake (ml/100g body weight) 6.48±1 14.62±1.71** 
Energy expenditure (kcal/h/100g body weight) 1.15±0.11 1.64±0.03** 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0* 
RER 0.85±0.02 1.04±0.02*** 
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Table 3: Food intake, eating behavior and metabolic parameters in WT and M3KO mice at 15 
months of age.*,**,***:p<0.05, 0.01, 0.001 between WT and M3KO mice. 
    15 months 
  Parameters WT (n=8) M3KO (n=8) 
Daytime 
Food Intake (g) 1.09±0.15 0.66±0.12* 
Food Intake (g/100g body weight) 2.9±0.45 2.39±0.46 
Number of meals 35.75±10.68 19.38±6.89 
Meal size (g/meal) 0.04±0.01 0.12±0.05 
Intermeal interval (min) 30.78±7.92 118.35±45.17 
Rate of eating (g/min) 0.15±0.05 0.07±0.01 
Water intake (mL) 0.82±0.16 0.78±0.28 
Water intake (ml/100g body weight) 2.24±0.51 2.83±1.06 
Energy expenditure (kcal/h/100g body weight) 0.99±0.08 1.36±0.07** 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0* 
RER 0.82±0.02 0.96±0.02*** 
Nighttime 
Food Intake (g) 1.88±0.46 3.07±0.4 
Food Intake (g/100g body weight) 5.34±1.64 11.02±1.77* 
Number of meals 57.25±11.66 23.5±8.4* 
Meal size (g/meal) 0.03±0.01 0.32±0.15 
Intermeal interval (min) 15.16±2.79 69.65±27.16 
Rate of eating (g/min) 0.06±0.02 0.14±0.03* 
Water intake (mL) 1.56±0.28 3.89±0.72* 
Water intake (ml/100g body weight) 4.24±0.95 14±2.99* 
Energy expenditure (kcal/h/100g body weight) 1.19±0.12 1.73±0.1** 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0* 
RER 0.82±0.03 1.07±0.02*** 
24 h 
Food Intake (g) 2.98±0.51 3.73±0.5 
Food Intake (g/100g body weight) 8.25±1.85 13.41±2.17 
Number of meals 93±21.96 42.88±13.88 
Meal size (g/meal) 0.04±0.01 0.22±0.1 
Intermeal interval (min) 20.42±4.11 82.2±32.6 
Rate of eating (g/min) 0.07±0.02 0.11±0.03 
Water intake (mL) 2.37±0.38 4.67±0.94* 
Water intake (ml/100g body weight) 6.49±1.35 16.83±3.84* 
Energy expenditure (kcal/h/100g body weight) 1.09±0.1 1.54±0.08** 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0* 
RER 0.82±0.03 1.01±0.02*** 
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Abstract
Background Ileal interposition–sleeve gastrectomy (II–SG)
has been developed as a metabolic surgery based on the
hindgut hypothesis. The aim of the present study was to test
this hypothesis by studying the eating behavior, metabolic
changes, and glucagon-like peptide-1 (GLP-1)-producing
cells in rat models.
Methods Male Sprague–Dawley rats were subjected to lap-
arotomy, II, SG, or II–SG. Eating behavior and metabolic
parameters were monitored by an open-circuit indirect cal-
orimeter designed for a comprehensive laboratory animal
monitoring system. GLP-1-producing cells were examined
by quantitative immunohistochemistry.
Results After II alone, satiety ratio, i.e., intermeal interval/
meal size, was reduced, while calorie intake was increased
at 2 and 6 weeks postoperatively. Respiratory exchange
ratio, VCO2/VO2, was increased to above 1.0 (i.e., carbo-
hydrate metabolism) during both daytime and nighttime at
2 weeks postoperatively. After SG alone, GLP-1-producing
cells were increased in the pancreatic islets (in terms of
volume density), but not in the ileum (number/mm). After
II–SG, the rate of eating was reduced, while meal duration
(min) was increased during both daytime and nighttime at
2 weeks postoperatively. GLP-1-producing cells were in-
creased by about 2.5-fold in the interposed ileum and also
increased to the same extent in the pancreatic islets as seen
after SG alone. The increased GLP-1-producing cells in the
pancreatic islets after SG or II–SG were located around the
insulin-producing β cells.
Conclusions The present study provides evidence supporting
the hindgut hypothesis. II–SG increased GLP-1 production
both in the interposed ileum and in the pancreatic islets, leading
to metabolic beneficial effects and altered eating behavior.
Keywords Food intake .GLP-1 . Ileal interposition . Ileum .
Pancreatic islets . Sleeve gastrectomy . Energy expenditure .
Respiratory exchange ratio
Introduction
Bariatric surgeries, such as Roux-en-Y gastric bypass, bil-
iopancreatic diversion, or sleeve gastrectomy, exhibit a bet-
ter therapeutic effect than conventional medical therapy on
type 2 diabetes by mechanisms other than weight loss and/or
reduced food intake [1–4]. The hindgut hypothesis has been
proposed to explain the underlying mechanisms, i.e., early
arrival of food in the hindgut suppresses gastrointestinal
motility, gastric emptying, and small intestinal transit by
neural as well as hormonal pathways, such as GLP-1 in
the ileum [5–8]. According to this hypothesis, ileal interpo-
sition (II) with or without sleeve gastrectomy (SG) has been
suggested as a novel method of metabolic surgery [1]. The
aim of the present study was to test this hypothesis by
studying the effects of II with or without SG on body
weight, body composition, eating behavior, metabolic
parameters, and GLP-1-producing cells. Anatomically cor-
rect surgical procedure in which only ileum was interposed
and accurate determination of eating behavior using Com-
prehensive Laboratory Animal Monitoring System
(CLAMS) were applied. GLP-1-producing cells in the ileum
as well as the pancreatic islets were examined by quantita-
tive immunohistochemistry.
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Materials and Methods
Animals
Rats (Sprague–Dawley, male, adults) were purchased from
Harlan™, Horst, The Netherlands. Males were used because
female rats have food intake coinciding with ovarian hor-
mones and males grow faster than females, making it easier
to detect changes in body weight. The rats were housed in
Makrolon Type-4 individually ventilated cages (four rats per
cage) with regulated room temperature and humidity (22±
2 °C, 50±10 %) and 12-h light/dark cycle. They had free
access to tap water and standard rat pellet food (RM1
811004, Scanbur BK AS, Sweden). The study was approved
by the Norwegian National Animal Research Authority
(Forsøksdyrutvalget, FDU).
Experimental Design
The animals were divided into two groups: II (14 ani-
mals) and laparotomy (LAP) (six animals). In consider-
ation of the “3Rs” for the human use of animals (i.e.,
reducing the number of animals while achieving the
scientific purposes of the experiment) [9], rats in both
groups were re-used and subjected to SG 7 weeks after
the first operation. In addition, four non-operated normal
rats were used as controls for immunohistochemical anal-
ysis of GLP-1.
The body weight was recorded regularly (three times/
week) throughout the study period. Each rat was placed in
the CLAMS cages five times and kept for 48 h at each time
point for measurement of eating behavior and metabolic
parameters (records from the second 24 h were used for
data analysis). The five time points were 2 weeks before II
or LAP, 2 and 6 weeks after II/LAP, and 2 and 6 weeks after
SG. At the same time points, the body composition was
determined and fecal energy content was measured (for
details, see the following discussion). At euthanization,
tissue samples from ileum and pancreas were collected for
analysis by immunohistochemistry.
Surgeries
Before all surgeries, the animals were fasted overnight
but with free access to drinking water. Surgeries were
performed under general anesthesia with isofluran (4 %
for induction, 2 % for maintenance). Atropin was given
to SG rats at a dose of 0.04 mg/kg subcutaneously
20 min before anesthesia. Buprenorphine was injected
subcutaneously (0.05 mg/kg) immediately after surgery
in all animals and at 1 day postoperatively if needed.
Physiological saline (0.9 % NaCl) was given subcutane-
ously at 10–15 mL after surgeries to keep the animals
hydrated. Drinking water (but not food) ad libitum was
started 4 h after the surgery and powdered food was
provided on the next morning, until it was switched to
ordinary pellet food on the 2nd postoperative day.
Ileal Interposition
II was performed through a midline abdominal incision. The
ligament of Treitz was located, and the insertion location for
the transposed ileum segment was marked approximately
3 cm distal to the ligament with saline-soaked gauze. The
ileum segment (2.5–3.5 cm in length) with blood vessels at
0.5–1 cm proximal to the ileocecal valve was isolated and
transected. Three anastomoses in an end-to-end fashion
were made between cecum–distal jejunum, Treitz-side jeju-
num–proximal ileum, and distal ileum–jejunum (Fig. 1b, c).
All anastomoses were performed in one layer with 6-0
absorbable sutures (Vicryl, Ethicon Inc., Sommerville, NJ,
USA). The abdomen was closed in two layers using 4-0
absorbable sutures (Vicryl, Ethicon Inc., Sommerville, NJ,
USA).
Sleeve Gastrectomy
SG was performed through a midline abdominal incision.
The stomach was clamped along the greater curvature from
the antrum to the rumen (forestomach) across the corpus
(fundus), approximately 70 % of the stomach was removed,
and then the stomach was closed in one layer with 6-0
absorbable sutures (Fig. 1b, c) [10]. The abdominal wall
was closed in two layers with 4-0 absorbable sutures.
Laparotomy
LAP was performed by making a midline abdominal inci-
sion, locating the ligament of Treitz and ileum, and then
closing the abdomen in two layers using 4-0 absorbable
sutures.
Eating Behavior and Metabolic Parameters
Rats were placed in the cages of CLAMS (Columbus Instru-
ments International, Columbus, OH, USA) with free access to
standard rat powdered food (RM1 811004, total metabolizable
energy of 2.57 kcal/g, Scanbur BK AS, Sweden) and tap
water. This system is composed of a four-chamber open-
circuit indirect calorimeter designed for continuous monitor-
ing of individual rats. In order for rats to acclimate to this
system, they were placed in these metabolic cages for 24 h
before the first CLAMS monitoring. Food intake, feeding
behavior, and metabolic parameters were recorded automati-
cally. High-resolution feeding data were generated by moni-
toring all feeder balances every 0.5 s. The end of an eating
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event (meal) was determined when the balances were stable
for more than 10 s and a minimum of 0.05 g of foodwas eaten.
An air sample was withdrawn every 5 min. The energy ex-
penditure (EE) (kcal/h) was calculated according to this equa-
tion: (3.815+1.232 RER) × VO2, where RER (respiratory
exchange ratio) was the volume of CO2 produced per volume
of O2 consumed. VO2 was the volume of O2 consumed per
hour per kilogram of mass of the animal.
Parameters that were obtained during daytime (7 am–7 pm)
and nighttime (7 pm–7 am) for each individual rat included
the number of meals, meal size, meal duration, accumulated
food intake, intermeal interval, rate of eating, satiety ratio,
drinking activity, energy expenditure, and ambulatory activity.
The intermeal interval was defined as the interval in minutes
between two meals. Rate of eating was calculated by dividing
the average meal size by the average duration of a meal, and
satiety ratio, an index of the non-eating time produced by each
gram of food consumed, was calculated by dividing the aver-
age intermeal interval by the average meal size.
Determination of Body Composition
Body composition was determined with dual-energy X-ray
absorptiometry (Hologic QDR 4500A, Hologic Inc., Bedford,
MA, USA) under general anesthesia with isofluran (4 % for
induction, 2 % for maintenance). Total fat mass, fat-free
mass, bone mineral content, and bone area were measured.
Determination of Fecal Energy Content
Feces were collected in CLAMS cages and dried for 72 h at
60 °C. The energy content was determined by using an
adiabatic bomb calorimeter (IKA-Calorimeter C 5000,
IKA-Werke GmbH & Co. KG, Staufen, Germany).
Western Blot Analysis and Immunohistochemistry
Western blot analysis was applied to test antibody specific-
ity. Ileum and pancreatic tissues were suspended in RIPA
buffer and ground on ice until homogenized. Determination
of protein concentration was performed using BioRad assay
and absorbance was measured at 595 nm. A total of 100 μg
ileum and pancreas tissue extracts, 1 μg GLP-1 peptide
(code: 028-11, Phoenix Pharmaceuticals, Inc., CA, USA),
and M.M (4.0 μL Seeblue + 0.5 μL Magic Marker, Invi-
trogen) were subjected to 1DE separation in 4–12 % Novex
Bis-Tris gels using MES running buffer (Invitrogen) for
25 min at 200 V prior to the Western blot analysis. The
tissue extracts, the GLP-1 peptide, and M.M were trans-
ferred to a Nitrocellulose membrane (UltraCruz) (Blot
30 V, 30 min, 220 mA, room temperature) as this membrane
was superior to PVDF membranes. The membrane was
dried and then blocked for 1 h in 5 % fat-free dry milk in
PBS-T and incubated overnight in rabbit monoclonal GLP-1
primary antibody (code: 2914-1, Epitomics, Inc., CA, USA)
diluted in blocking buffer. After washing 3×10 min in PBS-T,
membranes were incubated with secondary antibody swine
anti-rabbit (1:5,000) in blocking buffer for 1 h. After
4×10 min washes in PBS-T, blots were developed using
SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific) and scanned in a Kodak IS4000R imager
(Fisher Scientific).
Tissue samples of the ileum and the pancreas from con-
trol, SG, and II–SG rats were fixed in 4 % formaldehyde,
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Fig. 1 Anatomy of the gastrointestinal tract of human (a) and rat (b). Ileal interposition with sleeve gastrectomy (II–SG) is illustrated (b) (modified
from [26])
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dehydrated, and embedded in paraffin. Sections were cut at
a thickness of 4 μm, thawed on superfrost glass slides,
deparaffinized, and rehydrated. For immunostaining with
GLP-1 antibody, the tissue sections were blocked with
10 % normal goat serum and incubated with primary anti-
serum (dilution, 1:1,500; code: H-028-13, Phoenix Pharma-
ceuticals, Inc., CA, USA, and dilution, 1:250, code: 2914-1,
Epitomics, Inc., CA, USA) overnight at 4 °C. After being
thoroughly rinsed, the sections were incubated with Alexa
Fluor 488 goat anti-rabbit IgG (H + L) (dilution, 1:200, Alexa
Fluor 488, Molecular Probes, The Netherlands) for 1 h at
room temperature, washed several times in TRIS-buffered
saline, mounted in glycerol/TBS buffer (1:1) under glass
coverslips, and examined under a microscope (Olympus
BX50) equipped with epifluorescence illumination. For
double-immunostaining using primary antibodies of GLP-
1 and insulin, the sections were blocked with normal sera
and then incubated with a mixture of antibodies of GLP-1
and insulin (dilution, 1:800; code: A0564, DakoCytoma-
tion, Denmark) for 18 h at 4 °C. After several washes in
TRIS-buffered saline, the mixture of Alexa Fluor 488 goat
anti-rabbit IgG (H + L) (1:200) and Rhodamine-
conjugated donkey anti-guinea pig IgG (dilution, 1:80;
Jackson ImmunoResearch Europe) was applied to the sec-
tions at room temperature for 1 h. The sections were
rinsed and mounted in glycerol/TBS buffer (1:1) under
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glass coverslips and examined under a microscope (Olym-
pus BX50) equipped with epifluorescence illumination.
GLP-1-immunoreactive cells were counted and expressed
as number per millimeter in the mucosa of ileum and as
volume density (% of islet) in the pancreas using point-
counting technique.
Statistical Analysis
The results are expressed as mean ± SEM. Statistical com-
parisons were performed using independent t-test between
the surgical groups and ANOVA with Tukey’s test or
ANCOVA with Sidak test (the latter for EE analysis) be-
tween different time points. A p-value of <0.05 (two-tailed)
was considered as statistically significant. Data analysis was
performed in SPSS version 15.0.
Results
Mortality and Morbidity
Five of 14 II rats, five of 14 SG rats, and one of six LAP rats
were killed before the end of study due to surgical trauma
and complications, including opening of sutures, pica be-
havior, and partial obstruction of pylorus and infection.
Otherwise, the surviving rats had no morbidity. The impact
of learning curve on the mortality rate should also be con-
sidered (HJ was under micro-surgical training). Based on
inspection at euthanization, all surgeries were successfully
performed with the exception of two SG that led to partial
obstruction of pylorus, probably because of damage of the
vagal nerves. After II, there was hypertrophy of the trans-
posed ileal segment as reported in previous studies [11–14].
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Body Weight and Body Composition
Body weight was lower in II rats than LAP rats (at week
1, p<0.05) until 6 weeks (p>0.05) postoperatively. Com-
pared with LAP, II rats had a lower fat compartment at
2 weeks after surgery (p00.018) but no longer after
6 weeks (p00.687) (Fig. 2a, c). The body weight and
fat compartment tended to be lower in II–SG rats than in
SG rats at every time point examined, albeit insignifi-
cantly (Fig. 2b, d).
Food Intake and Eating Behavior
Effects by II
Food intake (in terms of g/100 g body weight) was higher in
II rats than in LAP rats at 2 weeks after surgery both during
day- and nighttime (p00.046 and p00.036, respectively).
Compared with LAP, II rats had fewer meals (p00.006) and
higher intermeal interval (p00.008) during nighttime and
also had larger meal size (g/meal) and longer meal duration
(min/meal) both during day- and nighttime (p<0.05). At
6 weeks after surgery, II rats still had higher food intake
(g/100 g body weight), particularly during nighttime (p0
0.027), larger meal size (g/meal) (p00.034) during daytime,
and longer meal duration (min/meal) (p00.049) during
nighttime in comparison with LAP rats. At both 2 and
6 weeks after surgery, II rats had lower 24-h satiety ratio
compared with LAP rats (p00.021 and p00.043, respective-
ly) (Fig. 3; Table 1).
Effects by SG or II–SG
At 2 weeks after SG surgery in LAP or II rats, II–SG
rats had a lower rate of eating (g/min) at both day- and
nighttime (p00.017 and p00.006, respectively), and lon-
ger meal duration (min) (p00.018) during nighttime com-
pared with SG rats. At 6 weeks after SG surgery, the
changes became non-significant (Fig. 4b, c). However,
II–SG rats had lower intermeal interval (min) during
daytime (p00.042) and higher food intake (g/100 g body
weight) during nighttime (p00.033) than SG rats (Fig. 4a).
Table 1 Eating behavior at 2 and 6 weeks after LAP or II
2 weeks after LAP/II 6 weeks after LAP/II
Parameters LAP (n05) II (n09) LAP (n05) II (n09)
Daytime Food intake (g) 6.54±0.93 9.45±0.96 5.54±0.39 6.07±0.57
Food intake (g/100 g body weight) 1.48±0.2 2.34±0.26 * 1.14±0.07 1.31±0.13
Number of meals 16.2±2.75 15.67±1.77 13.2±1.02 11.67±1.46
Meal size (g/meal) 0.42±0.04 0.66±0.09* 0.42±0.02 0.55±0.05*
Meal size (kcal/meal) 1.09±0.09 1.7±0.23* 1.08±0.04 1.41±0.13*
Meal duration (min) 13.31±2.1 24.19±4.19 11.68±0.82 13.21±1.72
Meal duration (min/meal) 0.85±0.05 1.61±0.24* 0.89±0.04 1.18±0.13
Intermeal interval (min) 47.55±10.71 46.01±5.23 50.82±3.3 61.01±5.87
Satiety ratio (min/g) 109.29±15.66 75.74±9.24 120.72±7.45 113.7±10.24
Rate of eating (g/min) 0.5±0.03 0.42±0.03 0.47±0.01 0.47±0.02
RER 0.99±0.02 1.11±0.02** 1.04±0.01 1.04±0.02
Ambulatory activity 2,307.2±419.87 1,925.89±288.24 2,280.4±330.23 1,814.67±260.68
Nighttime Food Intake (g) 16.36±1.38 18.76±1.34 15.97±0.76 17.94±0.68
Food Intake (g/100 g body weight) 3.68±0.26 4.56±0.24* 3.3±0.17 3.84±0.13*
Number of meals 40.4±5.22 22.11±3** 27.8±2.87 21.44±2.14
Meal size (g/meal) 0.42±0.04 0.94±0.11** 0.59±0.05 0.94±0.14
Meal size (kcal/meal) 1.09±0.12 2.41±0.27** 1.52±0.12 2.41±0.36
Meal duration (min) 40.7±3.21 51.64±4.29 36.08±0.97 43.52±3.06
Meal duration (min/meal) 1.05±0.12 2.55±0.27** 1.35±0.12 2.2±0.28*
Intermeal interval (min) 17.47±2.15 32.11±3.18** 24.73±2.49 33.35±4.27
Satiety ratio (min/g) 41.66±3.59 35.14±2.19 41.64±1.89 36.31±1.57
Rate of eating (g/min) 0.4±0.02 0.38±0.03 0.44±0.01 0.42±0.02
RER 1.02±0.04 1.12±0.02* 1.09±0.02 1.11±0.02
Ambulatory activity 6,298.6±970.17 5,450.56±835.2 5,877.2±593.57 5,900.22±750.46
*p<0.05; **p<0.01 (LAP vs. II)
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ANOVA with Tukey’s test showed that at 2 and 6 weeks
after SG surgery, II–SG rats had a lower rate of eating
both during day- and nighttime compared with the level
before operation (Fig. 4d). SG rats had increased food
intake (g/100 g body weight) both during day- and
nighttime at 2 weeks postoperatively when compared
with the level before surgery and reduced rate of eating
(g/min) at both 2 and 6 weeks after surgery during
daytime (Table 2).
Energy Expenditure and Fecal Energy Content
ANCOVA with Sidak test (using fat-free mass as cova-
riate), which is recommended for EE analysis [15],
showed no change in EE after II or LAP. Compared
to LAP rats, II rats had higher RER at 2 weeks after
surgery both during day- and nighttime (p00.009 and
p00.036, respectively), which was caused by increased
CO2 production. At 6 weeks after surgery, there was no
longer difference in RER between II and LAP, but II
rats had higher RER compared to the level before
surgery (Fig. 5). After II–SG, EE was reduced at
2 weeks postoperatively both during day- (p00.004)
and nighttime (p00.030) (Table 2).
Neither LAP, II, SG, nor II–SG led to changes in fecal
energy content, indicating that none of the procedures
caused malabsorption (data not shown).
GLP-1-Producing Cells
Western blot analysis showed a strong signal in the MW
range corresponding to synthetic GLP-1 peptide (about
3 kDa) and very faint signals that precluded direct
quantitative analysis of ileum and pancreatic tissue extracts
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(Fig. 6f). This likely reflects that only a minor fraction of
the cells in the tissues expressed GLP-1. GLP-1 was
detected in the mucosa of ileum and the α-cells of pan-
creatic islets in control rats as well as SG and II–SG rats
by immunohistochemistry using either of the two antibod-
ies without any difference.
GLP-1-immunoreactive cells were increased (in terms
of number per millimeter) in the interposed ileum in
II–SG rats compared with SG rats (p00.011) or control
rats (p<0.001). There was no difference between SG
rats and control rats (Fig. 6b, d, h). The volume density
of GLP-1-immunoreactive cells in the pancreatic islets
was increased in both II-SG rats and SG rats compared
with control rats (p00.010 and p00.023, respectively).
There was no difference between II–SG and SG rats
(Fig. 6a, c, e, g).
Discussion
Surgical Models
Previously, eating behavior data obtained in rats subjected to
II are confusing; food intake and body weight were reduced in
some reports [11–14, 16–20], but unchanged in others [7, 8,
21–24]. There are at least two possible explanations for these
controversial reports: imprecise monitoring of eating behavior
and different lengths and positions of transposed ileal seg-
ment. In most studies, an ileal segment of approximately
10 cm was transected from different positions [7, 8, 11–13,
16, 19, 21, 23–25]. There are substantial differences in the
intestinal anatomy between humans and rats; whereas ileum is
approximately 400 cm (58% of small intestine) in human, it is
only 2.5–3.5 cm (2 %) in rats (Fig. 1a, b) [26]. In many II
studies using rat models, not only the entire ileum (2.5–
3.5 cm) but also part of the distal jejunum (7–8 cm) were
transposed [7, 8, 11–14, 16–19, 21, 27], and II was often
performed without SG [7, 8, 11–14, 16, 17, 21, 22, 27].
In patients that undergo II, about 40 % (150–170 cm) of
ileum is transposed to 30–50 cm distal to the ligament of
Table 2 Eating behavior at 2 and 6 weeks after II–SG and SG
II–SG SG
Parameters 2 weeks after SG 6 weeks after SG 2 weeks after SG 6 weeks after SG
Daytime Food intake (g) 7.41±1.04 6.44±0.78 6.77±0.29 5.36±0.89
Food intake (g/100 g body weight) 2.02±0.35 1.71±0.29 1.56±0.07§* 1.09±0.17
Satiety ratio (min/g) 96.3±12.92 108.74±13.87 94.47±4.62 128.49±24.2
Rate of eating (g/min) 0.3±0.04* 0.33±0.05# 0.43±0.01* 0.4±0.01#
RER 1.06±0.04 1.03±0.02 0.99±0.01 1.07±0.04
Energy expenditure (kcal/h) 1.77±0.06* 1.96±0.06 1.98±0.06 2.07±0.06
Ambulatory activity 1,471.33±231.2 1,860.33±413.77 1,598.5±765.15 1,779.25±392.34
Nighttime Food intake (g) 14.86±1.19 14.57±1.35 16±0.25 15.5±0.6
Food intake (g/100 g body weight) 3.92±0.2 3.67±0.14 3.7±0.12§ 3.16±0.11
Satiety ratio (min/g) 43.7±3.55 46.24±5.46 40.68±0.82 42.08±1.4
Rate of eating (g/min) 0.24±0.03* 0.27±0.04# 0.37±0.02* 0.38±0.03
RER 1.12±0.03 1.09±0.03 1.07±0.009§ 1.17±0.02#
Energy expenditure (kcal/h) 1.91±0.09* 2.15±0.09 2.26±0.09 2.38±0.09
Ambulatory activity 4,314.5±824.13 4,939.5±818.59 3,868.25±1,406.08 5,673.5±1,402.69
*p<0.05 between before and 2 weeks after SG; §p<0.05 between 2 and 6 weeks after SG; #p<0.05 between before and 6 weeks after SG
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Fig. 6 Representative immunofluorescence micrographs showing GLP-
1 (indicated by arrows) and insulin (asterisks) in the pancreatic islets (a,
c, e) and GLP-1 (arrows) in the ileum (b, d) in rats subjected to sleeve
gastrectomy (SG), ileal interposition with sleeve gastrectomy (II–SG), or
sham operation (Control). Western blot analysis showing specificity of
GLP-1 antibody used to GLP-1 (7-36) and faint signals in ileum and
pancreatic tissue after SG (f). Quantitative values of GLP-1 (%v/v) in the
pancreatic islets (g) and the ileum (no./gland) (h). *p<0.05 between
control vs. SG; §p<0.05 between control vs. II–SG; #p<0.05 between
SG vs. II–SG
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Treitz [28–31], and II is usually performed in combination
with SG in an attempt to reduce body weight [5, 28–30,
32–34]. In the present study, only the ileum was transposed
to 3 cm distal to the Treitz ligament and II with and without
SG was performed in order to maximally mimic the clinical
procedure and to detect postoperative changes caused by
each procedure [26, 31].
Evidence Supporting the Hindgut Hypothesis
Previously, we and others have shown that gastric bypass-
induced weight loss was associated neither with reduced
food intake nor malabsorption but with increased EE,
whereas weight loss induced by duodenal switch with sleeve
gastrectomy was associated with reduced food intake, mal-
absorption, and increased EE in rodent models [35–38].
Using the same method of monitoring the eating behavior
and metabolic parameters, the results of the present study
showed that II alone did not reduce daily food intake. This is
at odds with other reports [11–14, 16], probably because of
different lengths of transposed intestine (3 cm in this study
vs. 10 cm in others) and different methods of monitoring
food intake (CLAMS vs. leftover chow weighing). CLAMS
analysis further showed normal eating cycle before surgery,
namely, more frequent meals during nighttime than daytime
and altered eating cycle and behavior after II, as manifested
by similar frequency through 24 h but eating slowly. It
should also be noticed that EE was unchanged and that
RER was above 1.0 after II, indicating an increased use of
carbohydrates as predominant fuel for cellular respiration.
Analysis of fecal energy content by bomb calorimetry did
not indicate malabsorption after II. Taken together, it is not
surprising that II alone did not cause a significant weight
loss, and the initial drop in body weight was likely due to
surgical stress.
We have also reported that SG alone resulted in a mar-
ginal weight loss (10 %) for about 6 weeks, which was
reproduced in the present study [35]. Body weight appeared
to be lower at the time points examined in rats subjected to
II–SG than those subjected to SG alone, although the differ-
ences at each time point did not reach statistical signifi-
cance. It should be noticed that the meal duration was
increased, the rate of eating per 24 h was reduced, but food
intake (g/100 g body weight/24 h) was increased eventually
after II–SG.
Interestingly, the results of the present study showed the
increased GLP-1-producing cells in the interposed ileum
after II, which is in line with a report showing that ileal
transposition procedure increased circulating GLP-1 levels
in Goto–Kakizaki rats [17]. Since about 90 % of GLP-1
secreted from L-cells is supposed to be degraded before it
reaches the circulation [39], the physiological significance
of increased GLP-1 in the ileum needs to be further
investigated. Even more interestingly, the present study
showed increased GLP-1 in α cells in the pancreatic islets
after SG alone or II–SG. It is likely that GLP-1 acts on β
cells via paracrine mechanism. In a separate study, we will
examine GLP-1 in rats subjected to gastric bypass, which
also causes the remission of diabetes.
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Abstract
Background: Both gastric bypass (GB) and duodenal switch with sleeve gastrectomy (DS) have been widely used as bariatric
surgeries, and DS appears to be superior to GB. The aim of this study was to better understand the mechanisms leading to
body weight loss by comparing these two procedures in experimental models of rats.
Methods: Animals were subjected to GB, DS or laparotomy (controls), and monitored by an open-circuit indirect calorimeter
composed of comprehensive laboratory animal monitoring system and adiabatic bomb calorimeter.
Results: Body weight loss was greater after DS than GB. Food intake was reduced after DS but not GB. Energy expenditure
was increased after either GB or DS. Fecal energy content was increased after DS but not GB.
Conclusion: GB induced body weight loss by increasing energy expenditure, whereas DS induced greater body weight loss
by reducing food intake, increasing energy expenditure and causing malabsorption in rat models.
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Introduction
Various bariatric surgical procedures, such as gastric banding,
gastric bypass (GB) and duodenal switch with sleeve gastrectomy
(DS), have been developed in order to reduce food intake and/or
lead to malabsorption [1]. GB was invented by Dr. Edward Mason
as a bariatric surgery in 1965, and later it was converted to Roux-
en-Y procedure which was created by Dr. Cesar Roux already in
1897. Recently, a laparoscopic mini-GB procedure has been
shown to be regarded as a simpler and safer alternative to
laparoscopic Roux-en-Y with similar efficacy at 5 or 10 year
experience [2]. However, the different procedures have shown
different efficacy in individual patients, and the underlying
mechanisms are not yet clear. Therefore, it is a challenge to
select the most effective bariatric procedure for individual patients.
Various rat models of bariatric surgery have been developed in
order to understand the underlying physiological mechanisms of
different surgical procedures. There have been many studies in the
literature reporting the surgical procedures (such as Roux-en-Y) in
rats that are made as same as they are used in humans [3,4].
However, there is a significant difference in the anatomy and
physiology of the gastrointestinal tract between rats and humans,
which should be kept in mind when creating the surgical models in
rats and translating findings from animals and humans. For
instance, the rat stomach consists of antrum, fundus (also called
corpus) and rumen (forestomach), while the human stomach is
divided into antrum, body and fundus (Fig 1A, E). The rat
jejunum represents almost 90% of the small intestine, the human
jejunum about 40% [5]. Unlike humans, rats are nonemetic (not
vomiting) and has no gallbladder. The Roux-en-Y reconstruction
was initially created to prevent post-gastrectomy bile vomiting in
patients [6]. Apparently, it is not necessary to create the Roux-en-
Y reconstruction in rats that are subjected to GB [7–9]. The
duodenal switch procedure was originally created as a surgical
solution for primary bile reflux gastritis and/or to decrease
postoperative symptoms after distal gastrectomy and gastroduo-
denostomy [10]. In patients, the operation usually consists of a
75% longitudinal gastrectomy (the so-called sleeve gastrectomy),
creation of an alimentary limb approximately 50% of total small
bowel length (i.e. bypassing jejunum), a common channel length of
100 cm, and cholecystectomy. In the present study using rats, GB
was performed without the Roux-en-Y reconstruction and the
postsurgical anatomy was similar to mini-GB on humans, and DS
was performed according to the rat anatomy (Fig 1A–H) [11].
GB is the most common procedure because of relatively high
efficacy and safety, whereas DS seems to be even more effective,
particularly in super-obese patients [12]. Both GB and DS are
believed to cause restriction in food intake and malabsorption by
decreasing stomach size and bypassing part of the small intestine.
In patients, DS is superior to GB in body weight loss as well as in
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improvement of comorbidities such as diabetes, hypertension and
dyslipidemia [12–18]. Mechanisms underlying the postoperative
weight loss and possible regain remain unclear. Whether this is
due to biological or behavioral factors is one of the major debates
[19]. The aim of the present study was to compare the
postoperative effects of GB vs.DS on eating behavior and energy
expenditure in rat models.
Materials and Methods
Animals and Experimental Design
Adult rats (male, Sprague-Dawley, 6–12 months of age) were
purchased from Taconic M&B, Skensved, Denmark and housed in
ventilated cages in a specific pathogen free environment with room
temperature of 22uC, 40–60% relative humidity and 12 hr day/
night cycle with 1 hr dusk/dawn. The rats had free access to tap
water and standard rat pellet food (RM1 801002, Scanbur BK AS,
Sweden). In our previous studies, we have reported that the male
rats gained body weight mainly as a result of continuous expansion
of the fat compartment after puberty (8 weeks of age with 200 g
body weight), and that the male rats that were fed a high-fat diet
starting at 5 weeks of age gained body weight up to ,650 g at
40 weeks of age as a result of increased fat mass [7,8]. In the
present study, normal adult male rats (,600 g body weight) were
chosen after considerations of the small difference in body weight
(,650 g vs.,600 g induced by high-fat diet) and the experimental
efforts in terms of time-consuming and financial expense (Fig 2A).
Furthermore, the body weight development of naı¨ve rats reaches a
plateau (580620 g) at 40 weeks of age, and laparotomy performed
at 13 weeks of age did not affect the development of body weight
(Fig 2A).
Thirty-four rats, at 587.068.1 g body weight, were randomly
divided into experimental (GB and DS) as well as control groups
(laparotomy, LAP): GB (14 rats), DS (7 rats), and LAP (13 rats).
The body weight was not different between the groups before
surgery (p=0.276). Because of markedly loss of body weight after
DS, the group of DS rats, together with age-matched group of
laparotomized rats (LAPDS, 7 rats), were followed up only for
8 weeks, while GB rats and the rest of laparotomized rats (LAPGB,
6 rats) were followed up for 14 weeks. In consideration of the
‘‘3Rs’’ for the human use of animals (i.e., reducing the number of
animals while achieving the scientific purposes of the experiment),
rats that had been used for studies of the effects of individual
surgical procedures were re-used [8,20]. The study was approved
by the Norwegian National Animal Research Authority (For-
søksdyrutvalget, FDU).
Surgery
All operations were performed under general anesthesia with
isofluran (4% for induction and 2% for maintenance) (Baxter
Medical AB, Kista, Sweden). Buprenorphine (0.05 mg/kg) (Scher-
ing-Plough Europe, Brussels, Belgium) was administrated as an
analgesic agent subcutaneously immediately during surgery. LAP
was performed through a middle-line incision with gentle
manipulation of viscera. A rat model of Roux-en-Y GB procedure
has been described by Stylopoulos and his colleagues [3]. Gastric
pouch in that rat model was created at the site of rumen which
does not exist in humans (Fig 1F). In the present study, GB was
Figure 1. Schematic drawing of anatomy. The gastrointestinal tract of human (A–D) and rat (E–H) before (A, E) and after Roux-en-Y gastric
bypass (GB) (B, F), mini-GB (C, G), and duodenal switch (D, H). Glandular stomach is indicated by grid gray and jejunum by light grid gray. The rumen
of rat stomach is non-glandular (white area). Note: In A, E, percentages mean % of small intestine, e.g. in E, jejunum is 90% of total small intestine in
rats based on [11]; in F, rat Roux-en-Y GB [3], and in G, Mini-GB used in the present study.
doi:10.1371/journal.pone.0072896.g001
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performed by anastomosing the distal esophagus to the proximal
jejunum about 2–3 cm distal to the Treitz ligament in an end-to-
side manner (Fig 1G) as described previously [7,8]. DS was
achieved in two stages. The two-stage procedure has been
recommended in patients because the single-stage procedure
increases the risk of postoperative complications and staged DS
may avoid biliopancreatic diversion in some patients [21]. In the
present study, sleeve gastrectomy was performed by resecting
approximately 90% of the rumen and 70% of the glandular
stomach along the greater curvature. Three months later,
duodenal switch was achieved by creating biliopancreatic limb,
alimentary limb (bypassing jejunum) and common channel length
of 5 cm (Fig 1H). The duration of surgical time was 30–60 min for
GB or DS. In all surgeries performed in the present study, proper
aseptic surgical techniques were applied, and therefore, neither
prophylactic nor postoperative antibiotics were used. This was
done according to the guidelines and recommendations by the
Federation of European Laboratory Animal Science Associations
(FELASA 2008) and the guide for the care and use of laboratory
animals by the Committee of USA National Research Council
(2010). After recovering from anesthesia, the animals were placed
2–4 per cage throughout the study period.
Measurements of Eating Behavior and Energy
Expenditure Parameters
These were monitored by the Comprehensive Laboratory
Animal Monitoring System (CLAMS, Columbus Instruments
International, Columbus, OH, USA) 2–3 weeks after GB, DS or
LAP and 14 weeks after GB, 8 weeks after DS or 8–14 weeks after
LAP. The CLAMS is composed of a 4-chamber indirect
calorimeter designed for the continuous monitoring of individual
rats from each chamber. The eating data was generated by
monitoring all feed balances every 0.5 s. In CLAMS program used
in the present study, the end of an eating event (meal) was when
the balance was stable for more than 10 s and a minimum of
0.05 g was eaten. The eating parameters during daytime and
nighttime (12 hr each time) for each rat included: accumulated
food intake (g or kcal), number of meals, meal size (g/meal), meal
duration (min/meal), intermeal interval (min), rate of eating (g/
min), and satiety ratio (min/g). The intermeal interval was defined
as the interval in minutes between two meals. The rate of eating
was calculated by dividing meal size by meal duration. The satiety
ratio, an index of non-eating time produced by each gram of food
consumed, was calculated as intermeal interval divided by meal
size [22]. The volume of O2 consumption (VO2 mL/kg/hr) and
the volume of CO2 production (VCO2 mL/kg/hr) were measured
by an air sample withdrawn every 5 min from each chamber
through the gas dryer. The energy expenditure (kcal/hr) was
calculated according to equation: (3.815+1.232 RER) 6 VO2,
where the respiratory exchange ratio (RER) was obtained by
VCO2 divided by VO2. In order for rats to acclimate to CLAMS,
they were placed in these metabolic chambers for 24 hr one week
before the first CLAMS monitoring. For the measurement of
eating and metabolic parameters, the rats were placed in the
CLAMS for 48 hr. In order to minimalize possible effect of stress,
only data from the last 24 hr in CLAMS were used for the
analysis. An analysis of eating pattern in control rats over a time
period from day 1 and 21 showed no significant differences in any
parameters, indicating that the animals had acclimated to CLAMS
(Table S1). The rats have had free access to standard rat powder
food (RM1 811004, Scanbur BK AS, Sweden) and tap water while
they were in CLAMS. The total metabolizable energy was
2.57 kcal/g for both the pellet food (RM1 811002) and the powder
food (RM1 811004).
Determination of Fecal Energy Density
Feces were collected while the rats were placed in CLAMS
chambers and dried for 72 hr at 60uC. The energy density was
determined by means of an adiabatic bomb calorimeter (IKA-
Calorimeter C 5000, IKA-Werke GmbH & Co. KG, Staufen,
Germany).
Determination of Plasma Levels of Cytokines
Blood was drawn from the abdominal aorta under the
anesthesia just before the animals were killed, and plasma was
stored at 280uC until determination of levels of cytokines. The
multiplex cytokine assay was used (Cat no:171-K1002M, Bio-plex
Pro Rat Cytokine Th1/Th2 12-plex Panel; Bio-Rad Laboratories,
Hercules, CA, USA). It contained the following analytics: IL-1a,
IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, granulocyte-macro-
phage colony stimulating factor (GM-CSF), interferon gamma
(IFNc), and tumor necrosis factor alpha (TNFa).
Statistical Analysis
The values were expressed as means 6 SEM. Two-tailed
independent-samples t-test or Mann Whitney U test was
Figure 2. Body weight. Naı¨ve rats (data from Taconic), rats that
underwent laparotomy (LAP) at 13 weeks (LAP) and rats that have had
high-fat since 5 weeks of age (data from [31]) (A). Rats after gastric
bypass (GB), duodenal switch (DS) and laparotomy (LAP) (B). Data are
expressed as means 6 SEM. **: p,0.01, ***: p,0.001 between LAP vs.
GB or DS.
doi:10.1371/journal.pone.0072896.g002
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performed for two-group comparisons. ANOVA followed by
Bonferroni test was performed for multiple comparisons. Homo-
geneity of regression assumption test and ANCOVA were
performed for analysis of energy expenditure. SPSS version 19.0
(SPSS Inc. Chicago, IL, USA) was used. A p-value of ,0.05 was
considered statistically significant.
Results
Mortality
No one died after LAP alone, 6 after GB, and 2 after DS due to
surgical complications, trauma and learning curve factors.
Body Weight
LAP alone did not reduce body weight during the study period
(maximum 14 weeks). GB caused approximately 20% weight loss
throughout the study period (14 weeks). DS induced approxi-
mately 50% weight loss within 8 weeks (Fig 2B).
Food Intake and Eating Behavior
In comparison with LAP, GB increased daytime (but not
nighttime) food intake (expressed as either kcal/rat or kcal/100 g
body weight) at 3 weeks, and had no effects afterwards (14 weeks
postoperatively). In contrast, DS reduced nighttime (but not
daytime) food intake (kcal/rat at both 2 and 8 weeks or kcal/100 g
body weight at 2 weeks). The food intake (kcal/100 g) at 8 weeks
was not reduced because of markedly loss of the body weight after
DS (Fig 3).
GB was without effects neither on satiety ratio (min/g) nor rate
of eating (g/min), whereas DS increased satiety ratio during
nighttime, and decreased rate of eating during both daytime and
nighttime at 2 weeks and 8 weeks postoperatively (Fig 4)
(Tables 1,2).
Energy Expenditure
Age-matched control rats that underwent LAP only were
included for comparisons because metabolic parameters are age-
dependent [23,24]. GB increased nighttime energy expenditure
Figure 3. Food intake. Total food intake (kcal/rat) (A,B) and relative food intake (kcal/100 g body weight) (C,D) during day- and night-time. Short-
term after surgery: 3 weeks after gastric bypass (GB), 2 weeks after duodenal switch (DS) or 2–3 weeks after lapatoromy (LAP). Long-term after
surgery: 14 weeks after GB, 8 weeks after DS or 8–14 weeks after LAP. Data are expressed as means 6 SEM. *: p,0.05, **: p,0.01, ns: not significant
between LAP (n = 13) vs. GB (n= 8) or DS (n = 5).
doi:10.1371/journal.pone.0072896.g003
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(kcal/hr/100 g body weight) at 3 weeks and daytime energy
expenditure at 14 weeks postoperatively (Fig 5A, C) (Tables 3, 4).
RER was unchanged after GB. DS increased daytime energy
expenditure both at 2 and 8 weeks as well as nighttime energy
expenditure at 8 weeks postoperatively (Fig 5B, D) (Tables 3, 4).
RER tended to be reduced during nighttime at 2 weeks after DS
(p=0.051) (Table 3).
Analysis of the homogeneity of regression slopes indicated that
there was positive correlation between the body weight and energy
expenditure (kcal/hr) particularly in LAPDS rats and similar
regression slopes between LAP and GB or DS (p.0.05) (Fig S1).
ANCOVA showed that there was no significant difference in
adjusted energy expenditure between LAP and GB or DS (p.0.05)
(Fig S2).
Fecal Energy Density
There was no change in the fecal energy density after GB. DS
had severe diarrhea within 2 weeks postoperatively, so that it was
difficult to collect the fecal samples. At 2 months, the solid feces
were collected and the energy density was increased (Fig 6).
Plasma Levels of Cytokines
There was no difference between LAP vs. GB or DS in the
plasma levels of the 11 cytokines measured (Table S2).
Discussion
The present study shows that the rat models provide results that
are in accordance with results from clinical series in patients , i.e.
greater weight loss by DS than GB [17,18,25]. Furthermore, the
results of the present study show different postsurgical effects of
GB vs. DS in terms of food intake, eating rate, energy expenditure
and absorption.
It is a common dogma that to reduce size of stomach by surgery
would lead to early satiety and consequently reduce food intake.
Regardless of difference in surgical procedure, either GB or DS
reduces stomach size and bypasses part of the small intestine
(duodenum and most of the jejunum). Previously, we have found
that the food intake was independent on the size of stomach by
comparing gastrectomy and GB in rat models [9]. In clinical
studies, the size of pouch after GB was found not to correlate with
weight loss outcome in patients [25,26]. In our previous and the
Figure 4. Eating behavior. Satiety ratio (min/g) (A,B) and rate of eating (g/min) (C,D) during day- and night-time. Short-term after surgery:
3 weeks after gastric bypass (GB), 2 weeks after duodenal switch (DS) or 2–3 weeks after lapatoromy (LAP). Long-term after surgery: 14 weeks after
GB, 8 weeks after DS or 8–14 weeks after LAP. Data are expressed as means 6 SEM. ***: p,0.001, ns: not significant between LAP (n = 13) vs. GB
(n = 8) or DS (n = 5).
doi:10.1371/journal.pone.0072896.g004
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present studies, GB did reduce body weight but not food intake in
rats [7–9]. Behavior of rats is mostly driven on instincts, while
behavior of humans is much more complicated. In fact, there is
still an open question: ‘‘Does GB reduce food intake in humans?’’.
A recent review shows that large and persistent alterations in
macronutrient intake after GB have not generally been reported,
and when the changes do occur, they are either transient or
relatively modest. The authors argue for more direct measures of
food intake in human studies that are similar to those used in
animal studies [27]. Food intake in patients is also affected by
following the ‘‘postoperative instruction’’ to achieve the best
possible conditions for weight reduction and to minimize side-
effects like gastro-esophageal reflux and dumping syndrome which
unlikely occur in rats. Recently, a human study of eating behavior
and meal pattern following GB was still performed by manually
weighing differences to determine food and water intake and by
the Three-Factor Eating Questionnaire to evaluate eating
behavior [28]. However, in that human study, the food intake
was not reported, but ad libitum meal size was reduced while
number of meals per day was increased, and hunger and satiety
scores did not change after GB, which are in line with our findings
in rats following GB [8]. Methods with more direct measures of
food intake (and food-selection and taste-related behavior) for
humans are needed in order to facilitate translation between
findings from animal models and clinical research [27].
Unlike GB, DS does reduce the food intake. Previously, we have
shown that food intake was reduced by duodenal switch alone but
not by sleeve gastrectomy alone by comparing sleeve gastrectomy
only vs. duodenal switch without sleeve gastrectomy in rats [20]. In
the present study, DS markedly reduced food intake and increased
satiety ratio particularly during nighttime. The rate of eating has
also impacts on body weight. It has been reported that there is a
correlation between rate of eating and body weight or body mass
index (BMI) [29,30]. Previously, we have shown that high-fat-diet-
induced obesity was associated with increased rate of eating,
increased size of meals, but not with daily calories intake [31]. In
the present study, DS decreased the eating rate during both day-
and night-time.
Mechanisms underlying postoperative weight loss and possible
regain remain unclear. A major point of controversy is whether
this is due to biological or behavioral factors [19,32]. We and
others have shown that GB increased the energy expenditure in
rats and mice, which could be one of the mechanisms explaining
the physiologic basis of weight loss after this procedure [8,33,34].
The increased resting energy expenditure in the animal models
after GB is in accordance with some, but not all, reports in
humans. The discrepancies in the clinical studies may include the
heterogeneity of patient populations and measurements of energy
expenditure for a limited time using portable metabolic carts
under artificial rather than ‘‘free-living’’ conditions [35]. Nerve-
less, resting energy expenditure has been suggested to be a
Table 1. Eating behavior.
Parameter LAP GB DS
Day Food Intake (g) 4.0860.3 5.6960.68* 3.6760.31{
Food Intake (g/100g body weight) 0.760.06 1.1460.13** 0.9360.11
Food intake (kcal) 10.560.76 14.6261.74* 9.4260.80{
Food intake (kcal/100g body weight) 1.8360.14 2.9360.33** 2.3960.28
Number of meals 12.1560.97 18.2962.48* 16.660.92
Meal size (g/meal) 0.3560.03 0.3260.02 0.2260.021*
Meal size (kcal/meal) 0.9160.08 0.8260.05 0.5760.05*
Meal duration (min) 13.561.39 17.9662.82 34.4763.29***,{{{
Meal duration (min/meal) 1.1460.1 0.9860.08 2.1360.29***,{{{
Intermeal interval (min) 57.564.42 40.3765.38* 39.3862.04
Satiety ratio (min/g) 171.89615.81 127.93616.63 182.34618.24
Rate of eating (g/min) 0.3260.03 0.3360.02 0.1160.01***,{{{
Night Food Intake (g) 16.4560.69 15.5861.72 4.9660.70***,{{{
Food Intake (g/100g body weight) 2.8660.15 3.1160.30 1.2460.19***,{{{
Food intake (kcal) 42.2861.77 40.0564.41 12.7661.81***,{{{
Food intake (kcal/100g body weight) 7.3560.39 7.9860.78 3.1960.50***,{{{
Number of meals 34.3863.92 31.7163.01 24.4063.85
Meal size (g/meal) 0.5760.09 0.5160.07 0.2160.03*
Meal size (kcal/meal) 1.4760.22 1.3060.17 0.5560.08*
Meal duration (min) 54.2164.54 56.2565.13 53.2169.39
Meal duration (min/meal) 1.8860.36 1.8260.18 2.2060.28
Intermeal interval (min) 22.663.08 21.3661.97 29.4365.57
Satiety ratio (min/g) 4061.86 44.6465.41 145.51631.17***,{{{
Rate of eating (g/min) 0.3260.02 0.3060.06 0.1060.01***,{{
Parameters during day- and night-time at 3 weeks after gastric bypass (GB), 2 weeks after duodenal switch (DS) and 2–3 weeks after laparotomy (LAP). Data are
expressed as means 6 SEM. *: p,0.05, **: p,0.01, ***: p,0.001 between LAP vs. GB or DS. {: p,0.05, {{: p,0.01, {{{: p,0.001 between GB vs. DS.
doi:10.1371/journal.pone.0072896.t001
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therapeutic target for obesity [32,36]. In the present study, we
further showed that the increased energy expenditure took place
only during nighttime (relevant to active energy expenditure)
shortly after GB (weeks) and switched to daytime (resting energy
expenditure) after months, whereas the energy expenditure was
increased during daytime shortly after DS and during both day-
and night-time months after DS.
The most extensively used method for calculation of energy
expenditure is dividing O2 consumption by body weight or body
surface area [37]. In the present study, the energy expenditure was
calculated by taking into account both O2 consumption and CO2
production, and expressed as kcal/hr/rat, kcal/hr/100 g body
weight, and kcal/hr/cm2 body surface. Dividing the energy
expenditure by body weight does not take into account differences
in body composition, and therefore, the fat-free mass or lean body
mass (as denominator) has often been used in both human and
mouse studies. However, this could be inappropriate because
brown fat can be the most metabolically active tissue in the body
[37]. ANCOVA has been suggested to be appropriate method for
analysis of the mouse energy expenditure, but it cannot be used
when the samples sizes are small [37,38]. In rat studies, ANCOVA
has not been used with the exception of a few reports including our
previous study of ileal interposition associated with sleeve
gastrectomy [5,39]. The reasons for not widely use of ANCOVA
than ANOVA in rat studies might be less statistical power when
sample size is small and nonlinear relationship between covariate
(s) and dependent variable. Another reason may be that
ANCOVA is best used with quasi-experimental data, such as
genetically-modified mice [37] or humans [40,41]. The results of
the present study showed that there were highly correlation
between the body weight and the energy expenditure (kcal/hr/rat)
in control LAP rats, and significant increases in the energy
expenditure (kcal/hr and/or kcal/hr/100 g body weight) after GB
or DS (by ANOVA). However, ANCOVA showed no significant
difference in the energy expenditure (kcal/hr) between LAP and
GB or DS. The difference in terms of p values by ANOVA vs.
ANCOVA (i.e. testing the body-weight independent differences)
can be interpreted as that GB or DS increases the energy
expenditure (possible cause) while reducing the body weight
(effect), which is at odds with the positive correlation between the
body weight and the energy expenditure in control animals (LAP).
Both GB and DS are designed for restriction and malabsorption
by creating the alimentary limb. However, DS, but not GB, caused
diarrhea shortly after surgery (2 weeks) and malabsorption
(measured at 2 months postoperatively) in rats, which is in line
with observations in patients [42].
It should be noticed that in the present study, neither
prophylactic nor postoperative antibiotics were used and none of
the 11 plasmas cytokines measured was changed after surgery,
indicating no or little impact of microflora and inflammation on
the eating behavior and the body weight changes. Recently, a
mouse study showed that specific alterations in the gut microbiota
Table 2. Eating behavior.
Parameter LAP GB DS
Day Food Intake (g) 3.9760.51 3.7160.85 3.4260.50
Food Intake (g/100g body weight) 0.6660.09 0.7260.19 1.2260.21
Food intake (kcal) 10.1961.32 9.5462.18 8.7861.29
Food intake (kcal/100g body weight) 1.7160.24 1.8560.48 3.1460.54
Number of meals 10.9261.29 11.2561.81 18.6064.50
Meal size (g/meal) 0.460.06 0.3460.06 0.2360.05
Meal size (kcal/meal) 1.0360.17 0.8660.15 0.5960.12
Meal duration (min) 13.5461.74 13.8963.86 37.1766.92***,{{{
Meal duration (min/meal) 1.3760.22 1.2360.22 2.3460.45
Intermeal interval (min) 68.3967.92 73.68616.91 50.16617.90
Satiety ratio (min/g) 200.34627.9 252.16657.01 203.50632.22
Rate of eating (g/min) 0.3160.03 0.2960.02 0.1060.01***
Night Food Intake (g) 14.1560.71 13.0060.38 6.4360.96***,{{{
Food Intake (g/100g body weight) 2.360.1 2.4560.10 2.2060.26
Food intake (kcal) 36.3561.82 33.4260.98 16.5262.46***,{{{
Food intake (kcal/100g body weight) 5.9260.25 6.2960.26 5.6560.68
Number of meals 26.9262.76 26.5063.69 34.2067.13
Meal size (g/meal) 0.5960.06 0.5860.09 0.2460.07*,{
Meal size (kcal/meal) 1.5260.15 1.4860.23 0.6160.19*,{
Meal duration (min) 50.6664.57 56.3662.96 70.5865.38*
Meal duration (min/meal) 2.0160.18 2.5360.47 2.3960.44
Intermeal interval (min) 27.7863.84 27.9164.11 21.4964.03
Satiety ratio (min/g) 46.7862.4 49.2061.56 108.18617.98***,{{{
Rate of eating (g/min) 0.360.02 0.2460.02 0.0960.01***,{{
Parameters during day- and night-time at 14 weeks after gastric bypass (GB), 8 weeks after duodenal switch (DS) and 8–14 weeks after laparotomy (LAP). Data are
expressed as mean 6 SEM. *: p,0.05, **: p,0.01, ***: p,0.001 between LAP vs. GB or DS. {: p,0.05, {{: p,0.01, {{{: p,0.001 between GB vs. DS.
doi:10.1371/journal.pone.0072896.t002
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contributed to the beneficial effect of bariatric surgery on energy
balance [43]. Whether GB or DS alters the gut microbiota and
consequently leads to the weight loss via same or different
pathways might be of interest for future study.
There are several limitations of the present study. 1) The rats
used were not obese. Whether or not the postsurgical effects of
these two procedures are different between normal and obese rats
that are induced by high-fat diet or developed spontaneously (e.g.
Zucker, Otsuka Long-Evans Tokushima Fatty, Obese SHR, or
Wistar Ottawa Karlsburg W rats), and which animal model of
obesity best mimics the obese humans in response to the bariatric
surgery could be the subjects for further research. 2) GB procedure
used in rats was not exactly the same as it was applied in humans.
Fig 1 shows different procedures of GB. A laparoscopic mini-
gastric bypass procedure (which is similar with one used in the
present study) has been shown to be regarded as a simpler and
safer alternative to laparoscopic Roux-en-Y procedure with similar
efficacy at 5 or 10 year experience [2,44]. It may be of interest to
compare different GB procedures in the future, if there is any
clinical relevancy. 3) Although the size of gastric pouch after GB
does not correlate with weight loss outcome in patients [25,26], it
cannot be excluded whether lack of the pouch in GB has impact
on food intake, satiety and eating behavior. 4) The differences
between rats and humans are not only in terms of the GI anatomy
but also the responses to surgery. For instance, sleeve gastrectomy
only (without duodenal switch) works in some patients but not in
rats [20,45]. It may be of interest to directly compare the effects of
sleeve only vs. sleeve with duodenal switch (one or two-staged) in
the future.
In general, research in patients is directly clinical relevant.
However, studies in animals provide much greater latitude in
control and experimental manipulation of the system, and
ultimately help to reveal the underlying mechanisms and to
adopt the protocols and methods that are tested in animals to
humans [46]. Research using animal models is an excellent way
of developing and learning bariatric surgical techniques as well as
understanding the postsurgical physiology [47]. Taken the data
from the previous and the present studies together, the
Figure 5. Energy expenditure during day- and night-time. Short-term after surgery: 3 weeks after gastric bypass (GB), 2 weeks after duodenal
switch (DS) or 2–3 weeks after laparotomy (LAP). Long-term after surgery: 14 weeks after GB, 8 weeks after DS or 8–14 weeks after LAP. Data are
expressed as means 6 SEM. *: p,0.05, **: p,0.01, ***: p,0.001, ns: not significant between LAPGB (n = 7) vs. GB (n= 8) or LAPDS (n = 6) vs. DS (n = 5).
doi:10.1371/journal.pone.0072896.g005
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appropriately designed rat models provide significant insights into
the mechanisms of bariatric surgery which explain well the
clinical observations, e.g. that DS is superior to GB in body
weight loss. The results of the present study may suggest further
that GB induces body weight loss by increasing energy
expenditure, whereas DS induces greater body weight loss by
reducing food intake, increasing energy expenditure and causing
malabsorption.
Table 3. Metabolism.
3 weeks after surgery 2 weeks after surgery
Parameter LAPGB GB LAPDS DS
Day Energy expenditure (kcal/hr) 2.0860.03 1.9360.06 2.0860.07 1.6660.12**
Energy expenditure (kcal/hr/100g body
weight)
0.3660.01 0.3960.01 0.3660.01 0.4160.01**
Energy expenditure (kcal/hr/cm2 body
surface)
0.00360.0001 0.00460.0001 0.00360.0001 0.00460.0002
RER 0.9460.01 0.9360.02 1.0260.03 0.9660.03
VO2 726.68615.56 779.91623.26 705.18618.00 823.91631.49**
VCO2 682.50612.08 727.85623.54 717.08626.45 791.69626.59
Night Energy expenditure (kcal/hr) 1.7560.14 1.8560.10 2.4560.08 1.6660.10***
Energy expenditure (kcal/hr/100g body
weight)
0.3060.02 0.3760.02* 0.4260.01 0.4160.02
Energy expenditure (kcal/hr/cm2 body
surface)
0.00360.0002 0.00360.0002 0.00460.0001 0.00460.0002*
RER 1.0060.01 1.0160.03 1.0760.03 0.9760.04
VO2 600.02636.70 737.88643.20* 820.65620.88 823.94635.51
VCO2 594.19637.54 735.07635.39* 877.73635.71 803.06649.36
Parameters during day- and night-time at 3 weeks after gastric bypass (GB) and the age-matched laparotomy-operated group (LAPGB), and at 2 weeks after duodenal
switch (DS) and the age-matched laparotomy-operated group (LAPDS). Data are expressed as means6 SEM. *: p,0.05, **: p,0.01, ***: p,0.001 between LAPGB vs. GB or
LAPDS vs. DS.
doi:10.1371/journal.pone.0072896.t003
Table 4. Metabolism.
14 weeks after surgery 8 weeks after surgery
Parameter LAPGB GB LAPDS DS
Day Energy expenditure (kcal/hr) 1.9260.08 1.9060.05 2.1060.06 1.2760.07***
Energy expenditure (kcal/hr/100g
body weight)
0.3160.01 0.3660.01** 0.3460.01 0.4460.01***
Energy expenditure (kcal/hr/cm2
body surface)
0.00360.0001 0.00360.0000* 0.00360.0000 0.00360.0001
RER 0.9860.03 0.9160.05 0.9960.03 0.9860.01
VO2 622.25627.61 720.95614.41** 681.99613.62 873.32625.35***
VCO2 605.31617.73 652.48625.93 675.60623.89 853.15625.17***
Night Energy expenditure (kcal/hr) 1.4860.11 1.6060.10 2.4560.12 1.3460.01***
Energy expenditure (kcal/hr/100g
body weight)
0.2460.02 0.3060.02 0.4060.01 0.4660.02***
Energy expenditure (kcal/hr/cm2
body surface)
0.00260.0002 0.00360.0002 0.00460.0001 0.00460.0001*
RER 0.9760.06 1.0460.05 1.0660.03 0.9960.03
VO2 475.14636.56 598.36645.29 778.37616.51 919.50628.99**
VCO2 487.63635.15 609.64655.95 825.43627.97 906.74639.86
Parameters during day- and nighttime at 14 weeks after gastric bypass (GB) and the age-matched laparotomy-operated group (LAPGB), and at 8 weeks after duodenal
switch (DS) and the age-matched laparotomy-operated group (LAPDS). Data are expressed as means6 SEM. *: p,0.05, **: p,0.01, ***: p,0.001 between LAPGB vs. GB or
LAPDS vs. DS.
doi:10.1371/journal.pone.0072896.t004
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Supporting Information
Figure S1 Scatterplot of energy expenditure against
body weight. LAPGB or DS: laparotomy as control for GB or
DS; GS: gastric bypass; DS: Duodenal switch.
(TIF)
Figure S2 Adjust energy expenditure by ANCOVA.
LAPGB or DS: laparotomy as control for GB or DS; GS: gastric
bypass; DS: Duodenal switch. Means 6 SEM.
(TIF)
Table S1 CLAMS measurements of normal rats. Data at
day 1 and 21 one week after 24 hours training with CLAMS cage
are expressed as means 6 SEM. ns: not significant between day 1
vs. day 21.
(DOC)
Table S2 Plasma levels of cytokines. Data of rats after
gastric bypass (GB) and duodenal switch (DS) compared with the
age-matched laparotomy-operated groups (LAPGB or LAPDS,
respectively) are expressed as means 6 SEM. ns: not significant
between LAPGB vs. GB or LAPDS vs. DS.
(DOC)
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Supplementary table 1. CLAMS measurements of normal rats at day 1 and 21 one week after 24 hours 
training with CLAMS cage. Data are expressed as means ± SEM. ns: not significant between day 1 vs. 
day 21. 
        
  Parameter Day 1 Day 21 
Day Food Intake (g) 6.76±0.67 7.36±0.60 ns 
Food Intake (g/100g body weight) 1.38±0.14 1.46±0.14 ns 
Calories intake (kcal) 17.36±1.72 18.90±1.53 ns 
Calories intake (kcal/100g body weight) 3.54±0.35 3.74±0.36 ns 
Number of meals 14.17±1.66 13.50±1.48 ns 
Meal size (g/meal) 0.52±0.10 0.56±0.05 ns 
Meal size (kcal/meal) 1.34±0.25 1.45±0.12 ns 
Meal duration (min) 18.98±2.07 21.10±1.95 ns 
Meal duration (min/meal) 1.45±0.27 1.61±0.15 ns 
Intermeal interval (min) 49.44±5.95 50.43±4.48 ns 
Satiety ratio (min/g) 101.03±9.37 90.73±6.44 ns 
Water intake (mL) 2.17±0.64 2.24±0.42 ns 
Water intake (mL/100g body weight) 0.45±0.13 0.45±0.09 ns 
Water intake during one interval (mL/time) 0.25±0.07 0.28±0.05 ns 
Ambulatory activity 1305.17±318.30 1451.17±326.57 ns 
Night Food Intake (g) 19.38±0.72 21.07±0.78 ns 
Food Intake (g/100g body weight) 3.94±0.13 4.15±0.19 ns 
Calories intake (kcal) 49.80±1.85 54.16±2.00 ns 
Calories intake (kcal/100g body weight) 10.13±0.33 10.67±0.50 ns 
Number of meals 29.17±2.65 28.83±3.89 ns 
Meal size (g/meal) 0.68±0.04 0.79±0.09 ns 
Meal size (kcal/meal) 1.75±0.11 2.02±0.24 ns 
Meal duration (min) 62.62±3.01 63.66±2.10 ns 
Meal duration (min/meal) 2.21±0.15 2.36±0.24 ns 
Intermeal interval (min) 22.57±1.80 23.88±2.95 ns 
Satiety ratio (min/g) 32.98±1.22 30.20±1.05 ns 
Water intake (mL) 16.14±0.74 17.70±0.60 ns 
Water intake (mL/100g body weight) 3.28±0.12 3.48±0.13 ns 
Water intake during one interval (mL/time) 0.87±0.15 0.89±0.09 ns 
Ambulatory activity 5292.00±1166.98 4484.00±833.95 ns 
 
 
 
Supplementary table 2. Plasma levels of cytokines in rats after gastric bypass (GB) and duodenal switch 
(DS) compared with the age-matched laparotomy-operated groups (LAPGB or LAPDS, respectively). Data 
are expressed as means ± SEM. ns: not significant between LAPGB vs. GB or LAPDS vs. DS.  
            
Cytokine LAPGB GB   LAPDS DS 
IL1Į (pg/mL) 66.20±21.31 33.48±21.01 ns   94.34±33.31 124.84±19.20 ns 
IL-1ȕ (pg/mL) 74.06±22.89 32.63±11.51 ns 310.22±175.16 215.53±87.70 ns 
IL-2 (pg/mL) 201.62±59.23 112.19±46.99 ns   190.21±40.10 373.21±69.13 ns 
IL-4 (pg/mL) 10.62±2.48 27.33±22.06 ns 39.37±17.56 41.69±9.90 ns 
IL-5 (pg/mL) 38.08±8.80 41.19±10.48 ns   129.45±26.03 106.05±18.71 ns 
IL-6 (pg/mL) 111.53±51.69 208.33±176.17 ns 216.85±82.11 158.36±49.23 ns 
IL-10 (pg/mL) 213.33±29.71 145.88±31.72 ns   534.60±139.86 588.50±74.00 ns 
IL-13 (pg/mL) 19.52±8.16 4.47±1.23 ns 61.05±33.76 55.41±19.65 ns 
GM-CSF (pg/mL) 9.42±4.59 1.23±0.41 ns   41.06±24.68 30.81±12.69 ns 
IFNȖ (pg/mL) 53.90±25.31 106.47±105.90 ns 76.90±38.39 75.45±24.11 ns 
TNFĮ (pg/mL) 9.25±6.98 3.72±0.35 ns   65.66±46.06 56.94±29.70 ns 
 
 

